Analysis of the Host Stress Response to Ebola Virus Infection and Generation of a Recombinant Marburg Virus Expressing EGFP to Study Viral Spread by Schmidt, Kristina Maria & Renkawitz-Pohl, Renate (Prof. Dr.)
  
 
 
 
Analysis of the Host Stress Response to 
Ebola Virus Infection 
and 
Generation of a Recombinant Marburg Virus 
Expressing EGFP to Study Viral Spread 
 
Dissertation zur Erlangung des 
Doktorgrades der Naturwissenschaften 
(Dr. rer. nat.) 
 
 
 
 
 
 
 
 
 
dem Fachbereich Biologie 
der Philipps-Universität Marburg 
vorgelegt von 
Kristina Maria Schmidt 
aus Haan 
Marburg/Lahn, 2012 
 
  
 
 
Vom Fachbereich Biologie der Philipps-Universität Marburg als Dissertation 
am _________ angenommen. 
 
Erstgutachter: Prof. Dr. Renate Renkawitz-Pohl 
Zweitgutachter: Prof. Dr. Elke Mühlberger 
 
 
Tag der mündlichen Prüfung am _______ . 
 
 
 
Table of Contents 
Page  I 
 
Table of Contents 
 
1. Zusammenfassung ...................................................................................................... 1 
2. Summary ...................................................................................................................... 4 
3. Introduction .................................................................................................................. 7 
3.1. Taxonomy ................................................................................................................................. 7 
3.2. Epidemiology ............................................................................................................................ 7 
3.3. Pathogenesis .......................................................................................................................... 10 
3.4. Morphology and genome structure ......................................................................................... 10 
3.4.1 Viral inclusion bodies and nucleocapsids .......................................................................... 12 
3.5. Replication and transcription .................................................................................................. 13 
3.6. Rescue system for full-length recombinant MARV ................................................................. 14 
3.7. Stress response and mRNA silencing .................................................................................... 16 
3.7.1 Stress granule assembly ................................................................................................... 17 
3.7.2 Processing body assembly ............................................................................................... 19 
3.7.3 Interplay of SGs and PBs .................................................................................................. 20 
3.7.4 Viruses and cellular stress response ................................................................................ 20 
3.7.5 PKR and PACT ................................................................................................................. 21 
3.8. EBOV RNA-binding proteins .................................................................................................. 22 
3.8.1 Inhibition of dsRNA-mediated cellular responses by VP35 ............................................... 22 
3.8.2 RNA-binding proteins VP30 .............................................................................................. 24 
3.9. Outline and goals ................................................................................................................... 25 
4. Material and Methods ................................................................................................ 27 
4.1. Equipment/Appliances ............................................................................................................ 27 
4.2. Consumables ......................................................................................................................... 27 
4.3. Kits and Buffer ........................................................................................................................ 28 
4.4. Plasmids and Nucleic acids .................................................................................................... 30 
4.5. Enzymes and antibodies ........................................................................................................ 32 
4.6. Cells and Viruses ................................................................................................................... 33 
4.7. Virus work performed under BSL 4 conditions ....................................................................... 34 
4.7.1 Infection of cells with Ebola virus and Marbrug virus ........................................................ 34 
4.7.2 Propagation and isolation of Ebola virus ........................................................................... 34 
4.7.3 Purification and concentration of Ebola virus stocks via ultracentrifugation ...................... 34 
Table of Contents 
Page  II 
 
4.7.4 Determination of virus titer by TCID50 ............................................................................... 35 
4.8. Propagation, isolation and preparation of nucleic acids ......................................................... 35 
4.9. Transfection of eukaryotic cell lines ....................................................................................... 36 
4.9.1 Lipid based transfection .................................................................................................... 36 
4.9.2 Calcium-phosphate transfection ........................................................................................ 36 
4.10. Analysis of proteins .............................................................................................................. 36 
4.10.1 Coimmunoprecipitation (CoIP) ........................................................................................ 36 
4.11. Western blot analysis of infected and transfected samples ................................................. 38 
4.12. Immunofluorescence analysis of infected and transfected samples .................................... 39 
5. Results ........................................................................................................................ 40 
5.1. Generation of a recombinant Marburg virus clone expressing EGFP .................................... 40 
5.1.1 Cloning and characterization of the rMARV expressing EGFP ......................................... 40 
5.1.2 EGFP accumulates in nucleocapsid protein-derived inclusion bodies .............................. 45 
5.2. Host cell stress response to Ebola virus infection .................................................................. 54 
5.2.1 Modulation of eIF3-containing SG formation in EBOV infection ....................................... 54 
5.2.2 U2OS cell line expressing the SG marker protein G3BP was used to analyze the role of 
SGs in EBOV infection ................................................................................................................. 56 
5.2.3 Stress response in EBOV-infected U2OS G3BP-EGFP cells ........................................... 58 
5.2.4 Impact of EBOV proteins on SG formation ....................................................................... 63 
5.2.5 Phosphorylation of PKR and eIF2! in EBOV-infected cells treated with As ..................... 77 
5.2.6 Binding of VP35 and PACT is disrupted during As-stress ................................................ 78 
5.2.7 Formation of DCP1a-containing PBs is altered in EBOV infection ................................... 80 
6. Discussion .................................................................................................................. 87 
6.1. Generation of a recombinant MARV clone expressing EGFP ................................................ 87 
6.2. Host cell stress response to EBOV infection .......................................................................... 90 
7. References ................................................................................................................. 98 
8. Curriculum vitae ...................................................................................................... 108 
 
 
Zusammenfassung 
 
Page  1 
 
1. Zusammenfassung 
Die hoch pathogenen Filoviren Ebola- (EBOV) und Marburg-Virus (MARV) sind Erreger eines 
hämorrhagisches Fiebers mit Lethalitätsraten von bis zu 90%. Bislang sind weder spezifische 
antivirale Medikamente noch eine Impfung für den Einsatz am Menschen verfügbar. Die hohe 
Sterblichkeitsrate sowie die fehlende Therapie und Prophylaxe bedingen, dass Filoviren als 
Erreger der höchsten biologischen Sicherheitsstufe (4) klassifiziert werden und somit eine 
Erforschung nur in Hochsicherheitslaboratorien erlaubt ist. 
Herstellung eines rekombinanten Marburg-Virus mit Fluoreszenzmarker  
Ziel dieses Projekts war die Herstellung eines rekombinanten MARV, welches das „enhanced 
green fluorescence protein“ (EGFP)-Gen von einer zusätzlichen, in das virale Genom eingefügten 
Transkriptionseinheit exprimiert. Viren, die fluoreszierende Proteine exprimieren, erleichtern die 
Untersuchung des viralen Vermehrungszyklus und sind wertvolle Hilfsmittel für das „Screenen“ von 
potentiellen antiviralen Medikamenten. Das EGFP-Gen wurde zwischen dem zweiten Gen des 
MARV-Genoms, dem VP35-Gen, und dem nachfolgenden VP40-Gen eingefügt. Das rekombinante 
Virus (rMARV-EGFP) wurde über ein cDNA-Zwischenprodukt in transfizierten Zellen generiert und 
anschliessend in „live-cell imaging“ Versuchen eingesetzt. Eine Expression von EGFP wurde 32 
Stunden nach Infektion erstmals detektiert und eine Infektion von Nachbarzellen nach 55 Stunden. 
Im Vergleich zum rekombinanten Wildtyp-MARV wurde ein eingeschränktes virales Wachstum 
festgestellt. Dies ist wahrscheinlich auf die Insertion einer zusätzlichen Trankriptionseinheit 
zurückzuführen, da Gene, die hinter dem eingefügten EGFP-Gen liegen, weniger stark exprimiert 
wurden. 
In filoviralen Infektionen können charakteristische virale Einschlusskörper (inclusion bodies) 
detektiert werden, die sich im Zytoplasma infizierter Zelle bilden. Initiiert wird die Bildung dieser 
Einchlusskörper durch die Akkumulation des viralen Nukleoproteins (NP). 
Immunfluoreszenzanalysen von Zellen, die mit rMARV-EGFP infiziert waren, zeigten eine 
Akkumulation des EGFP in viralen Einschlusskörpern. In Tansfektionsexperimenten wurde die 
Relokalisierung verschiedener Fluoreszenzproteine in filovirale Einschlusskörper untersucht. Dies 
zeigte, dass ektopisch exprimierte Fluoreszenzproteine sowohl mit MARV- als auch mit EBOV-
spezifischen Einschlusskörpern colokalisierten. Des Weiteren konnte nachgewiesen werden, dass 
die Expression von NP in der Abwesenheit anderer viraler Proteine ausreichend für die 
Akkumulation von EGFP in den Einschlusskörpern ist. Im Gegensatz dazu akkumulierten 
ektopisch exprimierte GFP-Fusionsproteine, die ein zelluläres Lokalisierungssignal besitzen, nicht 
in MARV-spezifischen Einschlusskörpern. Dies lässt darauf schließen, dass ektopisch exprimierte 
Proteine unspezifisch in den viralen Einschlusskörpern akkumulieren, wenn sie kein 
Lokalisierungssignal besitzen. Durch Immunfluoreszenzanalysen konnte zudem gezeigt werden, 
dass die EGFP-Aggregate zwar durch die Autofluoreszenz detektiert werden konnten, aber nicht in 
der Antikörperfärbung sichtbar waren. Dies weist darauf hin, dass Antikörper nicht in der Lage 
sind, virale Einschlusskörper zu durchdringen. 
Die zelluläre Stressantwort in Ebola-Virus Infektion 
Ebola-Viren sind in der Lage, essentielle antivirale Signalwege der Interferon-induzierten 
Immunantwort zu hemmen. Im Rahmen dieser Arbeit wurde die Interaktion von EBOV mit einem 
weiteren antiviralen Abwehrmechanismus, der zellulären Stressantwort, untersucht. Exogen 
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induzierter Stress kann zur Aktivierung vier verschiedener Kinasen führen, die in aktivierter Form 
die !-Untereinheit des eukaryotischen Initiationsfaktors 2 (eIF2) phosphorylieren. Dies wiederum 
führt zu einer Hemmung der Proteinsynthese, welche mit der Bildung von cytoplasmatischen 
„stress granules“(SG) und „processing bodies“ (PB) einhergeht. Viren, die auf den zellulären 
Proteinsyntheseapparat angewiesen sind, haben vielseitige Abwehrstrategien gegen die zelluläre 
Stressantwort entwickelt. Im Folgenden wurde untersucht, wie EBOV mit SG und PB interagiert. 
Aufgrund der dynamischen Struktur von SG und PB wurden vorwiegend mikroskopische Analysen 
durchgeführt.  
Zunächst wurde untersucht, ob filovirale Infektionen eine Stressantwort induzieren. Es konnte 
gezeigt werden, dass in EBOV-infizierten Zellen keine endogenen SG gebildet werden. Die 
Behandlung von EBOV-infizierten Zellen mit dem Stressinduktor Natriumarsenit (As) führte zur 
Bildung von SG, allerdings in einer geringeren Anzahl von infizierten Zellen, verglichen mit nicht 
infizierten, behandelten Zellen. Die Ergebnisse weisen auf eine Hemmung von SG in mit EBOV 
infizierten Zellen hin.  
Zur besseren Visualisierung von SG wurde für die weiteren Untersuchungen eine Zelllinie 
verwendet, die das SG-Markerprotein „ras-GAP SH3 domain binding protein 1“ (G3BP) konstitutiv 
exprimiert. In mit EBOV infizierten, G3BP-exprimierenden Zellen wurden SG mit zwei 
verschiedenen Toxinen induziert, As und Hippuristanol (Hip). Während As die Phosphorylierung 
von eIF2! induziert, bewirkt Hip die Hemmung der eIF4A-abhängigen Translationsinitiation, ein 
Prozess, der unabhängig von der Phosphorylierung von eIF2! zu der Bildung von SG führt. SG-
Bildung wurde durch beide Toxine in mit EBOV infizierten Zellen ausgelöst, eine Reduktion wurde 
allerdings nur für die Bildung von As-induzierten SG in mit EBOV infizierten Zellen beobachtet. 
Interessanterweise wurden zudem SG-ähnliche G3BP-EGFP-Aggregate in den viralen 
Einschlusskörpern beobachtet, die sowohl in behandelten als auch in nicht behandelten EBOV-
infizierten Zellen auftraten. Es konnte weiterhin durch Transfektionsversuche gezeigt werden, dass 
die Bildung viraler Einschlusskörper, die durch die Expression von Nukleokapsidproteinen induziert 
wurde, nicht ausreichend war, um die Aggregation von G3BP-EGFP in den viralen 
Einschlusskörpern zu bewirken. Dies lässt darauf schließen, dass andere Faktoren, wie 
beispielsweise virale RNA, benötigt werden, um SG-Komponenten in die viralen Einschlusskörper 
zu rekrutieren. Diese Ergebnisse weisen auf eine Hemmung der zellulären Stressantwort durch 
EBOV hin, die auf der Inhibition der Bildung von SG und auf einer Sequestierung essentieller SG-
Komponenten beruht.  
Zur weiteren Charakterisierung der Inhibition von SG durch EBOV wurden in 
Transfektionsversuchen die RNA-bindenden EBOV Proteine NP, VP30 und VP35 einzeln 
exprimiert. Während VP30 mit SG kolokalisierte ohne diese zu beeinträchtigen, wurde für das 
dsRNA-bindende VP35 eine inhibierende Wirkung auf die Bildung von SG beobachtet. In Zellen, 
die VP30 oder VP35 gemeinsam mit NP exprimierten, wurden beide Proteine in die von NP 
induzierten Einschlusskörper rekrutiert, und die Kolokalisation mit SG war entweder stark reduziert 
oder nicht vorhanden. Dies wurde auch in mit EBOV infizierten Zellen beobachtet. Diese 
Ergebnisse lassen darauf schließen, dass VP30 und VP35 nur in ungebundener Form mit SG 
interagieren. Die Menge an freien VP30- und VP35-Proteinen in EBOV-infizierten Zellen ist 
wahrscheinlich zu gering, um in der Immunfluoreszenzanalyse detektiert zu werden.  
Unter As-induzierten Stressbedingungen wird die „dsRNA dependent protein kinase“ (PKR) von 
dem zellulären Protein „PKR activating protein“ (PACT) aktiviert. Aktivierte PKR phosphoryliert 
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eIF2!, was zur Bildung von SG führt. Die Aktivierung von PKR durch dsRNA wird von dem EBOV-
Protein VP35 effizient inhibiert. Im Rahmen dieser Arbeit konnte gezeigt werden, dass die As-
induzierte Aktivierung von PKR nicht von EBOV inhibiert werden kann. Fabrozzi et al. (2011) 
konnten bereits eine Bindung zwischen VP35 und PACT in nicht gestressten Zellen nachweisen. In 
dieser Arbeit wurde diese Bindung durch Coimmunpräzipitationsanalysen bestätigt und zudem 
gezeigt, dass in mit As behandelten Zellen VP35 nicht in der Lage ist an PACT zu binden. Dies 
könnte eine Bindung von PACT an PKR ermöglichen und damit zu der beobachteten Aktivierung 
von PKR führen. Die Aktivierung von PKR in mit EBOV infizierten Zellen nach As-Behandlung 
könnte auch die Bildung von SG in diesen Zellen erklären. Aus der beobachteten Reduktion von 
As-induzierten SG in EBOV-infizierten Zellen wird geschlossen, dass VP35 SG-Komponenten 
inhibiert oder relokalisiert. Dies scheint mit der Expressionsrate von VP35 zusammenzuhängen.  
Zur weiteren Charakterisierung der zellularen Stressantwort wurde die Rolle von PB in EBOV 
infizierten Zellen näher untersucht. Hierzu wurde eine Zelllinie verwendet, die das PB-
Markerprotein „mRNA-decapping enzyme 1A” (DCP1a) exprimiert. Eine Rekrutierung von As-
induzierten PB an die viralen Einschlusskörper, die aber nicht zu einer Kolokalisation führte, 
konnte in EBOV infizierten Zellen beobachtet werden. Diese wurde auf die von NP initiierte Bildung 
von Einschlusskörpern zurueckgefuehrt. Expressionsstudien zeigten, dass PB mit VP35 
kolokalisierten, aber nicht mit VP30 oder NP. Des Weiteren konnte gezeigt werden, dass in Zellen, 
in denen es zu einer durch VP35 bedingten Hemmung der SG-Bildung kam, die entstandenen, 
diffusen G3BP-EGFP-Aggregate nicht nur mit VP35 kolokalisierten, sondern auch mit PB 
interagierten. Dies weist darauf hin, dass VP35 mit SG- und PB-Komponenten interagiert und 
diese verbindet.  
Zusammengefasst zeigen die Ergebnisse dieser Arbeit, dass EBOV Mechanismen zur Kontrolle 
der antiviralen zellulären Stressantwort entwickelt hat, in denen VP35 eine wichtige Rolle spielt, da 
es mit Komponenten von SG und PB interagiert. Des Weiteren scheint die Bindung zwischen VP35 
und PACT eine wichtige Rolle in der Kontrolle von PKR zu spielen.  
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2. Summary 
Ebola virus (EBOV) and Marburg virus (MARV) belong to the filovirus family and cause outbreaks 
with case fatality rates up to 90%. Currently there is no approved vaccine or antiviral treatment 
available. Therefore filoviruses are classified as priority A select agents, which can only be handled 
in high containment biosafety level 4 laboratories.  
Generation of an infectious Marburg virus clone expressing EGFP  
The generation of recombinant viruses expressing enhanced green fluorescent protein (EGFP) has 
significantly improved the study of their replication cycle and opened up the possibility for the rapid 
screening of antiviral drugs. The goal of this part of the work was to generate a recombinant MARV 
expressing EGFP from an additional transcription unit inserted between the second and third 
genes, encoding VP35 and VP40, respectively. The recombinant MARV containing the EGFP gene 
(rMARV-EGFP) was successfully rescued and used in live-cell imaging to follow viral spread in real 
time, revealing EGFP expression at 32 hours post infection (hpi), and infection of neighboring cells 
at 55 hpi. A slight growth restriction of rMARV-EGFP compared to the wt rMARV was observed 
which might be due to the additional gene insertion.  
During filovirus infection characteristic viral inclusions are formed in the cytoplasm of infected cells, 
induced by self-aggregation of the nucleoprotein (NP). Immunofluorescence analysis of rMARV-
EGFP-infected cells revealed an accumulation of EGFP in these viral inclusions. This was 
reproduced by transient expression of both EGFP and other fluorescent proteins (FPs) along with 
filovirus nucleocapsid proteins, which further showed that NP-induced inclusion formation was 
sufficient for the recruitment. In contrast, ectopic GFP fusion proteins containing a localization 
signal were not relocated into inclusions formed by MARV NP and VP35. Taken together, the 
observed relocalization of ectopically expressed, untagged FPs suggests an unspecific recruitment 
to the viral inclusions based on a weak interaction. Interestingly, EGFP aggregates observed by 
autofluorescence were undetected by antibody-based immunofluorescence. This indicates that 
antibodies might not be able to penetrate viral inclusions. 
Cellular stress response to Ebola virus infection  
EBOV is known to antagonize various antiviral signaling pathways including the interferon 
response. Here, the interaction of EBOV with another host antiviral defense mechanism, the 
cellular stress response, was analyzed. During environmental stress a small range of kinases 
phosphorylate the eukaryotic initiation factor 2! (eIF2!), which plays a central role in the control of 
translational arrest. Cellular stress is also accompanied by the formation of cytoplasmic stress 
granules (SGs) and processing bodies (PBs) containing stalled messenger ribonucleoprotein 
bodies. Since viruses depend on the cellular translation apparatus for viral protein synthesis, many 
viruses have evolved strategies to antagonize cellular stress response mechanisms. Here we 
demonstrate that EBOV interferes with the cellular stress response. Since, SGs and PBs are highly 
dynamic structures, which cannot be isolated from cells, most of the studies presented here were 
performed by microscopic analysis. Formation of endogenous SGs was not observed in EBOV-
infected cells, suggesting that filovirus infection per se does not induce a stress response. This 
raised the question of whether SG formation is actively inhibited in EBOV-infected cells. The 
oxidative stressor sodium arsenite (As) induces eIF2! phosphorylation and SG formation. After As- 
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treatment, SGs formed in EBOV-infected cells, albeit in fewer cells compared to non-infected cells, 
indicating that EBOV is able to inhibit As-induced SG formation to a certain level.  
For better visualization SG formation was further analyzed in U2OS cells expressing an EGFP-
tagged SG maker protein, ras-GAP SH3 domain binding protein 1 (G3BP). In EBOV-infected 
G3BP-EGFP-expressing cells, SG formation was induced by As and Hippuristanol (Hip). Hip leads 
to SG formation by inhibiting eIF4A-dependent translation initiation, a process, which does not 
involve phosphorylation of eIF2!. In some EBOV-infected cells treated with As, G3BP-EGFP was 
diffusely distributed and SG formation was impaired. This was not seen in Hip-treated cells, 
suggesting that EBOV inhibits SG formation to a certain level in response to phospho-eIF2!-
mediated stress. This inhibition seemed to be dependent on the size of the viral inclusions, 
suggesting that the level of viral protein expression is important for the inhibition. 
Intriguingly, G3BP-EGFP SG-like aggregates were observed within the viral inclusions in 
unstressed and in stressed EBOV-infected cells. Transient expression of viral nucleocapsid 
proteins leading to inclusion formation was not sufficient for the aggregation of G3BP granules 
inside the inclusions, suggesting that other viral components, including the viral RNA, are needed 
to sequester SG components in the inclusions. Together this data suggest a mechanism of EBOV 
to interfere with SGs by sequestering SG components in the viral inclusions. 
To further understand how EBOV interacts with SGs, the EBOV RNA-binding proteins NP, VP30, 
and VP35 were individually examined for their ability to interact with SGs. While VP30 colocalized 
with SGs without affecting their structure, the double-strand (ds) RNA-binding protein VP35 
inhibited SG formation induced by phospho-eIF2!-mediated stress when expressed at high levels. 
However, when VP30 and VP35 were coexpressed with NP, both proteins were relocated into NP-
derived viral inclusions and colocalization with SGs was strongly reduced or absent, which was 
also observed in EBOV-infected G3BP-EGFP cells. This indicates that only free VP35 and VP30 
are able to colocalize with SGs and that both proteins are preferentially relocated to viral 
inclusions. It is conceivable that the amount of free VP35 and VP30 in infected cells is too low to 
be detected by IFA. 
In As-treated cells the dsRNA-dependent protein kinase (PKR) is activated by the cellular protein, 
PKR activating protein (PACT). Activated PKR phosphorylates eIF2!, inducing SG formation. In 
EBOV-infected cells, activation of PKR by dsRNA has been shown to be efficiently inhibited by 
VP35. Our data revealed that EBOV was not able to block As-induced PKR activation. This 
indicates that PKR activation by PACT cannot be antagonized by VP35. Previous studies have 
reported that VP35 binds to PACT in unstressed cells (Fabozzi et al., 2011) Here we show that the 
VP35-PACT interaction was disrupted in stressed cells. This indicates that VP35 loses the ability to 
sequester PACT from binding to PKR, such that PKR can be activated. This further explains the 
presence of SGs in EBOV-infected cells but the questions remains, how eIF2!-induced SG 
formation is inhibited in EBOV-infected and VP35 expressing cells? Possible mechanisms include 
the inhibitory function of VP35 on SG formation or the sequestering of SG components. 
To analyze the role of PBs in EBOV infection, a U2OS cell line expressing the PB marker protein 
mRNA-decapping enzyme 1A (DCP1a) fused to mRFP was used. In EBOV-infected cells, As-
induced PBs were observed to surround viral inclusions, suggesting a recruitment of PBs. In 
transient transfection experiments, PBs colocalized with VP35 but not with VP30 or NP. 
Expression of VP35 in U2OS cells containing both G3BP-EGFP and DCP1a-mRFP resulted in 
diffusely aggregated SGs that colocalized with VP35 and intermingled with PBs. This suggests that 
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VP35 interacts and links constituents of PBs and SGs. The results indicate that EBOV exhibits 
antiviral control strategies at the level of the host stress response, where VP35 functions as a key 
player, since it directly interacts with cellular stress components of both SGs and PBs. 
Furthermore, the binding between VP35 and PACT seems to play an important role in the control 
of PKR.  
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3. Introduction 
3.1. Taxonomy 
Ebolaviruses and Marburgviruses constitute the family Filoviridae in the order Mononegavirales. 
Members of this order are characterized by their non-segmented, single-stranded (ss) RNA 
genomes of negative polarity and include the virus families Filoviridae, Rhabdoviridae, 
Paramyxoviridae and Bornaviridae (Fig. 1). Phylogenetic analysis of their genomes shows that 
filoviruses are closely related to the paramyxoviruses in the order Mononegavirales and particularly 
to the human respiratory syncytial virus (RSV) (Muhlberger et al., 1992; Sanchez et al., 1992) . 
 
 
Fig 1.: Taxonomy of single-stranded negative-sense RNA viruses.  
Marburgvirus isolates show a genome sequence variability of 21% and are therefore classified as a 
single species Marburg marburgvirus. Ebolaviruses are divided into five species on the basis of 
differences in gene and genome sequence, pathogenicity, geographic origin and occurrence, and 
in antigenicity. The five species are: Sudan ebolavirus (virus: Sudan virus (SEBOV)), Zaire 
ebolavirus (virus: Ebola virus (EBOV)), Thaï forest ebolavirus (virus: Thaï Forest virus (TAFV)), 
Bundibugyo ebolavirus (virus: Bundibugyo virus (BDBV)) (Kuhn et al., 2010), Reston ebolavirus 
(virus: Reston virus (RESTV)), all of which have a genome sequence homology of 60-70%.  
 
3.2. Epidemiology 
The first cases of filovirus infections were reported in 1967 following human outbreaks of acute 
hemorrhagic fever in the cities of Marburg and Frankfurt in Germany and Belgrade in the former 
Yugoslavia (Martini and Siegert, 1971; Slenczka, 1999). Initial infections occurred in persons 
working with blood, organs or tissue cell cultures from infected African green monkeys 
(Cercopithecus aethiops) that had been imported from Uganda. The pathogen was named 
Marburg virus (MARV) after the city with the most initial cases and where much of the initial 
research of the virus was performed, which included the first isolation of a filovirus. Reported 
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MARV outbreaks have resulted in case fatality rates of between 21-91% and are shown in Figure 
2.  
 
Fig. 2: Overview of cases of infection during filovirus outbreaks. Case fatality rates for Marburgvirus and Ebolavirus 
outbreaks. 
Similar cases of hemorrhagic fever were reported in 1976 with outbreaks occurring in two 
locations: southern Sudan and shortly thereafter in northern Zaire (now the Democratic Republic of 
the Congo, DRC). The causative agents isolated from patients in both outbreaks were named 
Ebolaviruses after a river in northwestern DRC. The two epidemics were caused by two different 
species, later named Sudan ebolavirus and Zaire ebolavirus. Case fatality rates from reported 
outbreaks have been between 80-90% for EBOV and 50-55% for SEBOV (Fig. 2). The Thaï forest 
ebolavirus species (formally named Cote d’Ivoire ebolavirus) was discovered in 1994 when virus 
was isolated from an infected ethnologist who had performed a necropsy on a chimpanzee in the 
Thaï forest reserve in Cote d’Ivoire, Africa. Bundibugyo ebolavirus, the most recently added 
species to the genus Ebolavirus (Kuhn et al., 2010), has a reported fatality rates of 36% since its 
discovery in the 2007 outbreak in Uganda (Fig. 2) (Towner et al., 2008). 
The only known ebolavirus species discovered outside of Africa, Reston ebolavirus, was identified 
in 1989 in Reston, VA, USA (Fig. 3). RESTV-infected Cynomolgus monkeys (Macaca fascicularis) 
were imported from the Philippines (Fig. 3), where the virus was found to be endemic. It represents 
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the only species in the genus Ebolavirus with no reported lethal human infections. Although it has 
caused deadly outbreaks in nonhuman primates and domestic pig populations, it is not certain if 
these animals died from additional infections with other viruses.   
Aside from Reston ebolavirus, filoviruses are endemic in Central Africa in an area that lies 
approximately between the 10th parallel north and south of the Equator as indicated by the 
locations of known outbreaks (see Fig. 3). The natural reservoir for filoviruses remains to be 
identified but infectious marburgvirus has been isolated from Egyptian fruit bats (Rousettus 
aegyptiacus) and infectious Reston virus has been isolated from domestic pigs (Sus scrofa).  
 
Fig. 3: Overview of filovirus outbreaks. MARV outbreaks occurred in Angola, DRC, Uganda and Zimbabwe (A, purple). 
Outbreaks of the different Ebolaviruses occurred in Sudan and Uganda (A, Sudan ebolavirus; blue), DRC, Republic of 
Congo, Gabon (A, Zaire ebolavirus; green), Cote d’Ivoire (A, Thai Forest ebolavirus; yellow), USA, Italy and the 
Philippines (B-D, Reston ebolavirus; red), Uganda (A, Bundibugyo ebolavirus; cream) (modified from (Feldmann and 
Geisbert, 2011) . 
Work with filoviruses is restricted to high-containment Biosafety Level 4 (BSL-4) laboratories due to 
the lack of an approved vaccine or treatment, the high lethality, and the risk of potential 
transmission via aerosols (CDC, DHHS, and NIH. 2009). Filoviruses are classified as Category A 
Bioterrorism Select Agents by the Centers for Disease Control and Prevention (CDC) for their 
potential threat to public health and safety. The National Institute of Allergy and Infectious 
Diseases (NIAID) further classified them as Category A Priority Pathogens and the World Health 
Organization (WHO) as Risk Group 4 agents.  
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3.3. Pathogenesis 
Filoviruses are mainly transmitted through direct contact with body fluids of infected patients or 
animals. Viruses enter the body through small lesions in the skin or mucosal skin. Early target cells 
are macrophages, monocytes, and dendritic cells (Ryabchikova et al., 1996; Geisbert et al., 2003). 
It is assumed that virus spread occurs from the initial infection site via the primary target cells to 
the local lymph nodes and through the blood to the liver and spleen. Viral particles are likely 
distributed systemically throughout the body by the lymphatic system (reviewed in (Feldmann and 
Geisbert, 2011). Symptomatic manifestation of the disease starts after an incubation time of 2-21 
days with sudden onset of unspecific flu-like symptoms. In the acute phase of the disease, 
hemorrhages develop in the mucosal epithelia of the intestinal tract, lungs, and mouth, due to the 
increased permeability of the endothelium (Martini, 1973; Bwaka et al., 1999; Slenczka, 1999). 
Viral replication is very efficient; at two days following the onset of symptoms, viral titers in the 
blood of infected patients with a fatal outcome of the disease were higher than 108 virus particles / 
ml (Towner et al., 2004). In fatal cases the adaptive immune response is severely inhibited and 
dysregulated, which might influence the outcome of the disease (Baize et al., 1999; Bradfute et al., 
2008). Massive apoptosis of non-infected lymphocytes might play a role in filovirus pathogenesis 
(Baize et al., 1999). In addition, it has been shown that filoviruses encodes several proteins that 
actively inhibit the innate immune response (Basler et al., 2000; 2003; REID et al., 2005; Cardenas 
et al., 2006; Prins et al., 2009; Valmas et al., 2010). Patients with a fatal course of infection 
succumb to infection six to sixteen days after the appearance of the first symptoms of hemorrhagic 
fever.   
 
3.4. Morphology and genome structure 
Filovirus particles have a characteristic filamentous shape that gave the virus family its name. 
Virions appear as branched, circular, U or 6-shaped and long filamentous forms, which vary in 
length from 974-1086 nm but sustain a constant diameter of 80 nm (Fig. 4A).  
The filamentous enveloped particles contain a negative-sense, ssRNA genome. The 19 kilobases 
genome is flanked by non-coding 3’ leader and 5’ trailer sequences and contains seven viral 
genes. The open reading frames (ORFs) are flanked by nontranslated regions and separated by 
highly variable intergenic regions (IRs) of varying lengths (Fig. 4C). The leader and trailer are non-
transcribed regions and contain the replication and transcription promoters as well as the signals 
for encapsidation of the genome.  
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Fig. 4: Schematic of the filovirus morphology and genome structure.  
The viral proteins encoded on the viral genome include the nucleoprotein (NP), the polymerase 
cofactor viral protein (VP) 35, the matrix protein VP40, the surface glycoprotein GP, the 
transcription initiation factor VP30, the minor matrix protein VP24 and the RNA-dependent RNA 
polymerase, L (Fig. 4B and C). Encapsidation of the viral RNA by the nucleocapsid (NC) proteins 
(detailed below) protects it from both RNase degradation and detection by the host immune 
response. Genomic and antigenomic RNA are both encapsidated by the NC proteins and serve as 
the template for viral RNA synthesis. In contrast, the viral mRNAs are not encapsidated 
(Muhlberger et al., 1998; 1998).  
NP encapsidates the viral genome and antigenome, which protects the RNA from RNases (see 
Replication and transcription). In addition, NP is important for the viral NC and inclusion formation. 
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Helical NP-structures formed by expression of NP associated with non-viral RNA, which is not 
protected from RNase digestion (Noda et al., 2010). The NCs form a helical structure consisting of 
genomic RNA and tightly associated proteins that are essential for replication and transcription of 
the viral genome. The NC is formed by NP, which interacts with VP35, VP30, and the polymerase 
L, either directly or via a linker protein.  
In infected cells, these interactions redirect all four NC proteins into cytoplasmic aggregates, 
described in more detail below. The membrane-associated VP24 protein has also been shown to 
be required for structured NC assembly (Huang et al., 2002; Mateo et al., 2011).  
 
3.4.1 Viral inclusion bodies and nucleocapsids 
Following infection of the cell, viral inclusions are formed in the cytoplasm. These cytoplasmic viral 
inclusions are thought to be active sites of viral replication and assembly of newly synthesized 
NCs. The first morphological sign of viral inclusion formation observed by electron microscopy 
(EM) analysis appears as high-density granular material in the cytoplasm that contains RNA and 
viral proteins at 9 hours post infection (hpi) with EBOV and 12 hpi with MARV (Ryabchikova and 
Price, 2004). Later, highly organized tubular structures with an average diameter of 50 nm can be 
detected, which are thought to represent the newly synthesized viral NCs (Ryabchikova and Price, 
2004; Noda et al., 2006; Olejnik et al., 2011)). By immunofluorescence microscopy viral inclusions 
appear as large aggregates in the cytoplasm of filovirus-infected cells (Becker et al., 1998; Schmidt 
et al., 2011) (Fig. 5A). These inclusions look similar to those formed in cells expressing NP alone 
due to self-assembly. However, these inclusions are more pronounced when VP35 is coexpressed 
(Fig. 5A).  
 
Fig. 5: Filoviral NC formation. (A) Immunofluorescence (IF) analysis of EBOV and MARV inclusions formed by NP and 
VP35. (B) Electron microscopy (EM) analysis of EBOV and MARV inclusions. EBOV: Expression of the viral proteins NP, 
VP35, VP30, and VP24 in transfected HEK293T cells (Huang et al., 2002). MARV: viral inclusion in MARV-infected Vero 
cells (Kolesnikova et al., 2000). (C) Cryo EM and electron tomography (ET) of EBOV and MARV NC conformation. 
EBOV: Transfection of viral proteins NP, VP35, VP24, VP40 (Bharat et al., 2012). MARV-infected Vero cells (Bharat et 
al., 2011). 
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EBOV NP, expressed in the absence of other viral proteins, forms loose coil-like helices of 
approximately 20 nm in diameter that are morphologically distinct from authentic NCs as shown by 
CryoEM (Noda et al., 2006; Watanabe et al., 2007; Bharat et al., 2012). The NP helices serve as 
the core for the formation of NC-like structures (Watanabe et al., 2007). EM studies further 
revealed that expression of EBOV NP, VP24 and VP35 results in the formation of highly structured 
NC-like helices of approximately 50nm in diameter that are morphologically indistinguishable from 
the NCs observed in EBOV-infected cells (Fig. 5B) (Huang et al., 2002; Noda et al., 2006). These 
three proteins are sufficient and essential for the structure of the NC-like helices whereas viral RNA 
is not essential for this process. The NC-like structures are transported to the plasma membrane 
where virus budding occurs upon coexpression of VP40. It is believed that VP40 interacts with NP 
and recruits the NC-like structures to the cell membrane during virus budding to form virus-like 
particles (VLPs). VLPs containing the NC helices (formed by the four viral proteins NP, VP24, 
VP35 and VP40) and EBOV virions have been shown to be indistinguishable in structure, 
symmetry and flexibility (Fig.5C) (Bharat et al., 2012).  
Detailed cryo-electron tomography (cryo-ET) analysis revealed the conformation of MARV NCs 
(Bharat et al., 2011). Core-conserved truncated versions of MARV NP (390 N-terminal residues) 
formed helices closely matching the helical parameters of viral NCs (e.g. innermost density, 
diameter, hand, and pitch) and assembled in the absence of any other viral proteins.  
 
3.5. Replication and transcription 
After entry into the cell, filoviral NCs are released into the cytoplasm of the infected cell where 
transcription and replication of the viral RNA genome takes place (Fig. 6). NP, VP35, L, and VP30 
form the polymerase complex needed for both viral transcription and replication. The polymerase 
complex transcribes the encapsidated negative-sense RNA genome, leading to monocistronic 
mRNAs. These mRNAs are co-transcriptionally capped and polyadenylated and subsequently 
translated by the cellular translation machinery (Fig. 6). It is believed that during transcription, the 
polymerase complex only has access to the promoter located in the leader region of the viral 
genome but frequently detaches from the template primarily at the gene borders. Consequently, 
genes located closer to the 3’ end leader region of the genome are transcribed at a higher 
frequency than the genes located at the 5’ end, which leads to an mRNA-gradient.  
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Fig. 6: Schematic of the filoviral replication and transcription cycle. Courtesy of Dr. K. Brauburger published in Olejnik et 
al., 2011. 
During replication, the genomic RNA serves as the template for the production of positive-sense 
antigenomes, which are complementary to the genomes. The antigenomes, encapsidated by the 
nucleocapsid proteins, are used as templates for genome synthesis (Fig. 6) (for review see 
(Mühlberger, 2007)). For EBOV it has been shown that VP40 and VP24 inhibit transcription and 
replication (Watanabe et al., 2007; Hoenen et al., 2010). This suggests that maturation of the NCs 
negatively regulates viral replication.  
 
3.6. Rescue system for full-length recombinant MARV 
Rescue systems allow for the generation of full-length recombinant infectious viruses entirely from 
cDNA plasmids. This technic can be used to rescue viruses expressing fluorescence maker 
proteins. These recombinant viruses can then be used as tools to study viral replication cycles and 
open up the possibility for rapid screening assays. Since, it is not possible to introduce specific 
mutations directly into the viral RNA genome , it has to be reverse transcribed into cDNA first. The 
cDNA allows mutations to be made and additional genes to be inserted into the genome (e.g. 
enhanced green fluorescence protein (EGFP); described in the results). The recombinant cDNA of 
the MARV full-length antigenome was cloned into a plasmid under the control of the T7 RNA 
polymerase promoter (Enterlein et al., 2006), and the NC genes are each also under the control of 
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the T7 RNA polymerase promoter. BSR-T7 hamster cells constitutively expressing the T7 RNA 
polymerase are transfected with the plasmid containing the MARV full-length cDNA along with the 
plasmids encoding the four NC protein genes (Fig. 7). To increase the amount of T7 RNA 
polymerase, a plasmid encoding the DNA-dependent T7 RNA polymerase is transfected along with 
the other plasmids. Using the transfected plasmids as templates, the T7 RNA polymerase 
synthesizes  an ssRNA representing the viral antigenome and the mRNAs of the NC protein 
genes. Subsequent translation occurs by the host protein synthesis machinery. MARV full-length 
antigenomes are then replicated by the NC proteins, which results in the generation of the 
negative-sense genome. In turn, the genome serves as a template for RNA replication and 
transcription, leading to viral mRNA production and subsequent protein synthesis. Finally, the 
genome is packaged by the viral proteins and released from the cell as mature infectious particles 
during the budding process.  
 
Fig. 7: The recombinant MARV rescue system. Filovirus-permissive cells are transfected with plasmids encoding the four 
nucleocapsid proteins along with a plasmid encoding full-length MARV cDNA cloned under the control of the T7 RNA 
polymerase promoter. Replication of the antigenome by the NC proteins results in the negative-sense genome. The 
genome serves as a template for replication and transcription, leading to viral mRNA production and subsequent protein 
synthesis. This leads to assembly and release of mature infectious viral particles from the cell. GP: Glycoprotein; VP24: 
Viral protein 24; L: RNA-dependent RNA polymerase; NP: Nucleoprotein; VP35: Viral protein 35; VP30: Viral protein 30; 
T7 pol: T7 RNA polymerase. 
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3.7. Stress response and mRNA silencing 
Virus infections induce stress responses at multiple levels since host cell processes are interrupted 
or co-opted. When cells are exposed to various types of environmental stress, translational 
initiation is reprogrammed to a state of global translational arrest of housekeeping transcripts. This 
process is accompanied by the formation of distinct cytoplasmic structures known as stress 
granules (SGs) and an increased number of processing bodies (PBs) (Fig. 8). Both SGs and PBs 
are multicomponent, compositionally related messenger ribonucleoprotein (mRNP) complexes. 
They cooperatively regulate translation and decay of mRNAs. SGs are compartments of 
translationally silenced mRNPs. In contrast to SGs, PBs not only store mRNAs for subsequent 
translation (Brengues et al., 2005) but also facilitate their degradation (Sheth and Parker, 2003; 
Cougot et al., 2004).  
 
Fig. 8: SGs and PBs in microscopic analyses. (A) U2OS cell line constitutively expressing tagged proteins, ras-GAP SH3 
domain binding protein 1 (G3BP1)-EGFP and mRNA-decapping enzyme 1A (DCP1a)-mRFP, which constitute marker 
proteins for SGs and PBs, respectively. Both tagged proteins (G3BP and DCP1a) exhibited very similar behavior to their 
endogenous counterparts in the parental U2OS cells (Kedersha et al., 2008). The stable cell line was treated with sodium 
arsenite (As), which induces oxidative stress. G3BP-containing SGs (green) and DCP1a-containing PBs (red) can be 
observed in the cytoplasm of As-treated cells. (B and C) SG (B) and PB (C) formation in the cytoplasm of HeLa cells in 
non-treated cells (upper panels) and As-treated cells (lower panels). Analyzed by immunofluorescence staining using an 
antibody-detecting eukaryotic initiation factor (eIF) 3 (SGs) and p54 (PBs) and by EM (from (Souquere et al., 2009). Pm: 
plasma membrane; M: mitochondrion; Nu: nucleus. Scale bars: (A) 200 µm (B) 10 µm, 1 µm and 200 nm for left, middle 
and right (C) 10 mm, 500 nm and 100 nm for left, middle and right panels, respectively. 
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3.7.1 Stress granule assembly  
SGs were first described in tomato cell lines submitted to heat shock (Nover et al., 1983; 1989). 
EM analyses showed that SGs do not have membranes, and their typical dimensions are 1 - 2 µm 
(Souquere et al., 2009) (Fig. 8B). Based on immunofluorescence analysis of SG components, SGs 
are defined as macromolecular aggregates of stalled 48S pre-initiation complexes that form in 
response to stress (Kedersha et al., 1999). Initiation pathways leading to SG formation are shown 
in Figure 9.   
 
Fig. 9: Pathways of SG formation initiation. The best-known pathway for SG formation initiates with the phosphorylation 
of the heterotrimeric eIF2 at its alpha (!) subunit on serine residue 51. The ! subunit is the target of a family of four 
serine or threonine kinases that regulate protein synthesis in response to their activation by different forms of 
environmental stress. The double-stranded (ds) RNA-dependent protein kinase (PKR) is a component of the interferon 
(IFN) response and is commonly activated by RNA viruses producing dsRNA as RNA replication intermediates (Maggi et 
al., 2000). PKR also senses heat, ultraviolet (UV) irradiation and oxidative stress (Williams, 2001). In addition, 
overexpressed PKR is a potent inducer of apoptotic cell death (Gil and Esteban, 2000).  PKR-like endoplasmic reticulum 
(ER) kinase (PERK) is activated by ER stress caused by unfolded proteins in the ER (Shi et al., 1998; Harding et al., 
1999; Harding, Novoa, Zhang, Zeng, Wek, Schapira, and Ron, 2000; Harding, Zhang, Bertolotti, Zeng, and Ron, 2000). 
General control non-derepressible-2 (GCN2) senses amino acid or serum starvation and UV irradiation (Berlanga et al., 
1999). GCN2 is not commonly linked to virus infection, although it has been shown that GCN2 is activated upon binding 
to Sindbis virus genomic RNA (Berlanga et al., 2006). Heme-regulated inhibitor (HRI) monitors changes in the availability 
of heme during erythrocyte differentiation and is activated under conditions of oxidative stress as well as heat shock (Han 
et al., 2001; Lu and Chen, 2002). Phosphorylation of eIF2! by each of these kinases increases the affinity of eIF2 for 
eIF2B, and thereby prevents the exchange of GDP for GTP. By functioning as a competitive inhibitor of eIF2B, phospho-
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eIF2! reduces the availability of the eIF2-GTP-tRNAMet ternary complex, preventing the assembly of the 48S pre-
initiation complex (Srivastava et al., 1998). A phospho-eIF2!-independent stimulus leading to the formation of SGs has 
been observed by the inhibition of the translation initiation factors eIF4G and eIF4A (Bordeleau et al., 2006; Mazroui et 
al., 2006). Both factors belong to the eIF4F protein complex composed of three subunits: eIF4E, the cap binding protein; 
eIF4A, a bidirectional ATP-dependent RNA helicase and eIF4G, a modular scaffolding protein that binds eIF4E, eIF4A, 
eIF3 and PABP1. Under normal conditions the mRNA 5’ cap structure (m7GpppN, where N is any nucleotide) interacts 
with eIF4F. Simultaneous interactions between eIF4G, eIF4E and PABP1 circularize mRNA and promote translation 
initiation (Tarun and Sachs, 1996; Imataka et al., 1998; Kahvejian et al., 2005) Modified from Cell Signaling and 
Kedersha.. 
When the stalled initiation complex is assembled at the 5’ end of polysomal mRNA, actively 
translating ribosomes detach from the transcript, resulting in polysome disassembly. Detachment 
of ribosomes from mRNA transcripts induces actively organized assembly of SGs, containing 
stalled mRNAs in mRNP complexes (Fig. 10) (Kedersha et al., 1999; 2005) (Wek et al., 2006). The 
SG assembly process is mediated by self-aggregation and the RNA binding ability of the 
translational silencer T cell-activated intracellular antigen (TIA) -1 and TIAR due to their prion-
related domain (Kedersha et al., 2002; Gilks et al., 2004). G3BP1 also contains a self-interacting 
and RNA binding domains and contributes to SG formation (Tourrière, 2003).  
 
 
Fig. 10: Formation of SGs and PBs. Modified from White et al., 2012. 
In the work presented here cellular stress was chemically induced by sodium arsenite (As), which 
causes oxidative stress that leads to the phosphorylation of eIF2! through the kinases HRI and 
PKR (McEwen, 2005; Daher et al., 2009)(see 3.7.5 PKR and PACT).  
To induce stress independently of eIF2! phosphorylation, hippuristanol (Hip) was used. Hip is a 
small molecule, discovered by Jerry Pelletier (Bordeleau et al., 2006) that was isolated from the 
coral Isis hippuris. The compound is a selective inhibitor of eIF4A RNA binding activity. eIF4A is a 
DEAD-box RNA helicase that is thought to unwind local secondary structures in the 5’ untranslated 
region of the mRNA to facilitate access of the 43S ribosome complex to the mRNA. As a 
component of the eIF4F complex eIF4A is required for recruitment of the ribosomes to cellular and 
many viral mRNAs (review see (Rogers et al., 2002)). Therefore Hip specifically inhibits eukaryotic 
cap-dependent translational initiation and it can be used to distinguish between modes of 
eIF4A/cap-dependent and independent, such as internal ribosomal entry sites (IRES) translational 
initiation.  
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Depending on their induction, SGs can consist of different components. The major components are 
a non-canonical, translationally silent 48S pre-initiation complex that includes the small (40S) 
ribosomal subunit and a number of early transcription initiation factors such as eIF3, eIF4A, eIF4E, 
and eIFG. SGs also contain mRNAs and a set of RNA binding proteins (RNA-BP) such as TIA-1, 
poly (A)-binding protein 1 (PABP1), human antigen R (HuR) and G3BP1 (Kedersha et al., 1999; 
2005; Mazroui et al., 2006). RNA-BPs regulate mRNA stability, structure and function of transcripts 
as well as translation initiation or silencing. SGs do not contain eIF2 ternary complex and the large 
ribosomal subunit (Kedersha and Anderson, 2002). 
 
3.7.2 Processing body assembly  
Mammalian PBs, like SGs, are dynamic structures constitutively present in the cytoplasm of cells. 
Their number and size increase during stress (Kedersha et al., 2005; Teixeira et al., 2005) and with 
the amount of mRNA to degrade (e.g. accumulation of mRNA by blocking mRNA decay or 
inhibition of translational initiation)(Sheth and Parker, 2003; Cougot et al., 2004; Andrei, 2005; 
Brengues et al., 2005; Wilczynska, 2005) Conversely, blocking transcription, deadenylation of 
mRNAs or translational elongation decreases the size and number of PBs (Sheth and Parker, 
2003; Cougot et al., 2004). The size of PBs ranges between 100-300 nm in mammalian cells 
(Eystathioy et al., 2002; Yang, 2004). Despite the fact that PB assembly is dependent on RNA 
(Cougot et al., 2004; Teixeira et al., 2005) the recruitment of mRNAs to PBs is not simply the 
consequence of not being translated, but rather the effect of an active silencing mechanism. 
Interrupting mRNA translation, which results in mRNAs accumulating in the cytoplasm only induces 
PB formation in the presence of active RNA interference (RNAi) or miRNA silencing pathways 
(Eulalio et al., 2007). 
In eukaryotes, mRNA degradation is regulated by two major mechanisms. One involves the 
multisubunit exosome, where transcripts are degraded by 3’ to 5’ exonucleases (for review see 
(van Hoof and Parker, 1999) The second mechanism involves PBs, which control mRNA turnover 
by the 5’ to 3’ mRNA decay machinery. PBs contain enzymes catalyzing decapping, deadenylation 
and 5’ to 3’ degradation such as the decapping complex DCP1/DCP2 and its cofactors LSm1-7, 
Rck/p54, Hedls/GE-1 (human enhancer of decapping large subunit, also known as GE-1) and the 
exonuclease, Xrn1. The 5’ cap is then irreversibly removed by a decapping complex and the 
mRNA is degraded by the 5’ to 3’ exonuclease Xrn1 (for review see (Eulalio et al., 2007).  
Proteins that function in posttranscriptional gene silencing are also localized in PBs. These include 
(i) proteins involved in nonsense-mediated mRNA decay (NMD) e.g. the Upf complex, which 
degrades mRNAs harboring premature termination codons (Sheth and Parker, 2006); (ii) proteins 
targeting AU-rich element (ARE)-containing mRNAs for decay such as tristetraprolin (TTP) and 
butyrate response factor 1 (BRF1) which both deliver ARE-containing mRNAs to PBs and TTP also 
enhances decapping of target RNAs (Franks and Lykke-Andersen, 2007); (iii) proteins involved in 
RNA interference which silences mRNAs targeted by microRNAs (miRNAs) or small interfering 
RNAs (siRNAs) including Argonaute (Ago) proteins which are part of the RNA-induced silencing 
complex (RISC) (Jakymiw et al., 2005; Liu, 2006). Notably, ribosomal proteins and proteins 
involved in translation initiation are absent in PBs with the exception of the cap-binding protein 
eIF4E and its binding partner eIF4E-transporter (eIF4E-T) (Andrei, 2005; Brengues et al., 2005; 
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Kedersha et al., 2005; Teixeira et al., 2005), suggesting that mRNPs must be free of ribosomes 
and eIFs to assemble into PBs.  
 
3.7.3 Interplay of SGs and PBs  
SGs and PBs are highly dynamic structures of constant mRNP exchange, which has made it 
impossible to isolate them (Mollet et al., 2008). Microscopy analysis is currently the most suitable 
method to study these structures. So far it is not known if SGs and PBs exchange mRNPs or other 
components. However, actively forming SGs are frequently observed next to pre-existing PBs. 
Further contacts can also be established after SG assembly (Fig. 8) (Kedersha et al., 2005; Mollet 
et al., 2008). Live-cell imaging has shown that the interactions between SGs and PBs are dynamic 
and transient (Kedersha et al., 2005; Wilczynska, 2005). Little is known about the mechanism of 
this interaction. Some RNA-BPs including TTP and BRF1 are present in both SG and PBs and 
their overexpression promotes and stabilizes the association between SGs and PBs ((Kedersha et 
al., 2005). Live-cell imaging has revealed a dynamic association between poly-C binding protein 2 
(PCBP2)-enriched PBs and SGs (Fujimura et al., 2008). A dynamic movement of Ago2 to newly 
assembled SGs in addition to PBs was detected by establishing a stably expressing EGFP-Ago2 
cell line (Leung et al., 2006). Further, miRNA was required for Ago2 localization to SGs but not to 
PBs. Fluorescence recovery after photobleaching (FRAP) experiments have revealed that many 
components such as TTP, TIA and G3BP1 cycle rapidly in and out of either PBs or SGs whereas 
others such as DCP1a and Fas-activated serine/threonine phosphatase (FAST) are more static 
(Kedersha et al., 2005; Fujimura et al., 2008). However, EM analyses have revealed discrete 
morphological structures for adjacent SGs and PBs, which do not intermingle (Souquere et al., 
2009). In mammals, SGs and PBs contain many of the same proteins, in particular translational 
repressors such as Ago2, TTP, BRF-1 (Wilczynska, 2005; Yang, 2006; Yang and Bloch, 2007) and 
the transcriptional regulator PCBP2 (Fujimura et al., 2008) a facilitator of IRES-mediated 
translation of both viral and cellular transcripts (Bedard et al., 2004).  
 
3.7.4 Viruses and cellular stress response 
In general, manipulation of SG formation has been described for a number of RNA viruses, 
especially viruses containing either a positive-sense ssRNA genome or a dsRNA genome. Viruses 
exhibit special strategies such as compartmentalization of their replication machinery in order to 
shield viral RNA from recognition by the innate immune system upon release into the cytoplasm.  
For some RNA viruses it has been shown that SG formation is induced upon entry but then 
inhibited at later stages of infection. Mammalian orthoreoviruses, which belong to the dsRNA 
viruses, and Semliki Forest virus, which belongs to the positive-sense RNA alphavirus family, 
induce SG formation in an early stage of infection by inducing eIF2! phosphorylation (McInerney et 
al., 2005; Qin et al., 2009). The induction of SG formation in an eIF2-independent manner has 
been reported for Poliovirus, another positive-sense RNA virus (Mazroui et al., 2006; White et al., 
2007). In each of these cases it has been suggested that increased viral replication and 
subsequent viral protein synthesis is linked to SG inhibition. Poliovirus synthesizes different 
proteases, that mediate cleavage of crucial components needed for SG formation e.g. G3BP1 and 
eIF4G subunits (Gradi et al., 1998; White et al., 2007). 
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Inhibition of SG formation during infection has been observed for segmented negative-sense RNA 
viruses including Junin virus and Influenza A virus. Both viruses block eIF2! phosphorylation either 
directly or upstream in the signaling process (Khaperskyy et al., 2011; Linero et al., 2011). For 
Influenza A virus, it has been shown that the viral protein NS1, a known type I IFN antagonist, 
inhibits PKR activation (Khaperskyy et al., 2011).  
Recent publications suggest that RSV, a negative-sense RNA virus closely related to filoviruses, 
modulates SG function to maximize replication efficiency. However, there are conflicting data on 
the ability of RSV to induce SGs formation in infected cells (Hanley et al., 2010; Lindquist et al., 
2010; 2011). 
 
3.7.5 PKR and PACT 
IFN-induced PKR is part of the innate immune response and crucial for establishing an antiviral 
state in the host cell. The best-studied activator of PKR is dsRNA, which plays a major role in 
activating PKR during viral infections (Hovanessian, 1989; Meurs et al., 1990). Endogenous PKR is 
constitutively expressed in low amounts and mostly monomeric and inactive. Activation of PKR 
leads to its autophosphorylation and subsequently to phosphorylation of its substrate eIF2!, 
leading to translational arrest (see 3.7.1 SG assembly). In addition to its central role in the antiviral 
response, PKR has been implicated in signal transduction pathways triggered by extracellular 
stress (see 3.7.1 SG assembly), specific cytokines, growth factors and dsRNA-induced pathways 
in the inflammatory response (Williams, 1999). Recently it has been reported that PKR can be 
activated independently of dsRNA by binding to PKR-activating protein (PACT) (Fig. 11). Activation 
of PKR by PACT requires exposure of cells to extracellular stress including As treatment, treatment 
with other stressors such as actinomycin D or hydrogen peroxide, andthe withdrawal of growth 
factors (Patel, 2000; Peters et al., 2001). Unlike PKR, PACT is not regulated by IFN or dsRNA 
(Peters et al., 2001).  
 
 
Fig. 11: Model for PKR activation by PACT or dsRNA. In non-stressed cells PACT and TRBP form heterodimers. This 
interaction dissociates upon treatment with different extracellular stresses such as As (Daher et al., 2009). In cells 
exposed to As stress, PACT is phosphorylated at serine residues Ser246 and Ser287 in domain 3 of PACT (recently 
referred to as the Medipal domain) (Peters et al., 2006). The Ser246 residue is constitutively phosphorylated in cells, 
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whereas Ser287 is phosphorylated following the application of stress. However, phosphorylation of Ser287 did not take 
place, in the absence of phosphorylated Ser246, indicating that the constitutive phosphorylation is a requirement for 
Ser287 phosphorylation. Phosphorylation of PACT decreases its interaction with TRBP thereby facilitating its binding to 
PKR with increased affinity (Singh et al., 2011). dsRBM=dsRNA binding domain. Modified from Sen and Peters, 2007 
Considering the critical role of PKR in cellular metabolism, cells have developed mechanisms to 
regulate its activity. Transactivation-responsive (TAR) RNA-binding protein (TRBP) controls the 
PACT-induced activation of PKR and has an opposite role, since direct binding of TRBP to PKR 
prevents PKR autophosphorylation (Benkirane et al., 1997; Gupta, 2003). TRBP was discovered 
due to its high affinity to TAR, an RNA hairpin formed by the HIV genome. PACT and TRBP have 
40% identity at the amino acid level and show a high degree of structural similarity (Patel and Sen, 
1998). Both proteins contain three copies of dsRNA-binding motifs. The two N-terminal copies are 
capable of binding dsRNA and the third C-terminal copy does not bind dsRNA but mediates 
protein-protein interaction with several proteins. For PACT-TRBP interaction all three dsRNA-
binding motifs are required (Laraki et al., 2008). Thus, TRBP regulates the activation of PKR by 
controlling PACTs accessibility to PKR and its inhibitory effect on PKR activation.  
Both, PACT and TRBP interact with Dicer together with the Argonaute proteins in the RISC 
complex. RISC is the effector complex that incorporates and processes miRNA and siRNA 
precursors. miRNAs and siRNAs are derived from hairpin- or dsRNA precursors, respectively, and 
facilitate the silencing process called RNA interference (RNAi). PACT and TRBP depletion leads to 
inhibition of miRNA-mediated gene silencing (Kok et al., 2007).  
 
3.8. EBOV RNA-binding proteins 
EBOV is known to antagonize crucial pathways in the interferon-induced innate immune response. 
Translational arrest in response to cellular stress leads to the formation of cytoplasmic SGs and 
PBs. Since filoviruses depend on the cellular translation apparatus for viral protein synthesis, this 
this represents an important antiviral defense mechanism. EBOV RNA-binding proteins, which are 
potentially involved in the antiviral stress response mediated by the formation of SGs and PBs, are 
described in the following section.  
3.8.1 Inhibition of dsRNA-mediated cellular responses by VP35  
The multifunctional EBOV VP35 plays an essential role in viral replication and is a structural 
component for virus assembly. In addition, VP35 contributes to filoviral immune modulation by 
impairing the host innate immune response. VP35 has been identified as a very efficient type I IFN 
antagonist (Basler et al., 2003; Hartman et al., 2004; Cardenas et al., 2006) (see Fig. 13). IFN 
antagonism is mediated by a C-terminal interferon inhibitory domain (IID), which contains a 
dsRNA-binding domain (Fig. 12).  
 
 
Fig. 12: VP35 IID domain.  
VP35IID was also shown to inhibit PKR-mediated shut down of the host translational machinery 
(Feng et al., 2006; Schumann et al., 2009). IID contains a cluster of basic amino acids involved in 
VP35, excluding an influence of VP35 on mRNA synthesis or
stability.
To assess a potential influence of VP35 on eGFP protein
stability, we analyzed the eGFP decay after the addition of
cycloheximide by quantitative Western blot analysis. As shown
in Fig. 2B, VP35 did not increase eGFP protein stability.
It has been shown before that VP35 is able to interfere with
PKR activity (4). Since PKR regulates translation by phosphor-
FIG. 1. VP35 enhances the expression of cotransfected transgenes. (A) C-terminal region of VP35 containing conserved basic amino acids
involved in dsRNA binding and interferon inhibition. Substituted amino acids in the mutant VP35_3A are indicated. (B) HEK293 cells were
transfected with 50 ng pCMV-GLuc (New England Biolabs), 20 ng pSV40-RLuc (Promega), or 500 ng pRSV-!-Gal along with 500 ng of
pcDNA3.1-VP35/Z_NHA (VP35wt) or the corresponding empty vector (noVP35). Twenty-four hours posttransfection, cells were lysed and
reporter enzyme activity was determined (n " 6). (C and D) HEK293 cells were transfected with 50 ng pCAGGS-eGFP along with 500 ng of
pcDNA3.1-VP35/Z_NHA (VP35wt) or pcDNA3.1-VP35/Z_NHA_3A (VP35_3A) or the corresponding empty vector (noVP35). (C) Twenty-four
hours posttransfection, cells were analyzed by fluorescence microscopy. (D) Fluorescence-activated cell sorter analysis was performed with
trypsinized cells. The mean fluorescence intensity is indicated in the top right corner of each plot. (E) Western blot analysis was performed with
specific primary antibodies against GFP (B-2; Santa Cruz Biotechnology) or !-actin (Abcam) and IRDye800-labeled secondary antibodies
(Rockland). Quantitative readout of the stained membrane was performed with the Odyssey infrared imager (LI-COR). The fluorescence intensity
of the eGFP signal in relation to the actin background was calculated from three independent experiments. (F) Huh7 cells were transfected with
pC-T7/Pol expressing the T7 RNA polymerase, pSV40-RLuc, all components of the EBOV polymerase complex (VP35wt or VP35_3A, NP, VP30,
and L), and the 3E-5E-Luc minigenome containing the firefly luciferase gene flanked by the 3# leader and 5# trailer sequences of the EBOV
genome that regulate viral gene transcription and genome replication. Twenty-four hours posttransfection, firefly luciferase activity was determined
and normalized for Renilla luciferase activity. The data from three independent experiments are shown. VP35 expression was determined by
Western blot analysis with specific antibodies against the hemagglutinin tag (HA.11; Covance) and !-actin.
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dsRNA binding. When three of the basic amino acids were substituted to alanine (R305A, K309A 
and R312A) (VP35-3A) dsRNA binding as well as dsRNA-binding-mediated IFN inhibition were 
abolished (Hartman et al., 2004; Leung et al., 2009; Zhu et al., 2012). Most importantly, VP35-3A is 
not able to antagonize PKR and subsequently eIF2! phosphorylation (Schumann et al., 2009).  
 
Fig. 13: Inhibition of the type I IFN response by EBOV VP35. Transfected filoviral 5’triphosphate ends of the genomic 
RNA can be recognized by RIG-I (Habjan et al., 2008). Activated RIG-I triggers a signal transduction cascade leading to 
the type I IFN response. EBOV VP35 is able to block the induction of the type I IFN response via RIG-I (Cardenas et al., 
2006). VP35 antagonizes the phosphorylation of interferon regulatory factor (IRF) -3/7 by interacting with TBK-1 and 
IKK" kinase domains. Phosphorylation of IRF3/7 by TBK-1/IKK" leads to the dimerization and translocation of IRF3/7 into 
the nucleus where it activates the IFN-β promoter (Basler et al., 2003). VP35 also promotes SUMOylation of IRF-7, 
repressing IFN gene transcription (Chang et al., 2009) and antagonizes PKR activation (Feng et al., 2006; Schumann et 
al., 2009). Modified from Leung et al., 2010. 
Furthermore, the dsRNA-binding activity of VP35IID suppresses the host RNAi pathway (Haasnoot 
et al., 2007; Zhu et al., 2012). More recent studies showed that VP35 interacts with Dicer 
constituents, TRBP and PACT (Fabozzi et al., 2011). Therefore, VP35 potentially targets both the 
RNAi- and PKR-related functions of TRBP and PACT.  
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3.8.2 RNA-binding proteins VP30  
In contrast to VP35, VP30 and NP are not known to interact with the host immune response. They 
are both part of the RNA replication and transcription competent NC (see above: 3.4 Morphology 
and genome structure; 3.5 Replication and transcription) and have been shown to be able to bind 
RNA.  
For VP30, ssRNA-binding activity by an arginine-rich region in the N-terminus has been reported 
but the function of this is not known (John et al., 2007). Phosphorylation of VP30 negatively 
regulates its transcriptional activity but increases its interaction with NP (Modrof et al., 2002; 
Martínez et al., 2008; 2011). The N-terminus of VP30 contains a zinc (Zn)2+-binding Cys3-His 
(CCCH Zn-finger) motif that is required for efficient viral transcription (Weik et al., 2002; Modrof et 
al., 2003). Interestingly, many cellular RNA-BPs that accumulate in SGs also contain this 
unconventional CCCH Zn-finger motif. This motif allows them to interact with and regulate the 
stability of ARE-containing mRNAs, such as interleukin-6 and other cytokines (see above: 3.7.2 PB 
assembly). In addition, VP30 interacts with Dicer and with TRBP in the presence of siRNA 
(Fabozzi et al., 2011). The function of this interaction is not known.  
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3.9. Outline and goals 
Part I: The goal of the work in part I was to generation and characterize a recombinant 
Marburg virus expressing EGFP. To achieve this goal, the following strategy was used: 
1. The cloning strategy was designed for the generation of a cDNA clone encoding the 
recombinant MARV expressing EGFP (rMARV-EGFP) with consideration of the positioning 
of the EGFP ORF near the 3’ end of the viral genome was to maximize the number of 
EGFP transcripts and thereby increase the sensitivity for virus detection. The cloning steps 
were verified on cDNA level by sequencing analysis and the genomic viral RNA level by 
RNA isolation and analysis.  
2. The viral protein expression and growth kinetics of rMARV-EGFP were characterized and 
compared to the wildtype recombinant MARV.  
3. Live-cell imaging was used to analyze the spread of rMARV-EGFP in infected cells. 
4. The data received from live cell imaging analysis of rMARV-EGFP revealed an EGFP 
aggregation at the sites of viral inclusion formation. To further characterize this EGFP 
aggregates, immunofluorescence analysis was used to study the relocalization of several 
fluorescence proteins to MARV, EBOV and RESTV inclusions. 
 
Part II: Filoviruses depend on the cellular translation apparatus for viral protein synthesis. It 
has been shown that EBOV antagonizes crucial pathways in the IFN-induced innate immune 
response. However, it is not known whether EBOV influences the host stress response 
mediated by the formation of SGs. The host stress response to EBOV infection was 
investigated considering the following aims: 
1. It was analyzed by immunofluorescence analysis if SG formation is induced in EBOV-
infected cells.  
2. To investigate if EBOV is able to interfere with the cellular stress response, EBOV-infected 
cells were treated with exogenous stress inducers and the formation of SG was analyzed.  
3. Our data revealed that stress-induced SG formation is reduced in EBOV-infected cells. To 
identify the viral component(s) interfering with the cellular stress reponse, EBOV RNA-
binding proteins NP, VP30, and VP35 were analyzed for their ability to alter a stress-
induced SG formation.  
4. It was examined if EBOV infection affects the stress-induced phosphorylation of PKR and 
eIF2!, which results in translational arrest and the formation of SGs and PBs. PKR is an 
important kinase for sensing viral infection. Phosphorylation of PKR and its substrate eIF2! 
have been shown to be suppressed in EBOV VP35 expressing cells (Hartman et al., 2004; 
Feng et al., 2006; Schumann et al., 2009). 
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5. During cellular stress the activation of PKR is induced by PACT (Patel and Sen, 1998). 
Since, PACT has been show to interact with EBOV VP35 in non-stressed cells (Fabozzi et 
al., 2011), it was analyzed if VP35 and PACT still bind during cellular stress, which 
suggests a possible mechanism for the stress-induced activation of PKR in EBOV infection.   
6. PB formation in EBOV infection was analyzed together with a potential interaction with 
EBOV RNA-binding proteins. PBs are part of the stress-induced translational arrest, which 
in contrast to SGs, can also facilitate mRNA degradation. 
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4. Material and Methods 
4.1. Equipment/Appliances 
Cell culture incubator Thermo Scientific 
Gel Doc 2000 BIO RAD 
Thermostat 5320 Eppendorf AG 
Thermomixer 5436 Eppendorf AG 
Horizontal shaker 3018 Gesellschaft für Labortechnik mbH 
Fastblot Whatman Biometra 
Zeiss Axiovert 200 M inverted microscope  Zeiss 
Zeiss LSM5 Pascal confocal microscope Zeiss 
Zeiss LSM710 confocal microscope  Zeiss 
Miniprotean 3 Western Blot chambers BIO RAD 
 
4.2. Consumables  
10 cm dish (cell culture) Sarstedt 
10 cm dish (bacteria) Sarstedt 
6- and 24-well plates Sarstedt 
Blotting paper (Whatman 3MM) Whatman 
Cryo vials Coring  
Screw cap 1.5 ml vials  Sarstedt 
Polystyrene tube 5 ml, round bottom Falcon 
PCR tubes 0.2 ml Fischer 
Tubes 1.5 ml  Sarstedt 
Tubes 15 ml  Falcon 
Tubes 50 ml Falcon 
Parafilm  Pechney Plastic Packaging 
ImmobilonTM P Membran Millipore 
Pipette tips (different sizes, filter and non-filter) Denville 
Serological pipettes (1 – 25 ml)  Sarstedt 
Cell culture flasks (25 cm2, 75 cm2, 175 cm2) Sarstedt 
GIBCO Leibovitz’s L-15 Medium Invitrogen 
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Chemicals and reagents  
TransIT-LT1  Mirus 
FuGeneHD Roche 
Paraformaldehyde (PFA) 32% Electron Microscopy Sciences 
TRIZOL Invitrogen 
Glycine Boston Bioproducts 
Triton X -100 Boston Bioproducts 
Laemmli 2x (S3401) Sigma  
NP40  IGEPAL 
Sodium Chloride (NaCl)  Boston Bioproducts 
HEPES (1M) Lonza 
Protease Inhibitor Cocktail (P2714-1BTL) Sigma 
Perce Protein A/G Agarose (20422) Thermo Scientific 
Needle: pink 18G1 " 305196, brown sub Q 
305115 
BD Bioscience, USA 
Cell lysis buffer Invitrogen 
Calyculin A  Cell Signaling 
Dithiothreitol (DTT) Fluka Analytical 
Protein marker: dual color (161-0374) BioRad 
PageRuler prestained protein ladder Fermentas 
Stripping buffer GM Biosciences 
Dulbecco’s modified Eagle medium (DMEM)  Lonza 
PBS Lonza 
BSA Atlanta Biologicals 
SDS Boston Bioproducts 
Ethanol (EtOH) Pharma 
TAE (10x) Boston Bioproducts 
Tween 20 Boston Bioproducts 
 
4.3. Kits and Buffer 
Kits 
CalPhosTM mammalian Transfection Kit Clonetech, USA 
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(631312) 
OneStep RT-PCR  Qiagen, Germany 
QIAFilter DNA plasmid Qiagen, Germany 
QIAquick PCR purification Kit Qiagen, Germany 
QIAquick Gel extraction Kit  Qiagen, Germany 
Kits were used according to the suppliers’ protocols if not otherwise indicated.  
 
Buffer 
Buffer for immunofluorescence analysis 
Blocking reagent 20 g BSA 
2 ml Tween 20 
30 ml Glycerin  
5 ml NaN3 (10 % solution)  
add 1 liter PBS  
! filter  
Glycine solution (0.1 M) 3.75 g Glycine 
add 500 ml ddH2O  
Triton solution (0.1%)  0.1 ml Triton X-100  
add 100 ml PBS 
 
Buffer for Western blot analysis 
10% SDS 50 g SDS 
500 ml H2O 
SDS sample buffer (2x) 20 ml Glycerin (50 %)  
5 ml DTT (1M)  
10 ml SDS (10 %)  
4.5 ml Tris-HCl (1 M, pH 6,8)  
1 spatula tip of Bromophenol blue 
RIPA buffer 20 mM Tris-HCl, pH 7.5 
150 mM NaCl  
10 mM EDTA  
0.1% (w/v) SDS  
1% (v/v) Triton X100 
1% (v/v) deoxycholate  
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10 mM iodacetamide 
1.5 M Tris pH 8.8 (SDS separation gel) 181.71 g Tris 
add 1 liter ddH2O 
! adjust to pH 8.8 
1.5 M Tris pH 6.8 (SDS stacking gel) 181.71 g Tris 
add 1 liter ddH2O 
! adjust to pH 6.8 
Protein runnning buffer for SDS-PAGE (10x) 10 g SDS 
30 g Tris 
144 g Glycine 
add 1 liter ddH2O 
Western blot Anode buffer I 36,34 g Tris  
200 ml EtOH 
add 1 liter H20 
Western blot Anode buffer II 3.03 g Tris  
200 ml EtOH 
add 1 liter H20 
Western blot cathode buffer 5,25 g 6-Aminocaproic acid  
3,03 g Tris 200 ml EtOH  
add 1 liter H20 
 
Buffer for Coimmunoprecipitation 
NP40 cell lysis buffer 50mM HEPES pH 7.4  
150mM NaCl 
1% NP40  
 
25 ml (1 M) 
30 ml (2.5 M) 
5 ml 
add 500 ml ddH2O 
NaCl  2.5M 73.05 g 
add 500 ml H2O 
 
4.4. Plasmids and Nucleic acids 
Plasmids 
pMARV (+) (vector: Bluescript) Enterlein et al., 2006 
pMBG-Apa/Sac (vector: Bluescript) Enterlein et al., 2006 
pTM1- MARV NP Mühlberger lab 
Material and Methods 
 
Page  31 
 
pTM1- MARV VP35 Mühlberger lab 
pTM1- MARV L Mühlberger lab 
pTM1- MARV VP30 Mühlberger lab 
pCAGGS-T7 (RNA-dependent DNA T7 
polymerase) 
Mühlberger lab 
pCAGGS-MARV NP Mühlberger lab 
pCAGGS- MARV VP35  Mühlberger lab 
pCAGGS-RESTV NP Mühlberger lab 
pCAGGS-RESTV VP35 Mühlberger lab 
pCAGGS-EGFP Mühlberger lab 
pGFP-250 Garcia-Mata et al., 1999 
pGFP-p50 dynamitin kindly provided by R. B. Vallee 
pCAGGS-EBOV NP  Mühlberger lab 
pCAGGS-EBOV VP30 Mühlberger lab 
pcDNA3.1-EBOV VP35HA Mühlberger lab 
pCK-PACTFlag  Kindly provided by N. Kim (Lee et al., 2006) 
pcDNA3- EBOV VP35-3AHA  Mühlberger lab 
pCAGGS-VP24 EBOV Mühlberger lab 
pCAGGS-GP EBOV Mühlberger lab 
 
Generated plasmids  
rMARV-EGFP (vector: Bluescript) Schmidt et al., 2011 
rMARV-EGFP-KanR (vector: Bluescript)  
rMARV-AvrII (vector: Bluescript)  
rMARV-AvrII-KanR (vector: Bluescript)  
pMBG-Apa/Sac-AvrII (vector: Bluescript)  
 
Primer  
#2070 EGFP-fwd 1 GCAAGGGCGAGGAGCTGTTCACCGGG 
#2071 EGFP-rev 1 GCGGTTCACCAGGGTGTCGCCCTCG 
# 867 EGFP  CAC CCA GTC CGC CCT GAG CAA AGA C 
#122 MARV VP40 NTR GGA CAA TTT AAG TAA CAA TTA A 
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4.5. Enzymes and antibodies 
Restriction enzymes 
AvrII NEB 
ApaI NEB 
SacI NEB 
Eco47III (AfeI) Fermentas 
 
Primary antibodies 
eIF3eta (N-20) goat Santa Cruz Biotechnology 
HuR mouse Santa Cruz Biotechnology 
phospho-PKR (pT446) Rabbit (1120-1) Epitomics  
PKR mouse BD Bioscience 
eIF2! mouse Biosource 
phospho-eIF2! rabbit  Biosource 
#-actin Abcam 
GFP B-2 Santa Cruz Biotechnology 
HA.11 Clone 16B12 mouse (Monoclonal) Covance 
Flag M2 mouse Sigma 
  
rabbit anti-NC MARV antiserum Mühlberger lab 
goat anti-MARV antiserum Mühlberger lab 
goat anti-EBOV antiserum, cross-reacts with 
RESTV NP 
Mühlberger lab 
mouse anti-EBOV VP35 Kindly provided by C. Basler 
mouse anti-EBOV NP Mühlberger lab 
rabbit anti-EBOV VP30 Mühlberger lab 
 
Secondary antibodies 
IRDye800-conjugated donkey anti-mouse Rockland 
Cy3 donkey anti-rabbit Dianova 
FITC donkey anti-mouse Dianova 
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Alexa Fluor 647 donkey anti-rabbit  Invitrogen 
Alexa Fluor 647 goat anti-mouse *highly cross-
adsorbed* 
Invitrogen 
Alexa Fluor 594 donkey anti-goat  Invitrogen 
Alexa Fluor 594 anti-mouse  Invitrogen 
DyLight 594 donkey anti-rabbit Jackson ImmunoResearch 
Alexa Fluor 568 donkey anti-rabbit  Invitrogen 
Alexa Fluor 488 chicken anti-mouse  Invitrogen 
Alexa Fluor 488 goat anti-rabbit  Invitrogen 
Alexa Fluor 350 donkey anti-rabbit  Invitrogen 
 
4.6. Cells and Viruses 
Prokaryotic cell lines  
NEB-10 beta competent E.coli (C3019) NEB 
NEB turbo competent E.coli NEB 
 
Eukaryotic cell lines 
HEK293T cells Mühlberger lab 
HeLa cells Mühlberger lab 
Human epithelial osteosarcoma (U2OS) cells ATCC #HTB-96  
U2OS-derived stable cell lines: U2OS G3BP-
EGFP and U2OS DCP1a-mRFP 
Kindley provided by N. Kedersha Harvard 
Medical School (Kedersha et al, 2008) 
Human fibro sarcoma (HT-1080)  Mühlberger lab 
African green monkey (Cercopithecus aethiops) 
Vero E6 cells (organ: kidney) 
ATCC #CRL-1586 
 
Eukaryotic cell lines were maintained in Dulbecco’s modified Eagle medium (DMEM) 
supplemented with penicillin (P) (50 units/ml), streptomycin (S) (50 mg/ml), L-glutamine (L-Gln) 
and 10% (v/v) fetal calf serum (FCS).  
Viruses 
Marburg marburgvirus (Musoke) Institute for Virology, Marburg 
Zaire ebolavirus (Mayinga isolate) Center of Diseases Control (CDC), Atlanta 
Zaire ebolavirus (Kikwit 95 isolate) NIAID, Rocky Mountain Laboratories, (Hamilton) 
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4.7. Virus work performed under BSL 4 conditions 
The work was performed under Biosafety level (BSL) 4 conditions at the facilities of the Philips 
University Marburg, Germany and at the National Institute of Allergy and Infectious Disease 
(NIAID), Rocky Mountain Laboratories, USA. All virus work was performed in a Biosafety Cabinet 
(BSC) inside the BSL 4 laboratory.  
 
4.7.1 Infection of cells with Ebola virus and Marbrug virus 
The infection of cells with Zaire ebolavirus (EBOV) (Kikwit isolate, 3x106 plaque forming units 
(PFU)/ml) or recombinant EBOV-EGFP (1x107 PFU/ml) at a multiplicity of infection (MOI) of 1 was 
performed at the BSL 4 facility of the NIAID, USA. The infection of cells with recombinant Marburg 
virus (recMARV) or rMARV-EGFP at different MOI (as indicated) was performed by Dr. Schümann 
at the BSL 4 facility of the Philips University Marburg, Germany.  
For infection, the medium of the cells was removed and cells were inoculated with 0.5 ml virus, 
diluted in DMEM supplemented with 2% FCS and incubated for 1 hour at 37 C in a cell incubator. 
After the incubation time the inoculum was replaced by fresh DMEM supplemented with 2% FCS. 
At indicated days post infection (dpi) cells were inactivated according to the following protocol and 
brought out of the BSL 4 facility.  
 
4.7.2 Propagation and isolation of Ebola virus 
Virus stocks were generated for EBOV. 30 – 50% confluent Vero E6 cells, seeded in 175 cm2 cell 
culture flasks were inoculated with 10 ml of a 1:10 dilution of EBOV in DMEM (2% FCS) and 
incubated for 1 hour at 37 C (see infection). After the incubation time, 35 ml DMEM (2% FCS) were 
added and the cells were incubated at 37°C until a cytopathic effect (CPE) was visible (3 – 6 days). 
The virus containing supernatant fluid was then transferred to 50 ml Falcon tubes and centrifuged 
at 5000 rpm for 10 minutes at 4°C, in order to remove cell debris. The supernatant containing 
isolated virus was either stored at 4°C for experiments or further purified and concentrated by 
ultracentrifugation (see 4.7.3).  
 
4.7.3 Purification and concentration of Ebola virus stocks via ultracentrifugation 
Ultracentrifugation was used to concentrate EBOV. Loading and unloading of the aerosol tight 
ultracentrifugation buckets takes place in the BSC. 25 ml supernatant of isolated virus was pipetted 
in each polyallomer ultracentrifugation tube. 5 ml of a 20 % sucrose solution (w/v) was pipetted 
carefully along the wall of the ultracentrifugation tube to underlay the supernatant. Each tube was 
then filled with additional 5 ml of supernatant up to ~ 1 cm underneath the rim of the polyallomer 
tube. All tubes were balanced to less than 0.08 g difference between the tubes using a precision 
scale. The tubes were loaded into the buckets, which are aerosol tight. Then the buckets are 
placed in the rotor and centrifuged at 25000 rpm for 2 hours at 4°C (Beckmann Ultracentrifuge). 
After unloading, the supernatant was removed and each concentrated virus pellet was 
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resuspended in 0.5 ml PBS. Aliquots were frozen at -80°C and then placed in liquid nitrogen for 
long-term storage.  
4.7.4 Determination of virus titer by TCID50  
EBOV titer was determined by using the Tissue Culture Infectious Dose50 (TCID50) assay. This 
endpoint dilution assay quantifies the amount of virus required to produce a CPE in 50% of the 
infected samples. 5x103 Vero E6 cells were seeded in 180 µl DMEM (2 % FCS) per well of a 96 
well plates and infected at a confluence of 30 – 50%. For infection, the medium of the first column 
was replaced by 200 µl of the first virus dilution (dilution 1:1000). Then 20 µl of each well in the first 
column was pipetted to the next column and resuspended with the 180 µl medium in each well of 
the second column. Fresh tips were used for each column to avoid a carry-over of virus at the tip. 
Diluted virus was used in the first four rows and two rows of cells were uninfected and used as 
control. The dilutions were between 10-3 and 10-10. The 96-well plate is incubated at 37°C and 
monitored daily by brightfield microscopy until a pronounced CPE is visible (minimum of 7 days). 
TCID50 was evaluated for the wells showing a CPE and the titer was determined by using the 
Spermann-Kärber method (Hierholzer and Killington, 1996)   
 
4.8. Propagation, isolation and preparation of nucleic acids 
Recombinant plasmid DNA was propagated by DNA transformation in Z-competent bacteria (NEB-
10 beta competent E.coli or NEB turbo competent E.coli). Transformation was performed 
according to the manufacture’s protocol. After bacteria propagation, DNA was isolated form the 
bacteria culture and purified. 
Plasmid preparation  
5 ml (small scale) or 150 ml (large scale) bacteria culture transformed with recombinant plasmid 
DNA was incubated over night at 37°C in a bacteria shaker (~200 rpm). Plasmid DNA preparations 
were performed according to the manufacture’s protocols (Qiagen Miniprep and QIAfilter).  
TRIZOL RNA isolation  
Total RNA form rMARV-EGFP infected cells and supernatant were isolated using TRIZOL reagent 
according to the manufacture’s recommendation. The isolated 20 µl RNA was amplified by reverse 
transcription-PCR. 
Reverse transcription-PCR (RT-PCR) 
RT-PCR is a two-step process in which a specific primer binds to an RNA template flanking the 
region of interest. This region is reverse transcribed to DNA and them amplified. The 20 µl RNA 
was denatured at 65°C for 10 minutes and then immediately transferred and incubated on ice. 2 µl 
RNA was used for the reverse transcription using the OneStep RT-PCR kit from Qiagen. The kit 
has the advantage that the reverse transcription and the PCR are carried out sequentially in one 
process. RT-PCR was carried out according to manufacture’s standard protocol.   
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4.9. Transfection of eukaryotic cell lines 
4.9.1 Lipid based transfection 
For immunofluorescence analysis, cells were grown on glass coverslips in 6-well plates and 
transfected using FuGeneHD (HT1080) and TransIT-LT1 (U2OS cells) according to the supplier’s 
protocols.  
 
4.9.2 Calcium-phosphate transfection 
HEK293T cells were seeded in a 10cm-dish and transfected at a 60% confluence.  
Transfection procedure using the CalPhosTM mammalian Transfection Kit: 
x µl (24 µg) DNA 
62 µl Calcium - solution 
Add 500ul H2O 
 
H2O and DNA were pipetted in a 1.5 ml tube. 62 µl of Calcium solution was added, each sample 
was vortexed immediately.  
The 2x HEPES buffered saline (HBS) was distributed into 500 µl aliquots in sterile 5 ml polystyrene 
tubes. During vortexing, the Calcium-DNA-H2O mix was added drop wise into the swirling 2x HBS 
and then incubated for 20 minutes at room temperature. After the incubation period a sample 
containing a total volume of 1 ml was pipetted drop wise on the HEK293T cells in 15ml 10% FCS 
DMEM supplemented with L-GLN and P/S. After an incubation period of 24 hours the DMEM 
medium was exchanged. At 48h post transfection the samples were harvested.  
 
4.10. Analysis of proteins  
4.10.1 Coimmunoprecipitation (CoIP)  
Harvesting of transfected samples (transfection see above 4.9.2): 
1. 4x 10 cm dishes each: 12 µg pCAGGS-EGFP + 12 µg pcDNA3.1-EBOV-VP35HA 
2. 4x 10 cm dishes each: 12ug pCAGGS-EGFP + 12 µg pCK-PACTFlag 
3. 4x 10 cm dishes each: 12 µg pcDNA3.1-EBOV-VP35HA + 12 µg pCK-PACTFlag  
Transfection (1. – 3.), which was performed in duplicate, were either treated with 2 mM As or left 
untreated and incubated for 30 minutes at 37°C. In addition, two sets (minus and plus As) were 
transfected. One was used for a pull-down using antibodies directed against the HA-tag and one 
was used with antibodies directed against the Flag-tag (see below). Cells were harvested for 
coimmunoprecipitation.  
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Preparation: The protein A/G-coupled agarose beads are stored in an Ethanol solution. Therefore 
they must be washed after removal of the Ethanol. 500 µl aliquots of the protein A/G- coupled 
beads are washed twice in 1000 µl of NP40 buffer plus protease inhibitor cocktail (PI) (dilution 
1:500) by vortexing and centrifugation at full speed in a tabletop centrifuge for 20 seconds to pellet 
the beads. The second time the liquid above was removed, the volume of the beads was estimated 
in order to add the same volume of NP40 buffer plus protease inhibitor cocktail (dilution 1:500), 
resulting in a 50% slurry of beads which can be stored at 4°C.  
 
HEK293T cells (samples 1. – 3.) were harvested on ice. Adherent cells were detached by gently 
pipetting down using 10 ml ice-cold PBS, then transferred to a 15 ml tube. The 15 ml tubes were 
centrifuged at 1000 rpm for 5 minutes at 4°C. The supernatant was discarded and the cell pellet 
was resuspended in 0.5 ml ice-cold PBS, transferred to 1.5 ml tubes and centrifuged at 13000 rpm 
in a tabletop centrifuge for 1 minute at 4°C. The supernatant was discarded and the cells were 
lysed by adding 1 ml of NP40 buffer plus PI (dilution 1:500). This was mixed by vortexing 
vigorously for 45 seconds. Cell lysate was then centrifuged at 13000 rpm for 20-30 minutes in a 
pre-cooled tabletop centrifuge and transferred to a new 1.5 ml tube on ice. An aliquot of 50 µl from 
the whole cell lysate (WCL) was removed and mixed with 50ul of 2-fold Laemmli loading buffer for 
Western blot analysis. 
Binding of antibodies: 
The remaining 950 µl of cell lysate was processed for CoIP by adding 2 µl of either a mouse anti-
Flag antibody or a mouse anti-HA antibody and incubated in an overhead rotator at 4°C over night.  
Binding of protein A/G-coupled beads: 
40 µl of the 50% slurry of beads (see above: preparations) were pipetted into the cell lysate on ice 
and incubated overhead rotating for 2 hours at 4°C. In order to keep the 50% slurry from 
separating, it must be vortexed before pipetting to each sample.  
CoIP: 
After the incubation CoIP samples were washed with 1ml NP40 buffer plus PI (dilution 1:500) on 
ice. Each sample was vortexed vigorously for 30 seconds and subsequently the beads were 
pelleted by centrifugation in a tabletop centrifuge at 13,000 rpm for 20 seconds. The supernatant 
was removed by using a needle (pink, 18G1 " 305196 BD), except for a small volume, which was 
left to not accidently discard the beads.  
After the last washing step all supernatant was removed using a needle (brown, Q 305115 BD), 
which is small enough to not let any beads through. All remaining liquid was removed from the 
beads by holding the needle in the middle of the beads and moving it around. The beads dry and 
turn white. Then 40 µl of the 2-fold Laemmli loading buffer was added to the CoIP samples. The 
CoIP samples and the WCL samples were incubated at 95C for 5 minutes, then vortexed for 2 
seconds and centrifuged in a tabletop centrifuge at full speed for 1 minute. All supernatant of the 
CoIP samples was transferred to a new 1.5 ml tube. The CoIP samples were subsequently 
subjected to Western blot analysis  
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4.11. Western blot analysis of infected and transfected samples 
Harvesting of whole-cell lysates of EBOV infected cells 
Whole-cell lysates of infected samples were prepared. Cells in a 6 well plate were scraped off into 
a 50 µl cell lysis buffer, transferred to a 1.5ml tube, and incubated for 20 minutes on ice. PI and the 
serine/threonine phosphatase inhibitor Calyculin A (0.1 µM) were added to cell lysis buffer prior to 
incubation. During the incubation, samples were mixed by vortexing. After the incubation, cells 
were centrifuged at 14,000 rpm for 10 minutes at 4°C. The supernatant was transferred to a fresh 
1.5 ml tube. EBOV-infected samples were mixed with 50 µl 2x SDS sample buffer and boiled for 10 
minutes before the samples were brought out for Western blot analysis.  
Electrophoresis of proteins  
Binding of SDS to proteins results in a negative charged denatured protein - SDS complex. 
Proteins of different molecular weight can be separated by SDS-polyacrylamide gel electrophoresis 
(SDS-PAGE).  
   Stacking gel   Separation gel 
 4% 10% 12% 
1.5 M Tris pH 8.8  2.5 ml 2.5 ml 
1.5 M Tris pH 6.8 1.25 ml   
H2O 2.9 ml 4.0 ml 3.3 ml 
Polyacrylamide 750 µl 3.3 ml 4 ml 
10 % APS 50 µl 100 µl 100 µl 
TEMED 5 µl 5 µl 5 µl 
Table 1: SDS-gel components 
SDS gels were loaded with samples and run at 140-180 V. 
 
Western blot analysis  
The proteins run in an SDS-PAGE were transferred to a membrane for specific detection using 
antibodies directed against the protein of interest. The membrane was activated by 1 minute 
incubation in 100% MeOH and then incubated in Anode buffer II until the blot was assembled. 
Whatman papers were soaked in either Anode buffer I, II, or Cathode buffer and the blot was 
assembled in the blotting chamber as shown in Figure 14. Transfer by blotting is done by 30 V for 
30 minutes (fast blot).  
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Fig. 14: Western blot set up.  
After blotting, blots were incubated in 5% milk powder for 1 hour and then detected by specific 
antibodies targeting the protein of interest. In between antibody incubations blots were washed 3 
times in TBS supplemented with Tween for 5 minutes.  
Western blot detection was done with horseradish peroxidase-conjugated secondary antibody 
using an enhanced chemiluminescence detection reagent kit (Pierce) according to the 
manufacturer's protocol.  
 
4.12. Immunofluorescence analysis of infected and transfected samples 
At indicated days post infection (dpi) or post transfection (dpt) cells were treated with As or Hip 
(concentration indicated) for 30 minutes at 37°C or left untreated. Virus-infected cells were fixed 
and inactivated for 1 day with 4% PFA (v/v) at 4°C or room temperature. To assure proper 
inactivation the glass cover slips were transferred to a 24 well plate containing fresh 4% PFA (v/v) 
and incubated for another day before being brought out of the BSL 4 facility. After the inactivation 
period, cells were subjected to immunofluorescence analysis. Transfected cells were fixed in 4% 
PFA (v/v) for 20 minutes to 1 hour and subjected to immunofluorescence analysis. 
Permeabilization was either done by acetone/methanol treatment for 5 min at -20°C or by 
treatment with 0.1% (v/v) Triton X100 for 5 min at room temperature. Primary antibodies were 
diluted (as indicated) in 25 µl of blocking reagent and cells on glass cover slips were placed upside 
down in the antibody dilution and incubated for 1 hour (or as indicated) in a wet chamber at room 
temperature. After the incubation, the cells were washed 3 times with PBS and the secondary 
antibody incubation was performed in the same manner as the primary. After incubation of the 
secondary antibodies, the cells were washed 3 times for 10 minutes and mounted with mounting 
solution on glass slides.  
All immunofluorescence analysis imaging was performed using a Zeiss Axiovert 200 M inverted 
microscope at a magnification of 63x (or as indicated). 
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5. Results 
5.1. Generation of a recombinant Marburg virus clone expressing EGFP 
The rMARV-EGFP infection experiments in this part of the results section were performed in 
collaboration with Dr. M. Schümann at the University of Marburg, Germany and resulted in a 
publication (Schmidt et al., 2011).  
The aim of this work was to generate a recombinant Marburg virus (rMARV) containing an 
additional transcription unit (ATU) expressing EGFP that allows for the visualization of MARV 
spread in infected cells by fluorescent microscopy.  
 
5.1.1 Cloning and characterization of the rMARV expressing EGFP 
The following cloning strategy was used for generating the rMARV, which contains an ATU 
expressing EGFP. 
The EGFP ORF was inserted into the intergenic region between the second and the third gene, 
encoding VP35 and VP40, respectively (Fig. 15). The rationale for positioning of the EGFP ORF 
near the 3’ end of the viral genome was to maximize the number of EGFP transcripts and thereby 
increase the sensitivity for virus detection. At the same time, the ratio of the proteins NP and VP35 
(first and second gene in the MARV genome) was not altered because it is known to be critical for 
the replication efficiency in the MARV minigenome system (Muhlberger et al., 1998). To keep the 
protein ratio in balance, EGFP was inserted at the third position instead of the second.  
The pMARV(+) plasmid containing the full-length anti-genomic cDNA of MARV strain Musoke 
(described in (Enterlein et al., 2006; 2009)) was used as a template. First, an additional restriction 
site, AvrII, was inserted into the intergenic region (IR) between the second and the third genes (Fig 
15). The intergenic region spanning 5 nts (CTATG) was mutated by in vitro mutagenesis, 
generating the AvrII restriction site (CCTAGG; inserted or substituted nts are underlined). 
Mutagenesis of the 22,152 kb pMARV(+) plasmid is both difficult and error prone due to its large 
size. Therefore, a shuttle plasmid containing only a part of the MARV genome was used for  
 
 
Fig. 15: Scheme of rMARV-EGFP genome. The EGFP coding sequence is flanked by conserved MARV transcription 
start and stop signals. The EGFP ORF was inserted between the VP35 and VP40 gene via a newly created AvrII 
restriction site within the intergenic region (IR). The intergenic region spanning 5 nts (CTATG) was altered to CCTAGG.   
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insertion of the AvrII recognition site. This pMBG-Apa/Sac plasmid (described in (Enterlein et al., 
2006)) contains a part of the MARV Musoke genome, spanning nucleotides 3919-8991 (GenBank 
accession number DQ217792). This region includes the 3’ end of the VP35 gene, the complete 
VP40 and GP genes, and the 5’ end of the VP30 gene. Following the insertion of the AvrII site, the 
mutated region was cut out of the shuttle plasmid using the enzymes ApaI and SacI, which are 
also present in pMARV(+). This cloning step turned out to be highly inefficient. In order to increase 
efficiency and to successfully select for positive bacteria clones containing the mutated pMARV(+) 
plasmid including the AvrII site, a kanamycin antibiotic resistance gene (KanR) was inserted into 
the AvrII site of the pMBG-Apa/Sac-AvrII shuttle construct. The resulting plasmid pMBG-Apa/Sac-
AvrII-KanR allowed the insertion of the AvrII site into the pMARV(+) using the restriction enzymes 
ApaI and SacI. The kanamycin resistance gene was removed from the rMARV-AvrII-KanR cDNA 
clone by digestion with the AvrII enzyme and subsequent re-ligation. The AvrII site within the 
MARV full-length cDNA clone (rMARV-AvrII) was then used to insert the ATU consisting of the 
EGFP ORF flanked by conserved MARV transcription-start and -stop signals (Fig. 15) and AvrII 
sites. Since this cloning step turned out to be very inefficient as well, the clone selection approach 
described above was used again. The EGFP gene contains a unique restriction site, which is not 
present in the rMARV-AvrII clone. This restriction site, Eco47III, was used to insert the KanR gene 
with flanking Eco47III sites into the EGFP ORF. Then, the EGFP-KanR construct, flanked by AvrII 
sites was cut using the AvrII restriction enzyme and ligated into the rMARV-AvrII plasmid cut with 
AvrII. The rMARV cDNA clone containing EGFP (rMARV-EGFP-KanR) was successfully selected 
taking advantage of the kanamycin resistance. Finally, the KanR gene was removed by digesting 
with Eco47III and re-ligating the rMARV-EGFP cDNA construct.  
 
Detection of recombinant genomes in supernatants and cell lysates of rMARV-EGFP-
infected Vero E6 cells by reverse transcription PCR 
The rMARV containing the EGFP gene (rMARV-EGFP) was successfully rescued by Dr. Olga 
Dolnik under BSL 4 conditions at the Philips University Marburg. To verify stable integration of the 
EGFP gene in the viral genome, total RNA isolated from the supernatant of rMARV-EGFP infected 
Vero E6 cells was harvested. The isolated RNA was subjected to reverse transcription-PCR using 
primers flanking a 362 bp PCR fragment of the EGFP gene (#2070, #2071, for sequence see 
material and methods) (Fig. 16).  
 
Fig. 16: rMARV-EGFP cDNA confirming EGFP insertion. Vero E6 cells were infected with rMARV-EGFP and total RNA 
was isolated from cells and supernatants at 6 days post infection (dpi) using TRIZOL reagent. Cellular RNA from Vero E6 
cells transiently expressing EGFP was used as a positive control. Total RNA was isolated and subjected to reverse 
transcription-PCR. cDNA was the separated on a 1% agarose gel and visualized using ethidiumbromide.  
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RT-PCR was performed using primers binding in the EGFP ORF. Amplification of the PCR 
fragment confirmed that the rMARV-EGFP genome contains the inserted foreign gene (Fig. 16). 
Integration of EGFP in the MARV genome was also confirmed by sequencing the rMARV-EGFP 
plasmid DNA (#867, #122, primer sequences in material and methods).  
Expression of EGFP in cells infected with rMARV-EGFP was analyzed by fluorescence microscopy 
(Fig. 17).  
 
Fig.17: Fluorescence microscopy of rMARV-EGFP-infected cells. 105 Vero E6 cells were infected with rMARV-EGFP at a 
multiplicity of infection (MOI) of 0.05 in a 6-well plate. Living cells were analyzed by phase contrast and fluorescence 
microscopy. Images were collected at 2 and 5 dpi. Bottom panel shows rMARV-EGFP-infected cell at higher 
magnification. Aggregates of EGFP are indicated by an arrow. Images were taken by Dr. M. Schümann. 
Living cells were monitored for EGFP expression. Foci formation of green fluorescent cells was 
initiated at 1-2 dpi without inducing visible cytopathic effects (CPE). The initial signs of CPE were 
observed at 5 dpi, when EGFP was detected in clusters of infected cells (Fig. 17). These data 
show that rMARV-EGFP productively infects susceptible cells and can be used as a sensitive 
marker to visualize virus spread over time. It was observed that the EGFP was not only 
homogeneously distributed in the cytoplasm of the cells but also formed aggregates (Fig. 17, 
arrow). 
 
Comparison of progeny production of recombinant wild-type MARV and rMARV-EGFP 
To assess the replication efficiency of rMARV-EGFP compared to recombinant wild-type virus 
(recMARV; described in (Enterlein et al., 2006; Yi et al., 2011), foci of infected cells were counted 
by fluorescence microscopy (Fig. 18). Progeny virus production of rMARV-EGFP was 
approximately four-fold reduced compared to wild-type virus, indicating a growth restriction of the 
EGFP-expressing recombinant virus. 
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Fig. 18: Virus titration performed by counting foci of infected cells. Supernatants of 
Vero E6 cells infected with recMARV or rMARV-EGFP (MOI=0.05) were collected at 6 
dpi and used for infection of Vero E6 cells seeded on coverslips. At 2 dpi, cells were 
subjected to immunofluorescence analysis. Supernatants collected at 2 and 6 dpi, were 
purified by low-speed centrifugation, and 500 #l of the supernatants were used for 
infection of 105 Vero E6 cells per well of a 6-well plate. At 2 dpi cells were fixed in 4% 
(w/v) paraformaldehyde for at least 24 hours, permeabilized with a mixture of acetone 
and methanol (1:1, v/v) for 5 min at -20°C, and incubated in blocking solution (10% 
(v/v) FCS in PBS++) for 10 min. Staining of infected cells was performed using an 
antiserum directed against MARV-specific nucleocapsid proteins (anti-NC antiserum) 
and an Alexa Fluor 568-conjugated donkey anti-rabbit secondary antibody. Foci of 
infected cells were counted by UV fluorescence microscopy. The experiment was 
performed in triplicate by Dr. M. Schümann. The bars represent mean values including 
standard deviations.  
 
 
To further address the growth restriction shown for rMARV-EGFP, the protein expression of both 
viruses was compared. The viral genes of the detected proteins were located either before or after 
the EGFP-insertion (Fig. 19).  
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Fig. 19: Quantitative Western blot analysis of virus protein and EGFP levels in Vero E6 cells infected with wild-type 
recMARV or rMARV-EGFP. Vero E6 cells were infected as described in Fig. 17. At 2 and 5 dpi, cells were scraped into 
200 #l RIPA buffer and transferred to tubes containing 100 #l 4x protein loading buffer, boiled for 10 minutes and 
subjected to Western blot analysis. For Western blot analysis mouse monoclonal antibodies directed against EGFP (B-2; 
1:5000 dilution), MARV NP (1:5000 dilution), MARV VP40 (1:1000 or 1:5000 dilution), and $-actin (1:10000 dilution) were 
used. IRDye800-conjugated donkey anti-mouse antibody was used as secondary antibody (1:10000 dilution). The 
intensity of the protein bands was quantified using an Odyssey imaging system (LI-COR) and standardized to $-actin. 
Assays were performed in triplicate by Dr. M. Schümann. Standard deviations are shown. 
While viral proteins could be readily detected at 2 dpi, EGFP accumulated to detectable levels only 
at 5 dpi, which might be due to differences in the sensitivity of the antibodies used (Fig. 19). NP 
levels were similar between recMARV and rMARV-EGFP at all time points, whereas VP40 levels 
were reduced in rMARV-EGFP-infected cells at 2 dpi and to a lesser extent at 5 dpi. Since the 
EGFP gene is located downstream of NP and upstream of VP40 gene (Fig. 19), the reduced VP40 
expression in rMARV-EGFP indicates that the presence of the ATU causes a decrease in 
downstream protein expression, which might explain the slightly growth-restricted phenotype of 
rMARV-EGFP. 
 
Cell-to-cell spread of MARV-EGFP observed in live-cell imaging of infected cells  
Live-cell imaging was used to visualize the spread of rMARV-EGFP in cell culture. VeroE6 cells 
were infected with rMARV-EGFP and the cell monolayer was analyzed by collecting EGFP 
fluorescence and phase contrast photomicrographs. Photomicrographs of 25 different positions 
were captured every hour from 1 hpi for a period of 9 days ((Schmidt et al., 2011, supplementary 
movie; Ward et al., 2011). Single infected cells expressing EGFP were observed at 26 hpi. In most 
of the infectious centers, EGFP expression in neighboring cells was detected 20-30 hours later 
with a mean value of 24.6 hours, which correlates with the MARV Musoke replication cycle of 
approximately 21 hours (Muhlberger, 2004). However, in some infectious centers, EGFP 
expression in surrounding cells was observed as late as 48 hpi. Intriguingly, even late in infection, 
EGFP fluorescence was not homogenously distributed throughout the monolayer but restricted to 
individual foci, suggesting that virus spread occurred rather by direct cell-to-cell contact than by 
release of viral particles. Typically, individual infected cells were observed early in infection and 
later on the infection spread to cells in close proximity to the primarily infected cell (Fig. 20 and 
(Schmidt et al., 2011, supplementary movie). In addition, virus spread was promoted by viral 
replication in actively dividing cells (Fig. 20A and (Schmidt et al., 2011, supplementary movie).   
After the first signs of CPE appeared at 5 dpi, the cell monolayer began to disintegrate at 6-7 dpi, 
followed by cell rounding and blebbing of EGFP-expressing cells, which correlates with impending 
cell death (Fig. 20B, arrows).  
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Fig. 20: Time-lapse fluorescent microscopy of rMARV-EGFP spread. Vero E6 cells were infected with rMARV-EGFP at 
an MOI of 0.05 in a #-Dish35mm. At 1 hour post infection (hpi), the inoculum was replaced by GIBCO Leibovitz’s L-15 
Medium containing 20% (v/v) FCS. EGFP fluorescence and phase contrast images were captured every hour for a 
period of 9 days by an inverted fluorescence microscope (DM16000B Leica). (A) Cell division of infected cells. (B) 
Cytopathic effects at late stages of infection. Blebbing cells are indicated by arrows. Time points pi, when images were 
taken, are indicated. Images were taken with a 20x objective. Time-lapse experiment was performed by Dr. M. 
Schümann.  
rMARV-EGFP was successfully rescued and can be used as a tool for live cell imaging, allowing 
the investigation of intracellular dynamic processes during the course of infection. It also provides a 
fast and quantitative readout for antiviral drug screening assays and virus-spread studies.  
 
5.1.2 EGFP accumulates in nucleocapsid protein-derived inclusion bodies 
EGFP accumulation during rMARV-EGFP infection 
Higher magnification of cells infected with rMARV-EGFP revealed that EGFP was not only 
homogenously distributed in the nucleus and in the cytoplasm, but was also observed in 
intracytoplasmic aggregates (see Fig. 17). Since MARV infection leads to the formation of 
inclusions in infected cells, we examined if the EGFP aggregates were colocalized with NC-derived 
inclusions. Therefore, at 2 and 5 dpi, rMARV-EGFP-infected cells were examined by indirect 
immunofluorescence using anti-NC antiserum recognizing the nucleocapsid proteins. EGFP 
autofluorescence was assessed in parallel.  
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Fig.21: Fluorescence microscopy analysis of EGFP and immunohistochemically labeled viral proteins in rMARV-EGFP-
infected cells. Vero E6 cells were infected with rMARV-EGFP and subjected to immunofluorescence analysis at 2 and 5 
dpi. Antibodies are directed against intracellular viral proteins (upper panels) or viral surface proteins (lower panels). 105 
Vero E6 cells per well of a 6-well plate were infected with rMARV-EGFP at a MOI of 0.05. At 2 and 5 dpi, cells were fixed 
in 4% (w/v) paraformaldehyde for at least 24 hours, permeabilized with a mixture of acetone and methanol (1:1, v/v) for 5 
min at -20°C, and incubated in blocking solution (10% (v/v) FCS in PBS++) for 10 min. (A) As primary antibody, a rabbit 
antiserum directed against the nucleocapsid complex of MARV (anti-NC antiserum; 1:100) was used and a Alexa Fluor 
568-conjugated donkey anti-rabbit secondary antibody (1:500 dilution). (B) A goat anti-MARV antiserum (1:500 dilution) 
was used, visualized by using a donkey anti-goat Alexa Fluor 594-labeled antibody (1:500 dilution). In addition, the cells 
were stained with 100 ng/ml 4'-6-diamidino-2-phenylindole (DAPI) for 10 min. Immunofluorescence was performed by Dr. 
M. Schümann. 
Cytoplasmic EGFP aggregates colocalized with MARV-induced inclusions (Fig. 21A). Interestingly, 
immunofluorescence analysis revealed infected cells that were stained with the virus-specific 
Results 
 
Page  47 
 
antiserum but lacked detectable EGFP expression at 5 dpi, indicating that immunodetection using 
virus-specific antibodies is more sensitive than EGFP detection. To exclude the possibility of 
“cross-talk” or non-specific binding of antibodies, rMARV-EGFP-infected cells were stained with a 
goat anti-MARV antiserum that predominantly recognizes the MARV surface protein GP. Surface 
staining of infected cells was observed with the GP-specific antibody (Fig. 21B). However, green 
fluorescent inclusions were also visible (Fig. 21B).  
 
EGFP accumulates in nucleocapsid protein-derived inclusion bodies 
To further investigate the nature of the EGFP-positive viral inclusions, EGFP expression was 
monitored by live cell imaging in the absence or presence of MARV nucleocapsid proteins NP and 
VP35. U2OS cells were used for the transfection experiments because these cells are large and 
flat, resulting in high-quality images. U2OS cells were transfected with 500 ng or 50 ng EGFP 
expression plasmids along with plasmids encoding MARV NP and VP35 genes. When 50 ng of 
EGFP plasmid was used for transfection, EGFP accumulated in the nucleus but was also observed 
in the cytoplasm of transfected cells, where it was concentrated in inclusion-like aggregates 
surrounded by homogenously distributed protein (Fig. 22). 
  
 
Fig. 22: Live-cell imaging of EGFP colocalization with MARV inclusions formed by NP and VP35. U2OS cells were 
transfected with an EGFP expression construct alone or together with 500 ng plasmids DNA encoding MARV NP and 
MARV VP35, as indicated. EGFP autofluorescence is shown in green. Intracytoplasmic EGFP aggregates are indicated 
by arrows. Zeiss Axiovert 200 M inverted microscope was used for live-cell imaging of the transfected cells. Images were 
taken with a 40x objective. 
Cells in which EGFP was not concentrated in intracytoplasmic inclusions were also observed. 
However, since it was not possible to verify the expression of the nucleocapsid proteins in the live-
cell imaging studies, it is not clear if these cells expressed NP and VP35.  When 500 ng of EGFP 
plasmid was used for transfection, it was difficult to distinguish between concentrated EGFP and 
homogeneously distributed EGFP due to the high intensity of overexpressed EGFP. Inclusions 
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were only observed in a few cells with lower EGFP expression (Fig. 22). EGFP inclusions were not 
detected in cells expressing EGFP in the absence of NP and VP35 (Fig. 22, bottom panels). 
 
Driving force for EGFP relocalization  
Next, the distribution of EGFP in transfected cells was analyzed by indirect immunofluorescence. 
Since aggregated EGFP could not be differentiated from the homogenous non-specific distribution 
when 500 ng EGFP plasmid was used for transfection, U2OS cells were transfected with 50 ng 
EGFP plasmid along with plasmids for NP and VP35 (Fig. 23A). As shown in the upper panels of 
Fig. 23A, EGFP was distributed in a punctate pattern and colocalized with intracytoplasmic 
nucleocapsid inclusions. Interestingly, the amount of intracytoplasmic homogenously distributed 
EGFP was reduced compared to the live-cell imaging data, which might be due to fixation and/or 
permeabilization effects, or due to the fact that EGFP is constantly being formed in the live cells, 
leading to limited bleaching. To exclude the possibility of antibody cross-reactivity, antibody 
staining was omitted. Fluorescence analysis revealed that EGFP was distributed in large 
cytoplasmic aggregates (Fig. 23A). In contrast, EGFP was homogenously distributed when 
expressed in the absence of NP and VP35 (Fig. 23A). Additionally, MARV NP and VP35 were 
individually expressed along with EGFP (Fig. 23B). NP-induced inclusion formation was sufficient 
for the relocalization and aggregation of EGFP. While EGFP colocalized with NP inclusions, it was 
homogeneously distributed in cells coexpressing VP35 and EGFP (Fig. 23B). Although the 
expression of VP35 in the absence of NP does not lead to inclusion formation, some VP35 
aggregates were observed in cells expressing VP35 and EGFP. Interestingly EGFP did not 
colocalize with these aggregates (Fig. 23B).  
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Fig. 23: EGFP relocalization to MARV NP-derived inclusions. A. U2OS cells transfected with 50 ng EGFP plasmid along 
with 500 ng NP and 500 ng of VP35 plasmid. Cells were stained using a rabbit antiserum directed against the 
nucleocapsid complex of MARV (anti-NC antiserum; 1:100) or a goat anti-MARV antiserum (1:500 dilution). Antibody 
binding was visualized by using Alexa Fluor 568-conjugated donkey anti-rabbit secondary antibody (1:500) and donkey 
anti-goat Alexa Fluor 594-labeled antibody (dilution 1:500). B. U2OS cells transfected with 50 ng EGFP plasmid along 
with 500 ng of either NP or VP35 plasmid. Rabbit anti-NC antiserum (see A) and anti-rabbit Dylight 594-labed secondary 
antibody (dilution 1:100) were used for staining. U2OS cells were stained with 100 ng/ml 4'-6-diamidino-2-phenylindole 
(DAPI) for 10 min (A and B). 
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EBOV inclusion formation and EGFP 
Next we addressed the question if the observed relocalization of EGFP in virus-derived inclusions 
was specific for MARV or could also be observed with other filovirus species. Therefore, EGFP 
was coexpressed with either Reston ebolavirus (RESTV) or EBOV NP and VP35 proteins. EGFP 
colocalized with both EBOV and RESTV inclusions (Fig. 24A), demonstrating that EGFP 
accumulation in inclusion bodies is not restricted to MARV. These observations were additionally 
verified in samples infected with a rEBOV expressing EGFP from an ATU between the first and the 
second gene in the viral genome (rEBOV-EGFP, kindly provided by H. Ebihara, published in 
(Ebihara et al., 2007)). EGFP expressed in rEBOV-EGFP-infected cells also colocalized with the 
viral inclusions (Fig. 24B). These data demonstrate that EGFP accumulation in inclusion bodies is 
not restricted to MARV but occurs irrespective of filoviral species. 
 
 
Fig. 24: EGFP colocalization with EBOV. (A) Fluorescence microscopy analysis of EGFP coexpressed along with EBOV 
(upper panel) or RESTV (lower panel) NP and VP35 proteins in HT-1080 cells. Cells were subjected to 
immunofluorescence analysis at 1 day post transfection (dpt) using a goat anti-EBOV antiserum (1:500) that cross-reacts 
with RESTV NP. Experiments in A were performed by Dr. M. Schümann. (2) U2OS cells were infected with rEBOV-
EGFP at an MOI of 1. At 1 dpi cells were fixed and subjected to immunofluorescence analysis using a goat antiserum 
directed against EBOV (1:500) and an anti-goat Alexa Fluor 594-labeled secondary antibody for detection.   
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Different fluorescent proteins relocated into the viral inclusions 
To analyze if the association with filovirus inclusions is restricted to EGFP or can also be observed 
with other fluorescent proteins, we expressed MARV NP and VP35 proteins along with various 
fluorescent proteins from a range of different taxa and exhibiting different physico-chemical 
features. As genealogically different proteins, we selected TagRFP and DsRed, which share about 
20% amino acid sequence identity with EGFP (Shaner et al., 2004; Chudakov et al., 2010). In 
addition, the monomeric mCherry derivative of the tetrameric DsRed was included (Shaner et al., 
2004). Intriguingly, each of the fluorescent proteins colocalized with nucleocapsid-derived 
inclusions, when coexpressed with NP and VP35 (Fig. 25).  
 
 
Fig. 25: Accumulation of various coexpressed fluorescence proteins in inclusions induced by MARV NP and VP35. HT-
1080 cells were transfected with 50 ng expression plasmid for TagRFP (red), DsRed (orange), or mCherry (pink) along 
with 500 ng of each MARV NP and VP35. For fluorescence microscopy analysis, samples were stained with either anti-
NC antiserum (green) and DAPI (blue), or DAPI alone (right panels). FP: fluorescent protein. Experiments were 
performed by Dr. M. Schümann.  
Similar to EGFP, fluorescent inclusions were also observed when antibody staining was omitted 
(Fig. 25, right panels). As a control, the examined fluorescent proteins were expressed in the 
absence of NP and VP35 and were found to be homogeneously distributed in the cells (data not 
shown). These data demonstrate furthermore that accumulation of ectopically expressed proteins 
in NP-induced inclusions is not restricted to EGFP but a general feature of fluorescence proteins.  
 
GFP-tagged fusion proteins with altered localization do not colocalize with viral inclusions 
To further analyze the relocation of ectopic fluorescent proteins, it was examined whether 
fluorescence-tagged proteins relocalized to NP-induced inclusions. Therefore, two host proteins 
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fused to GFP were tested for their ability to colocalize with inclusions formed by MARV NP and 
VP35 (Fig. 26).  
 
Fig. 26: Ectopic GFP fusion proteins do not colocalize with viral inclusions. U2OS cells were transfected with plasmids 
encoding MARV NP and VP35HA along with GFP-250, GFP-dynamitin, or EGFP plasmid DNA. MARV inclusions were 
visualized using a rabbit serum directed against the MARV nucleocapsid (1:100) and an anti-rabbit Dylight 594-labled 
secondary antibody (1:100). Nuclei were stained with DAPI (1:2000).  
GFP-250 is a truncated version of the cellular protein p115 (containing the first 252 AS; kindly 
provided by E. Sztul, published in (García-Mata et al., 1999)). It has been shown that GFP-250 is a 
misfolded GFP fusion protein, which accumulates in aggresomes (García-Mata et al., 1999). Cells 
were transfected with GFP-250 plasmid DNA along with MARV NP and VP35. In the transfected 
cells, GFP-250 accumulated in juxtanuclear aggresomes as described in (García-Mata et al., 1999) 
and did not colocalize with NP-derived inclusions (Fig. 26).  
The other fusion protein tested was GFP-dynamitin, which has been shown to block retrograde 
transport along the microtubules (kindly provided by R. B. Vallee). Since aggresome formation is 
dependent on dynein-mediated movement along the microtubules, inhibition of this microtubule 
function leads also to the inhibition of aggresome formation (García-Mata et al., 1999). GFP-
dynamitin was coexpressed with MARV NP and VP35 (Fig. 26). NP-induced inclusion formation 
was observed in the cytoplasm of transfected cells. GFP-dynamitin was found in large aggregates 
in the cytoplasm of the cell, which did not colocalize with MARV inclusions.  
These data show that GFP-tagged proteins, when targeted to specific cellular compartments/sites, 
are not redirected to MARV inclusions, indicating a weak interaction between EGFP and the NP-
induced inclusions that can easily be overcome by specific localization signals.  
Results 
 
Page  53 
 
EGFP antibodies did not penetrate NP-induced inclusions 
It is shown above that ectopically expressed fluorescent proteins relocalized into viral inclusions. 
Thus, it is imaginable that other ubiquitously expressed proteins also relocate but are not detected 
in the NP-derived inclusions via antibody staining. Accordingly, only autofluorescence proteins 
would be detectable inside the inclusions. Therefore, it was analyzed if antibody detection of EGFP 
proteins relocated to the inclusions formed by EBOV NP and VP35 is possible (Fig. 27).  
 
Fig. 27: Antibodies directed against EGFP did not penetrate viral inclusions. U2OS cells were transfected with of 0.5 ug 
EGFP plasmid along with 0.75 ug of each plasmid encoding EBOV NP and VP35HA. A. In immunofluorescence analysis 
VP35HA was detected by a mouse anti-HA antibody (1:500) and an anti-mouse Alexa Fluor 594-labed secondary 
antibody (1:100). B. For immunofluorescence detection of EGFP a mouse anti-GFP antibody (dilution 1:50) was used 
and incubated over night at 4°C. The secondary anti-mouse Alexa Fluor 594-labeled antibody (1:100) was incubated for 
1h at room temperature.  
U2OS cells were transfected with EGFP along with EBOV NP and VP35, which led to the EGFP 
colocalization of EGFP with the viral inclusions as shown in Fig. 27A and described above. 
Antibody staining of the viral inclusions (shown in red) revealed bright rings surrounding the 
inclusions, whereas the inner part was less bright. EGFP autofluorescence did not appear as ring-
like structure. Rather, inclusion-associated EGFP was evenly distributed.  
In parallel, the transfected samples were used for immunofluorescence analysis using an antibody 
directed against EGFP. EGFP autofluorescence is shown in green and antibody staining of EGFP 
in red (Fig. 27B). While EGFP autofluorescence was concentrated in aggregates, antibody-stained 
EGFP was mostly evenly distributed in the cell and did not colocalize with inclusions.  
This indicates that inclusion formation excludes antibody penetration. 
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5.2. Host cell stress response to Ebola virus infection 
An important host antiviral defense mechanism is the stress-induced translational arrest, which is 
often accompanied by the formation of stress granules (SGs) and an increase in the number of 
processing bodies (PBs) present in the cytoplasm of the cell. The eIF2! subunit of the GTP-eIF2-
tRNAMet ternary complex plays a central role in the control of translation. Phosphorylation of eIF2! 
by a small range of kinases leads to an arrest of the translation machinery and to the formation of 
SGs and PBs, containing stalled mRNP bodies. Many viruses including filoviruses depend on the 
cellular translation apparatus for viral protein synthesis and an increased yield of viral proteins. 
Therefore, phosphorylation of eIF2! is an effective antiviral defense mechanism to which viruses 
have evolved a certain level of tolerance.  
The oxidative stressor sodium arsenite (As) externally induces eIF2! phosphorylation by the 
activation of the kinases PKR and HRI, resulting in SG formation.  
This work focuses on the question of whether Zaire ebolavirus (EBOV) infection has an influence 
on the host cell stress response mediated by the formation of SGs and PBs. 
  
5.2.1 Modulation of eIF3-containing SG formation in EBOV infection  
SG formation in EBOV infection was examined using Vero E6 cells, which are commonly used to 
investigate the cellular response to filovirus infection.  
Vero E6 cells were infected with EBOV and subjected to immunofluorescence analysis (Fig. 28A). 
Cells were examined for SG formation using an antibody against endogenous eukaryotic initiation 
factor 3 (eIF3), a SG marker protein in the cytoplasm. In EBOV-infected cells eIF3-containing SGs 
were not observed (Fig. 28A). This raised the question if the formation of eIF3-containing SGs 
were inhibited during EBOV infection. Therefore, SG formation was induced in EBOV-infected cells 
using As-mediated stress (Fig. 28B). In non-infected Vero cells, formation of eIF3-containing SGs 
was observed in almost all cells after As treatment (Fig. 28B). In EBOV-infected cells, SGs induced 
by As seemed to be reduced in number compared to the non-infected cells. 
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Fig. 28: SG formation in EBOV-infected Vero E6 cells. Vero E6 cells were infected with EBOV at a high MOI.  At 18 hpi 
Vero E6 cells were left untreated (A) or treated with As (2.5 mM) (B) and subjected to immunofluorescence analysis. 
(EBOV infection was detected using a monoclonal antibody directed against NP (dilution 1:15) and an anti-mouse FITC 
(dilution 1:100) antibody. SG formation was visualized using a goat antibody staining against endogenous eIF3 (dilution 
1:50) and an anti-goat Alexa Fluor 594-labled secondary antibody (dilution 1:100). Nuclei were stained using DAPI 
(1:200). 
 
In order to quantify SG formation, the number of EBOV-infected and non-infected cells containing 
As-induced SGs was determined (Fig. 29). 
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Fig. 29: Reduced number of cells forming eIF3-positive SGs in EBOV infection in the presence of As. Vero E6 cells were 
infected with EBOV at a low MOI or a high MOI and harvested at 18 hpi (high MOI) or 3 dpi (low MOI). Two different virus 
preparations were used for the infection with supernatant harvested from EBOV-infected Vero E6 cells. Cells were 
treated with As (2.5 mM) and harvested for immunofluorescence analysis (for antibody staining see Fig. 28). SG 
formation was analyzed for a total number of 400 of either the infected or the non-infected. 
The cells infected with a low MOI were fixed at 3 dpi. The infection rate was 53%. 
Immunofluorescence analysis revealed formation of eIF3-containing SGs in 89% of the examined 
non-infected, treated cells. Compared to the non-infected cells, the ability to form eIF3-positive 
SGs was substantially reduced in EBOV-infected cells. In EBOV infection, SG formation was 
reduced in both the infected and non-infected cells; only 15% of the EBOV-infected cells and 25% 
of the non-infected cells showed formation of eIF3-positive SGs (Fig. 29). 
When the infection was performed at a high MOI, EBOV-infected and non-infected cells were 
harvested at 18 hpi and analyzed by immunofluorescence. The infection rate was 96%. 57% of the 
non-infected, treated cells formed SGs compared to 19% of the EBOV-infected, treated cells (Fig. 
29).  
Using the eIF3 antibody for detection, formation of endogenous SGs was not observed in EBOV-
infected Vero E6 cells. After treatment with As, SGs were detected in EBOV-infected cells albeit in 
a reduced number of cells compared to the non-infected cells. This indicates that EBOV is able to 
partially inhibit As-induced SG formation.  
 
5.2.2 U2OS cell line expressing the SG marker protein G3BP was used to analyze the 
role of SGs in EBOV infection  
The dynamic structure of SGs makes it impossible to isolate them. Therefore microscopy analysis 
was used to examine if cellular stress responses play a role during EBOV infection. This analysis 
required cells that were both suitable for immunofluorescence analysis and for studying the host 
stress response to EBOV. The Vero E6 cell line was not well suited for the experiments since it is a 
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non-human cell line and difficulties using the eIF3 antibody were experienced as it exhibited an 
unreliable staining. This might be due to the nature of the eIF3 complex which is composed of at 
least 11 protein subunits, some of which are present in distinct eIF3 subcomplexes (Zhou et al., 
2005). A human epithelial osteosarcoma (U2OS) cell line was used after testing the cells for their 
suitability by establishing protocols for EBOV infection and transfection. The U2OS cell line is used 
extensively for studies of SG formation because the cells exhibit a large and flat morphology, which 
is crucial for immunofluorescence observation and quality imaging of the cytoplasm of single cells. 
In addition, it expresses wildtype p53 and has the ability to undergo cell cycle arrest on serum 
withdrawal. U2OS cell line expressing the SG marker proteins G3BP were kindly provided by N. 
Kedersha (detailed protocol for cell line generation in (Kedersha et al., 2008). 
To analyze SG formation, U2OS cells stably expressing an EGFP-tagged SG marker protein, ras-
GAP SH3 domain binding protein 1 (G3BP), were used (U2OS G3BP-EGFP cells; Fig. 30). Similar 
to the endogenous G3BP, the tagged version of the protein is located in G3BP-positive SGs after 
treatment with As or other stress inducers (Kedersha et al., 2008).  
 
Fig. 30: U2OS cell line expressing an SG marker protein. The different U2OS cell lines were treated with 2mM As or 1µM 
Hip for 30 minutes. In the parental U2OS cell line SG formation was detected using a goat anti-eIF3 antibody (dilution 
1:50) or a mouse anti-HuR (dilution 1:10) antibody, incubated over night at 4°C. The stably expressed EGFP-tagged 
G3BP was detected by autofluorescence.  
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The U2OS parental cell line was used to analyze endogenous SG marker proteins by 
immunofluorescence antibody staining (Fig 30). To confirm formation of SGs in the two cell lines, 
cells were treated with either As or hippuristanol (Hip). In contrast to As, Hip leads to SG formation 
by inhibiting eIF4A-dependent translation initiation, a process, which does not involve 
phosphorylation of eIF2!. While G3BP-EGFP was homogeneously distributed in the cytoplasm of 
untreated cells, treatment with As or Hip resulted in formation of G3BP-positive SGs in the 
cytoplasm of G3BP-EGFP-expressing cells (Fig 30). Both eIF3 and human antigen R (HuR) were 
redistributed in SGs in the parental U2OS cells after As treatment. Hip-induced SGs that formed in 
U2OS cells were not detectable using the eIF3 antibody, suggesting that these SGs did not contain 
eIF3 or the eIF3 subcomplex (Fig. 30). However, SGs were detected by using an antibody directed 
against HuR, confirming that Hip-induced SGs were formed.  
 
5.2.3 Stress response in EBOV-infected U2OS G3BP-EGFP cells  
The U2OS G3BP-EGFP cell line was used to further analyze SG formation during EBOV infection. 
Since As-treatment induces SG formation in a phospho-eIF2!-dependent manner, the question 
arose of whether the observed inhibition of SGs by EBOV is due to the ability of EBOV to block 
PKR-mediated phosphorylation of eIF2!. Therefore, EBOV-infected cells were either treated with 
As or Hip. 
An overview of U2OS G3BP-EGFP cells infected with EBOV and either treated with As or Hip is 
shown in Figure 31. Most intriguingly, G3BP-EGFP-positive granules accumulated in viral 
inclusions, which are shown in red. The accumulation of G3BP granules in the viral inclusions was 
observed in treated and in non-treated cells. In non-treated cells infected with EBOV, these G3BP 
granules were completely restricted to the viral inclusions and not found in the cytoplasm of the cell 
(Fig. 31, 1st panel). 
Cytoplasmic G3BP-EGFP-containing SGs were observed in EBOV-infected and non-infected cells 
after treatment with As or Hip. SG formation seemed to be impaired in some of the As-treated 
infected cells as reflected by the diffuse distribution of G3BP-EGFP in the cytoplasm (Fig. 31, 2nd 
panel, arrow). Nevertheless, G3BP granules accumulated in the viral inclusions in these cells, 
indicating that the absence of SGs in the cytoplasm was not due to a lack of G3BP-EGFP 
expression. In many infected cells treated with As, SGs were observed in the cytoplasm. In Hip-
treated cells, impaired SG formation was not observed in the infected cells (Fig. 31, 3rd panel).  
In general, a larger number of EBOV-infected cells formed G3BP-EGFP-containing SGs compared 
to EBOV-infected Vero cells stained for endogenous eIF3 (see discussion). 
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Fig. 31: 2x105 G3BP-EGFP cells seeded on glass cover slips were infected with EBOV (Kikwit isolate) at an MOI of 1. At 
2 dpi, cells were treated with As (2 mM) or Hip (1 µM). Cells were subjected to immunofluorescence analysis using a 
rabbit anti-VP30 antibody (1:100) or the mouse anti-VP35 antibody (1:400). As secondary antibodies mouse or rabbit 
Alexa Fluor 594-labeled (1:500) antibodies were used. Images were taken using a confocal microscope (Zeiss LSM710).  
A wide range of interactions between EBOV inclusions and G3BP-EGFP aggregates were 
observed in treated as well as in non-treated cells indicating a highly dynamic interaction process. 
Therefore a representative spectrum of EBOV-infected cells is depicted in Figure 32. Images from 
left to right show early stages of virus inclusion formation on the left and later stage inclusions on 
the right (Fig. 32).  
 
Fig. 32: Spectrum of interactions of EBOV viral inclusions with G3BP-EGFP aggregates in EBOV-infected cells. For 
immunofluorescence labeling see Fig. 31.  
SG formation in the cytoplasm of the infected cells was negatively correlated with the size of the 
viral inclusions. Thus, in cells containing large viral inclusions, SG formation was reduced 
compared to cells containing smaller inclusions.  
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In contrast, G3BP-containg SG-like aggregates within the viral inclusion were observed at all 
stages of viral inclusion formation. Remarkably, G3BP-EGFP aggregates observed within the viral 
inclusions looked different from the cytoplasmic SGs, since they were aggregated but not as 
round-shaped compared to the cytoplasmic stress-induced SGs.  
To determine if viral inclusion formation itself is sufficient for the aggregation of G3BP-granules 
within the inclusions, inclusion formation was induced by the expression of EBOV proteins. NP, 
which is the driving force for inclusion formation, was expressed in cells along with different 
combinations of EBOV nucleocapsid proteins. Since VP24 has been shown to be part of the 
nucleocapsid complex and crucial for viral inclusion formation (Huang et al., 2002), it was included 
in this study. The transfected cells were either left untreated or treated with either As or Hip (as 
indicated). G3BP-granule formation in transfected and infected cells was compared using confocal 
microscopy (Fig. 33).   
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Fig. 33: Comparison of EBOV-infected G3BP-EGFP cells with cells expressing EBOV-derived proteins involved in 
inclusion formation. The images of EBOV-infected cells are derived from the same samples shown in Fig. 31. G3BP-
EGFP cells were transfected with 0.75 µg of each plasmid DNA encoding the EBOV nucleocapsid proteins (as 
indicated). At 2 dpt cells were (A) left untreated, (B) treated with As (2mM), or (C) treated with Hip (1 µM). The samples 
were stained using the same antibodies and concentrations as described in Fig. 31 (EBOV-infected samples). Images of 
the transfected cells were taken using a confocal microscope (Zeiss LSM5 Pascal).  
In non-treated transfected cells expressing NP and VP35, G3BP-EGFP was homogeneously 
distributed, but the EGFP autofluorescence diffusely colocalized with NP-induced inclusions (Fig. 
33A). This interaction might be unspecific, since it has been observed that ectopic fluorescence 
proteins relocated to NP-derived inclusions (see part I). Nevertheless, formation of G3BP-EGFP 
aggregates was not observed in transfected cells, whereas almost all of the EBOV-infected cells 
contained G3BP granules inside the viral inclusions. This indicates that the EGFP portion of G3BP-
EGFP did not mediate formation of G3BP-EGFP granules in the viral inclusions (see discussion). 
As treatment led to the formation of SGs in the cytoplasm of transfected cells and partially in 
EBOV-infected cells (Fig. 33B). Transfection of NP and VP35 resulted in inclusion formation in the 
cytoplasm of the cell. In contrast to EBOV-infected cells, G3BP-containing SG-like granules were 
not observed inside of the inclusions. G3BP-EGFP-positive SGs were frequently observed in close 
proximity to the NP-induced inclusions but did not intermingle (Fig. 33B, arrowheads). This 
indicates a recruitment of SGs to the inclusions. In cells transfected with NP, VP35, VP30, and 
VP24, viral inclusions appeared more diffuse and were occasionally surrounded by SGs but never 
colocalized with them. In addition, As-induced SG formation was never impaired in the transfected 
cells, which is different to the observation made for the As-treated EBOV-infected cells. 
Transfected cells treated with Hip did not show a significant difference to As-treated transfected 
cells (Fig. 33C/B).  
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The diffuse colocalization of G3BP-EGFP with NP-derived inclusions observed in transfected cells 
(described for Fig. 33A) was most apparent in non-treated cells. After treatment with As or Hip, 
G3BP-EGFP was mostly observed inside of SGs.  
In conclusion, accumulation of G3BP granules within viral inclusions of treated and non-treated 
cells suggests a mechanism of EBOV to interfere with SG components by protein sequestration. In 
addition, the size of the viral inclusion did not seem to influence the aggregation of G3BP. To date, 
it is not known if cellular components play a role in EBOV inclusion formation or if inclusions are 
utilized to sequester potentially antiviral cellular components. 
The impaired G3BP-containing SG formation in some As-treated but not in Hip-treated cells 
suggests a reduced ability to form SGs in response to phospho-eIF2!-mediated stress in EBOV-
infected cells. This inhibition seemed to be dependent on the size of the viral inclusions, 
suggesting that a certain level of viral protein expression is important for the inhibition. 
Nevertheless, inclusion formation induced by the expression of nucleocapsid proteins was not 
sufficient for the accumulation of G3BP granules inside the inclusions or for the inhibition of SG 
formation observed in infected cells.  
These results suggest that EBOV exhibits control strategies at the level of SG formation.  
 
5.2.4 Impact of EBOV proteins on SG formation 
To further analyze how EBOV interacts with SGs, EBOV proteins were examined for their ability to 
interfere with SG formation. The three NC proteins, NP, VP35 and VP30 represent promising 
candidates since all of them play a role in viral replication, are involved in NC formation, and 
furthermore are RNA-binding proteins. The viral glycoprotein, GP, was used as a control. As a 
surface protein, GP is not located in the cytoplasm but at the cell membrane, in the ER, and in the 
Golgi apparatus. SG formation was initiated by treatment with the external stressor As that leads to 
phosphorylation of eIF2!.  
Expression of NP in the absence of other viral proteins results in the formation of inclusions, similar 
to those found in infected cells but less structured. In addition, NP forms loose coil-like helices that 
are distinct from the condensed ones in the viral NCs (Huang et al., 2002; Noda et al., 2006; 
Watanabe et al., 2007; Noda et al., 2010; Bharat et al., 2012).  
In the absence of external stressors, G3BP-EGFP was mostly homogenously distributed 
throughout the cytoplasm (Fig. 34A). G3BP-EGFP was also observed at the sites of NP-derived 
inclusion formation. As discussed above, this colocalization might be unspecific and not due to a 
direct interaction between NP and G3BP. After treatment with As, G3BP-EGFP mostly relocated 
into SGs, but a small moiety also colocalized with the NP-derived inclusions (Fig. 34A). SGs were 
observed in close proximity, and often surrounding, NP-derived inclusions, which was similar to 
observations made for cells expressing NP and VP35 (see Fig. 33). However, NP never 
colocalized with SGs and SG formation was not impaired by the expression of NP.  
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Fig. 34: Impact of EBOV proteins on SG formation in the U2OS G3BP-EGFP cell line. G3BP-EGFP cells were 
transfected with expression plasmids encoding different EBOV proteins. (A) Cells were transfected with 0.75 µg NP 
expression plasmid (plus 0.75 µg pC-empty vector), treated with As (2mM) at 24 hpt and subjected to 
immunofluorescence using a monoclonal mouse NP antibody (B6C5 97, dilution 1:10). Antibody binding was visualized 
by using an Alexa Fluor 647-conjungated goat anti-mouse antibody (dilution 1:100). (B) Cells were transfected with 1 µg 
VP30 expression plasmid and treated with As (2 mM) at 48 hpt. VP30 expression was detected using a rabbit anti-VP30 
antibody (dilution 1:100) and for visualization an anti-rabbit Cy3 (dilution 1:100). (C) 0.75 µg EBOV VP35HA plasmid DNA 
(plus 0.75 µg pC-empty vector) was transfected and cells were treated with As (2mM) at 24 hpt. VP35HA expression was 
detected using a mouse anti-HA antibody (dilution 1:500) and an anti-mouse Alexa Fluor 647-conjungated secondary 
antibody (dilution 1:100). (D) 1 µg of the GP expression plasmid was transfected along with 1 µg VP30 (not depicted) and 
cells were treated with As (2 mM) at 24 hpt. GP was visualized using a goat anti-EBOV antiserum (dilution 1:750) and an 
ultraviolet-excitable anti-goat Alexa Fluor 350 secondary antibody (dilution 1:100).  
The next protein analyzed was VP30 (Fig. 34B). VP30 has previously been shown to bind ssRNA, 
(John et al., 2007). VP30 contains an unconventional CCCH Zn-finger motif that is required for 
efficient viral transcription ((Weik et al., 2002; Modrof et al., 2003). Many cellular RNA-binding 
proteins that accumulate in SGs also contain this unconventional domain, which allows them to 
interact and regulate mRNA stability.  
VP30 and G3BP-EGFP were both homogenously distributed in the cytoplasm of non-treated cells 
(Fig. 34B). When As-stress was applied, G3BP-EGFP relocated into SGs. VP30 was partially 
homogenously distributed but also relocated and colocalized with the SGs (Fig. 34B). SG formation 
did not seem to be impaired in VP30-transfected cells. 
The effect of VP35 expression on SG formation was examined next. The multifunctional VP35 
protein is a crucial virulence factor that blocks the host innate immune response and RNA silencing 
pathways, which are important in context of SG formation (reviewed in (Ramanan et al., 2011)). 
VP35 formed patch-like structures in the cytoplasm of non-treated cells, whereas G3BP-EGFP was 
homogenously distributed (Fig. 34C). As treatment led to SG formation and a distinct redistribution 
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of VP35, which colocalized with SGs (Fig. 34C). Interestingly, SG formation seemed to be 
influenced by the expression of VP35 in the G3BP-EGFP cell line, which will be analyzed in more 
detail (see below).  
The non-cytoplasmic GP was predicted to not colocalize with SGs. GP was found to locate mostly 
to the cell membrane and around the nucleus rather than in close proximity to SGs (Fig. 34D). This 
distribution did not change after As treatment.  
Since GP did not interact with SGs, it was not further examined. The observed interaction between 
SGs and the EBOV RNA-binding NC proteins NP, VP30, and VP35 was analyzed in more detail.  
 
Interaction of NP-derived viral inclusions with SGs  
It was analyzed if Hip-induced and As-induced SGs show a different pattern of interaction with NP 
in the G3BP-EGFP cell line. After Hip treatment, SG formation was observed and formation of NP-
derived inclusions was not impaired by the treatment (Fig. 35). SGs were located in close proximity 
to NP-derived inclusions, similar to the observation made for As-treated cells. This suggests that 
NP-derived inclusions relocate SGs to the sites of inclusion formation.  
NP was never observed in colocalization with As- or Hip-derived SGs. This indicates that NP does 
not relocate into SGs induced by As or Hip. As shown above, the colocalization of diffusely 
distributed G3BP-EGFP with NP-derived inclusions was more abundant in non-treated cells (Fig. 
35, insert) but also visible in As and Hip-treated cells (Fig. 35, inserts). 
  
 
Fig. 35: Interaction of NP-derived inclusions with G3BP-containing SGs. G3BP-EGFP cells were transfected with 0.75 µg 
NP expression plasmid (plus 0.75 µg pC-empty vector). At 24 hpt, cells were treated with As (2mM) or Hip (1 µM) and 
stained using a monoclonal mouse NP antibody (B6C5 97, 1:10) and a secondary anti-mouse Alexa Fluor 647-labeled 
antibody (1:100).  
Interaction of VP30 and SGs 
To further analyze the effects of VP30 on SG formation, VP30 was expressed in G3BP-EGFP-
containing cells and subsequently treated with either As or Hip. In the absence of external 
stressors, G3BP-EGFP was homogenously distributed in the cytoplasm. It aggregated into SGs 
when either As or Hip was applied (Fig. 36). In As and Hip-treated cells, a fraction of the otherwise 
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homogeneously distributed VP30 accumulated in aggregates colocalizing with G3BP-EGFP SGs 
(Fig. 36). However, the interaction with VP30 did not seem to influence the formation or distribution 
of the G3BP-containing SGs.  
 
 
Fig. 36: Colocalization of EBOV VP30 with G3BP-EGFP-containing SGs. U2OS G3BP-EGFP cells were transfected with 
1 µg VP30 plasmid DNA. At 48 hpt, cells were treated with As (2 mM) or Hip (1 µM) and subjected to 
immunofluorescence analysis using an antibody directed against EBOV VP30 (rabbit anti-VP30, dilution 1:100) and for 
visualization an anti-rabbit Cy3 (dilution 1:100). Experiment was performed n=5 and representative images were chosen. 
To confirm the colocalization of VP30 and G3BP-EGFP, VP30-expressing cells treated with Hip 
were examined by confocal microscopy (Fig. 37). A set of images was captured axial throughout 
the sample (z-stack) in order to ensure that SGs residing outside of the focal plane were accounted 
for. The single image of confocal z-stack depicted in Figure 37A was then used for intensity 
measurements of the different wavelengths within the G3BP-EGFP-containing SGs of VP30-
expressing cells and cells in which VP30 was not expressed (Fig. 37B). 
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Fig. 37: Confirmation of the colocalization of VP30 and G3BP-EGFP-containing SGs by confocal microscopy. U2OS 
G3BP-EGFP cells were transfected with a plasmid expressing VP30 and analyzed by immunofluorescence staining (see 
Fig. 36). (A) Single image of captured z-stack by confocal microscopy (Olympus FV1000) used for colocalization 
analysis. (B) VP30 localization to G3BP-EGFP-positive SGs was detected by line scans within the image. Fluorescence 
intensities were plotted measuring G3BP-EGFP in SGs of untransfected cells (line 1) and in VP30-transfected cells (line 
2).  
In VP30-expressing cells, two distinct but overlapping peaks were measured (Fig. 37B, line 2), 
whereas in the absence of VP30 only the EGFP emission peak was detected (Fig. 37B, line 1). 
This confirmed the close proximity of VP30 and the G3BP-EGFP-containing SGs.  
 
Interaction of VP30 and SGs when coexpressed with NP 
NP interacts with VP30, leading to the relocalization of VP30 into NP-derived inclusion. To analyze 
if NP has an influence on the observed colocalization of VP30 with SGs, VP30 was coexpressed 
with NP in G3BP-EGFP-expressing cells (Fig. 38).  
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 Fig. 38: Relocation of VP30 in the presence of NP. The U2OS G3BP-EGFP cell line was transfected with 1 µg VP30 
expression plasmid along with 1 µg of the EBOV NP plasmid. At 24 hpt, cells were treated with As (2 mM) and subjected 
to immunofluorescence staining. NP was detected using an anti-EBOV antiserum (goat anti-EBOV serum, dilution 1:750) 
and a donkey anti-goat Alexa Fluor 594-labeled antibody (dilution 1:100). VP30 was detected using a rabbit-VP30 
antibody (dilution 1:100) and, as secondary antibodies, an ultraviolet-excitable anti-rabbit Alexa Fluor 350-labeled 
antibody (1:100) was used. 
Expression of VP30 along with NP led to the relocalization of VP30 into viral inclusions formed by 
NP. NP and VP30 colocalized in untreated and As-treated cells (Fig. 38). As described above for 
NP-VP35 inclusions (Fig. 33), G3BP-EGFP colocalized with NP-VP30 inclusions in untreated cells, 
although most of the protein was homogenously distributed in the cytoplasm (Fig. 38). In As-
stressed cells, SGs were shown to be in close contact with the NP-VP30 inclusions (Fig. 38). 
Neither NP nor VP30 were observed at the site of SG formation.  
Figure 39 shows a cell, which formed large NP-VP30 inclusions. Formation of large inclusions is 
most likely due to large quantities of expressed viral proteins. Interestingly, a different viral protein 
distribution was observed in cells containing large viral inclusions. A small moiety of VP30 that was 
not relocalized in NP inclusions colocalized with the SGs (Fig. 39, detail view, arrows).  
 
 
Fig. 39: Interaction of VP30 with SGs in the presence of NP. For transfection and immunofluorescence staining 
procedure see Fig. 38.  
Antibody staining of VP30 and NP revealed a ring-like pattern around the inclusions, which 
furthermore colocalized with the G3BP-EGFP autofluorescence (Fig. 39). This was often observed 
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for large inclusions, suggesting that the antibodies were not able to penetrate the inclusions 
efficiently and predominately bound to the surface of the inclusions. Also, colocalization of G3BP-
EGFP with viral inclusions was more frequently observed for large inclusions, suggesting that 
larger inclusions are more prone to recruit ectopic proteins non-specifically.  
These results indicate that in the presence of NP VP30 was primarily localized in viral inclusions 
but also colocalized with G3BP-positive SGs in a protein expression-dependent manner. 
 
Interaction of VP35 with G3BP-EGFP-containing SGs 
As shown above VP35 colocalized with SGs in As-treated cells (Fig. 34). However the VP35 
distribution was different than the distribution of VP30. To analyze this colocalization in more detail, 
VP35 was expressed in the U2OS G3BP-EGFP cell line and treated with As. VP35 and G3BP-
EGFP did not colocalize in unstressed cells. While G3BP-EGFP was homogenously distributed in 
the cytoplasm of VP35-expressing cells, VP35 was found to accumulate in patches without an 
obvious pattern (Fig. 40). No interaction was observed between VP35 and G3BP-EGFP in 
untreated cells. The uneven distribution of VP35 did not change when different amounts of plasmid 
DNA encoding VP35 were transfected. Even low amounts of VP35 DNA (0.3 $g) led to a non-
homogenous distribution of VP35 in the transfected cells (data not shown). In As-stressed cells, 
the VP35 aggregates relocalized and colocalized with the G3BP-positive SGs (Fig. 40). Three 
immunofluorescence images were selected that show an increasing accumulation of VP35 from 
top to bottom (Fig. 40, panels i to iii). Interestingly, these images revealed that increased 
expression of VP35 corresponded to altered SG formation. VP35 colocalized with SGs but also 
aggregated in small globular structures surrounding the SGs (Fig. 40, panels i and ii). SGs 
colocalizing with VP35 were frequently different from typical SGs. Instead of being round and 
globular they exhibited a more diffuse, polymorphic shape (Fig. 40, panels i) In cells expressing 
large amounts of VP35, G3BP-EGFP colocalized with VP35 patches and SG formation was not 
observed (Fig. 40, panels iii). These results suggest that As-induced G3BP-containing SG 
formation was inhibited in cells expressing VP35, in a manner that appeared to be dependent on 
VP35 protein expression level.  
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 Fig. 40: VP35 expression alters G3BP-EGFP-containing SG formation in As-treated cells. G3BP-EGFP cells were 
transfected with 0.75 µg EBOV VP35HA plasmid DNA (plus 0.75 µg pC-empty vector). At 24 hpt, cells were treated with 
As (2mM) where indicated (rows 2-4). VP35HA expression was detected using a mouse anti-HA antibody (dilution 1:500) 
and an anti-mouse Alexa Fluor 647-labeled secondary antibody (dilution 1:100). The experiment was performed 5 times. 
Representative images are depicted.  
 
It was further investigated if the ability of VP35 to block SG formation was restricted to phospho-
eIF2!-mediated stress. Therefore, in addition to the As treatment, VP35-transfected G3BP-EGFP 
cells were stressed using Hip, an eIF2!-independent inducer of SG formation (Fig. 41). The 
distribution of VP35 was compared in the differently treated cells. 
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Fig. 41: VP35 shows different localization patterns in As or Hip-treated G3BP-EGFP cells. As-treated cells were 
harvested after 24 hpt (upper panel) and 48 hpt (middle panel). Hip (1 µM) treated samples were transfected in parallel 
with As-treated samples and were harvested 48 hpt (bottom panel). Transfection and immunofluorescence staining are 
described in Fig. 40. 
As-treated cells were harvested after 24 h and 48 hpt (Fig. 41). At 24 hpt, VP35 was found to 
accumulate in small, round aggregates that surrounded the SGs in As-treated cells (Fig 41, 24 
hpt). At 48 hpt, the amount of VP35 increased (Fig. 41, 48 hpt) which correlated with the inhibition 
of G3BP-EGFP containing SG formation.  
Hip-treated cells expressing VP35 were transfected in parallel with As-treated cells (see Fig. 40). It 
is shown in the insert of Figure 41 that VP35 accumulated in small, round aggregates, which 
colocalized with the SG. VP35 showed a punctate localization pattern different from that in As-
treated cells (Fig. 41). 
In conclusion, expressed VP35 seemed to exhibit an inhibitory effect on G3BP-containing SG 
formation at high VP35 expression levels. A different distribution pattern of VP35 was observed in 
As and Hip-treated samples, suggesting an interaction with differently distributed components. 
 
Interaction of VP35 with endogenous eIF3-containing SGs 
Based on the observed effects of VP35 on SG formation in G3BP-EGFP-expressing cells it was of 
interest to determine if similar results could be seen with endogenous SGs in cells, which do not 
overexpress SG proteins. Therefore, the intracellular distribution of VP35 and endogenous eIF3, 
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an SG marker protein, was examined in the parental U2OS cell line. The results were compared to 
those obtained from the G3BP-EGFP-expressing cell line.  
The distribution of VP35 was similar in both the parental U2OS and U2OS G3BP-EGFP cell lines 
(compare Fig. 40 and 42). In non-treated cells, VP35 was not homogenously distributed but was 
found to be aggregated (Fig. 42). These aggregates did not correspond to the distribution pattern 
observed for endogenous eIF3. 
 
 Fig. 42: Increased expression of VP35 alters eIF3-containing SG formation in U2OS cells treated with As. U2OS cells 
were transfected with 0.75 µg EBOV VP35HA plasmid DNA (plus 0.75 µg pC-empty vector). At 2 dpt cells were treated 
with As (2mM) and subjected to immunofluorescence analysis. VP35HA expression was detected using a mouse anti-HA 
(1:500) and a chicken anti-mouse Alexa Fluor 488-labled secondary antibody (1:100). Endogenous eIF3 was detected 
using a goat anti-eIF3 antibody (1:50) and a donkey anti-goat Alexa Flour 594-labeled secondary antibody (1:100). 
Increasing protein expression of VP35 is indicated by i to iii (from low to high). The experiment was performed 5 times. 
Representative images are depicted. 
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When different levels of VP35 expression (Fig. 42, panels i to iii, low to high expression) were 
compared in As-treated cells, the VP35 distribution was similar to that observed in G3BP-EGFP 
cells. VP35 was distributed in small globular aggregates in cells expressing low amounts of VP35. 
These aggregates accumulated when the expression level increased. High expression levels of 
VP35 correlated with decreased or the complete absence of eIF3-containg SG formation.  
Next, the interaction of VP35 with eIF3-positive SGs was examined in more detail (Fig. 43).  
 
Fig. 43: VP35 surrounds eIF3-containing SGs in cells treated with As. U2OS cells expressing VP35HA were transfected in 
parallel (see Fig. 42) and treated with As (2 mM) or Hip (1 µM). For antibody staining details see Fig. 42. 
In As-treated cells, small VP35 aggregates surrounded the eIF3-positive SGs. Although Hip-
treatment did not lead to eIF3-positive SG formation (see Fig. 30) the cytoplasmic distribution of 
VP35 differed from that in As-treated cells (Fig. 43). The punctate appearance of VP35 in Hip-
treated cells was similar to that observed in Hip-treated G3BP-EGFP cells (see Fig. 41) but differed 
from the As-treated cells (Fig. 43). In G3BP-EGFP cells, VP35 completely colocalized with the 
G3BP-positive SGs upon Hip-treatment. Taken together, this supports the observation that VP35 
interacts differently with SGs formed independently of eIF2! phosphorylation. The eIF3 antibody 
staining in the Hip-treated cells also indicated that VP35 does not bind to eIF3 since no 
colocalization was observed between eIF3 and VP35.  
Finally, the impact of VP35 on SG formation in the presence of NP was analyzed using U2OS 
cells. SG formation in As-treated cells was visualized using an anti-eIF3 antibody. The data 
obtained from G3BP-EGFP cells expressing NP and VP35 are described above (Fig. 33). As a 
control, NP was expressed in U2OS cells in the absence of VP35. Similar to the NP-transfected 
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G3BP-EGFP cells (Fig. 35), NP expression led to inclusion formation in both non-treated and As-or 
Hip-treated cells (Fig. 44A). 
 
 
Fig. 44: NP-derived inclusions are frequently located adjacent to eIF3-positive SGs. U2OS cells were transfected with 
0.75 µg NP alone or along with 0.75 µg VP35HA as indicated. At 2 dpt cells were treated with As (2mM) or Hip (1 µM). 
Immunofluorescence staining of (A) NP was performed using a monoclonal mouse-anti NP (B6C5) antibody (1:10) and 
(B) VP35HA was performed using a mouse anti-HA antibody (1:500). A chicken anti-mouse Alexa Fluor 488-labeled 
secondary antibody (1:100) was used for (A) and (B). eIF3-positive SGs were detected as described in Fig. 42. The 
experiment was performed 5 times. Representative images shown. 
In cells cotransfected with VP35 and NP, VP35 colocalized in the NP-mediated inclusions (Fig. 
44B). The viral inclusions were found in close proximity to the eIF3-positive SGs in As-treated 
cells, however the colocalization of VP35 with eIF3-containg SGs was no longer detected. eIF3 
was homogeneously distributed in the cytoplasm of the untreated cells. eIF3 staining was not 
observed at the sites where the inclusions were localized (Fig. 44B). This was observed in 
untreated and treated (As and Hip) cells. These data further support the previous observation that 
antibodies are not able to efficiently penetrate the NP-derived inclusions (see part I). Another 
possible explanation for the observed lack of eIF3 staining in the inclusions could be that eIF3 is 
physically displaced by the inclusions. 
In summary, in VP35-expressing cells treated with As, leading to phospho-eIF2!-mediated stress, 
VP35 and SGs were found in close proximity. High magnification immunofluorescence analysis 
revealed that SGs were surrounded by VP35. This was observed in both G3BP and eIF3-
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containing SGs. In contrast, after Hip-induced stress VP35 exhibited a punctate distribution pattern 
that colocalized with G3BP-positive SGs. 
Inhibition of phospho-eIF2!-mediated SG formation was shown when VP35 was expressed at high 
levels and in the absence of other viral proteins. It was not observed when VP35 was located in 
NP-derived inclusions, which further suggests that the inhibition of SG formation by VP35 depends 
on the VP35 protein expression level. This is in line with the observation that the reduction in 
G3BP-containing SGs in EBOV-infected cells seemed to be dependent on the level of viral protein 
expressed.  
It is important to emphasize that the observed colocalization of VP30 and VP35 with SGs was 
strongly reduced or absent in cells coexpressing NP and in EBOV-infected G3BP-EGFP cells. This 
indicates that only free VP35 and VP30 are able to colocalize with SG proteins and that both 
proteins are preferentially relocated to viral inclusions. It is conceivable that the amount of free 
VP35 and VP30 in infected cells is too low to be detected by immunofluorescence analysis. Of 
note, SGs were not detected in NP-VP35 or NP-VP30 inclusions, suggesting that this environment 
does not allow for SG formation. 
 
Interaction of VP35-3A with G3BP- or eIF3-containing SGs 
In EBOV-infected cells, G3BP-EGFP-containing granules are often formed in viral inclusions even 
in the absence of cytoplasmic SGs. The results of the VP35 transfection experiments suggest an 
inhibition of SG formation in an eIF2! phosphorylation-dependent manner by VP35. To further 
investigate the role of VP35 in the host stress response, a VP35 mutant (VP35-3A) containing 
three mutations in the C-terminal dsRNA-binding domain (R305A, K309A, and R312A; VP35-3A) 
was tested. VP35-3A has been previously reported to be defective in dsRNA binding-mediated IFN 
inhibition and PKR inhibition (Cardenas et al., 2006; Schumann et al., 2009).  
For the first set of experiments, VP35-3A was analyzed for its ability to interact with SGs and/or 
inhibit their formation. VP35-3A was expressed in both the parental U2OS cells and the U2OS-
G3BP-EGFP cell line. Overall the VP35-3A distribution was very similar in U2OS-G3BP-EGFP and 
U2OS-transfected cells (Fig. 45).  
In non-treated G3BP-EGFP and U2OS cells, VP35-3A was mostly homogeneously distributed 
throughout the cell (Fig. 45A and B). In cells expressing high levels of VP35-3A, aggregated 
globular and a few small ring-like structures were visible. The ring-like structures had not been 
seen in VP35 wt-transfected cells (compare to Fig. 41 and 43 ).  
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Fig. 45: VP35-3A is not able to inhibit SG formation. U2OS G3BP-EGFP (A) and U2OS cells (B) were transfected with 
0.75 µg of VP35-3AHA plasmid. At 2 dpt VP35-3AHA-transfected cells were treated with As (2 mM). SG formation was 
detected by expression of G3BP-EGFP (A, green) or by eIF3-antibody staining (B, red). VP35-3AHA was detected using a 
mouse anti-HA antibody (1:500) and an anti-mouse Alexa Fluor 594-labeled secondary antibody (A, red, dilution 1:100) 
or a chicken anti-mouse Alexa Fluor 488-labled secondary antibody (B, green, dilution 1:100) were used for visualization. 
SGs (B) were detected by using a goat anti-eIF3 antibody (1:50) and an Alexa-Flour 594-labeled secondary antibody.   
During As stress, the number and size of the globular aggregates formed by VP35-3A increased 
(Fig. 45). These VP35-3A structures accumulated next to and around the SGs, which were either 
detected by G3BP-EGFP (Fig. 45A, green) or by eIF3-antibody staining (Fig. 45B, red). The 
interaction of VP35-3A with SGs is similar to the observations made for wt VP35 at low expression 
levels (see Fig. 40i and 42i). Depending on the expression level, VP35-3A appeared in ring-like 
structures, which were increased in size and number compared to the non-stressed cells. These 
ring-like structures were also localized next to SGs but not in all cases. Interestingly, VP35-3A did 
not accumulate in large aggregates shown for the wt VP35 and was not able to inhibit SG 
formation in either cell line (Fig. 45).  
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In conclusion, VP35-3A was not able to inhibit As-induced SG formation. In addition, large VP35 
aggregates observed in wt VP35-expressing cells that correlated with SG inhibition were not 
detected. This further indicates that the accumulation might important for the inhibition of SGs. 
VP35-3A has also been described to exhibit lower expression levels than the wild-type (wt) VP35, 
which is likely due to its inability to inhibit PKR (Schumann et al., 2009).  
To analyze if the VP35-3A mutant behaves differently than the wt VP35, inclusion formation was 
induced by cotransfection of NP. The VP35-3A mutant colocalized with the NP-derived inclusions 
since the NP binding domain is not affected by the mutation (REID et al., 2005) (Fig. 46).  
 
Fig. 46: Interaction of viral inclusions formed by NP and VP35-3A with G3BP-containing SGs. G3BP-EGFP cells were 
transfected with 0.75 µg of NP and 0.75 µg VP35HA-3A expression plasmids. At 2 dpt cells were treated with As (2mM). 
Immunofluorescence staining of NP was performed using a monoclonal mouse-anti NP (B6C5) antibody (1:10) and a 
chicken anti-mouse Alexa Fluor 488-labeled secondary antibody. 
Inclusions formed by NP and VP35-3A did not colocalize with SGs, and were similar to those 
formed by NP and VP35wt, described above (see Fig. 33). VP35-3A was relocated to the viral 
inclusions and did not colocalize with SGs. Therefore, only the G3BP-EGFP transfected cells are 
depicted, however these results were also verified in the U2OS cell line.  
 
5.2.5 Phosphorylation of PKR and eIF2! in EBOV-infected cells treated with As 
Oxidative As-induced stress has been shown to activate the kinase PKR. Different environmental 
stressors, such as heat, UV irradiation, and dsRNA also activate PKR (Williams, 2001). Activation 
leads to autophosphorylation of PKR and subsequently to eIF2! phosphorylation and translational 
arrest. It has been shown that wt VP35 is able to inhibit dsRNA-mediated activation of PKR (Feng 
et al., 2006; Schumann et al., 2009).  
To examine the ability of EBOV to block the activation of PKR by oxidative stress, it was analyzed, 
whether PKR and eIF2! are phosphorylated in EBOV-infected cells after treatment with As. 
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HeLa cells have been extensively used to analyze PKR and eIF2! phosphorylation during EBOV 
infection. HeLa cells were used for Western blot analysis of PKR and eIF2! phosphorylation in 
EBOV-infected cells treated with As (Fig. 47). Immunofluorescence analysis was performed to 
evaluate the infection efficiency and revealed that approximately 90% of the cells were infected 
with EBOV (data not shown).  
Western blot analysis of the EBOV-infected samples in the absence of As showed that neither 
PKR nor eIF2! were phosphorylated (Fig. 47). After As treatment, PKR and eIF2! were 
phosphorylated in both non-infected and EBOV-infected cells. This suggests that EBOV was not 
able to antagonize As-induced phosphorylation of PKR.  
 
Fig. 47: EBOV is not able to antagonize PKR and eIF2! phosphorylation induced by As. HeLa cells were seeded at 
4x104 (low confluence) in a 6-well plate and infected with EBOV at an MOI of 1. At 24 hpi cells were either treated with 
As (1 mM) or left untreated and subjected to Western blot analysis. EBOV- and non-infected cells were harvested in 50 
µl cell lysis buffer (see material and methods) and subjected to Western blot analysis using antibodies directed against 
PKR (dilution 1:5000), phospho-PKR (dilution 1:500) incubated over night at 4°C and eIF2! (dilution 1:300) and 
phospho-eIF2! (dilution 1:1000) incubated for 1 h at room temperature. The corresponding horseradish peroxidase-
conjugated secondary antibodies (dilution 1:40.000) were incubated for 1 h at room temperature. Western blot samples 
were obtained in triplicate.  
In conclusion, phosphorylation of PKR and eIF2! has been shown to be inhibited in EBOV-infected 
cells, even when induced by Sendai virus infection or poly(I:C) (unpublished data Olejnik et al.). 
However, EBOV was not able to inhibit As-induced phosphorylation of PKR and eIF2!. This 
indicates an additional mechanism leading to PKR phosphorylation, which is not antagonized by 
EBOV.  
 
5.2.6 Binding of VP35 and PACT is disrupted during As-stress 
During environmental stress, such as As treatment, the cellular protein PACT is able to bind and 
activate PKR (Patel and Sen, 1998). Since VP35 has been shown to bind to PACT in unstressed 
cells (Fabozzi et al., 2011), the interaction of PACT and VP35 was analyzed during As-induced 
cellular stress. The observed phosphorylation of PKR in EBOV-infected cells treated with As could 
potentially be a result of a disrupted binding of VP35 and PACT. 
VP35 was coexpressed with PACT in HEK293T cells. The cells were treated with As or left 
untreated and subjected to immunoprecipitation. In non-stressed cells expressing VP35 and PACT, 
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PACT coimmunoprecipitated with VP35, indicating that the proteins interact (Fig. 48A, lanes 2 and 
6). This result is in line with previously published data (Fabozzi et al., 2011).  
Interestingly, in As-treated cells expressing VP35 and PACT, PACT did not coimmunoprecipitate 
with VP35, indicating that PACT did not bind to VP35 (Fig. 48A, lanes 3 and 7). As a control, PACT 
and VP35 were individually expressed along with EGFP and immunoprecipitated (Fig. 48A, lanes 
4, 5, 8, 9 and Fig. 48B lanes 1, 2, 5, 6).  
To verify these results, the experiment was repeated using an antibody immunoprecipitating PACT 
(Fig. 48B). While PACT was bound to VP35 in the absence of As (Fig. 48B, lane 3), it was not 
possible pull-down VP35 in As-treated cells (Fig. 48B, lane 4). This confirmed an interaction 
between coexpressed VP35 and PACT, which is disrupted during As-treatment.  
Interestingly, previous studies have reported that PACT can enhance expression of cotransfected 
reporter genes, which has also been shown for VP35 (Li and Sen, 2003; Yang, 2004; Schumann et 
al., 2009). This could be related to the observed high expression levels of VP35 and PACT (Fig. 
48B). The Western blot films depicted were exposed for 10 seconds. In addition, longer exposure 
times were performed to exclude that weaker bands remain undetected (data not shown).  
 
Fig. 48: PACT does not bind to VP35 during As stress. HEK293T cells were transfected with 12 µg PACTFlag expression 
plasmid along with 12 µg EBOV VP35HA or 12 µg EGFP plasmid DNA. At 2 dpt, cells were treated with As (2 mM) or left 
untreated and subjected to immunoprecipitation (IP) using protein A/G agarose beads followed by immunoblotting (IB). 
For IP, mouse anti-HA antibodies (panel A, dilution 1:2000) or mouse anti-Flag antibodies (panel B, dilution 1:2000) were 
used. For Western blot analysis, mouse anti-Flag (dilution 1:2000) and mouse anti-HA (dilution 1:2000) antibodies were 
used. For $-actin, a mouse anti-$-actin antibody (dilution 1:5000) was used. For detection, horseradish peroxidase-
conjugated secondary antibodies (dilution 1:40.000) were used. Abbreviations: P=PACT, 35=VP35, E=EGFP, 
WCL=Whole-cell lysate.   
An additional band of about 24 kDa was detected by the anti-Flag (PACT) antibody, which only 
appeared in the whole-cell lysates when PACT was expressed along with VP35. It is possible that 
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this band represents a cleaved version or a degradation product of PACT, however, further 
investigation is required to test this. 
In conclusion, the loss of binding between VP35 and PACT in As-treated cells might lead to the 
inability of VP35 to sequester PACT from binding to PKR, such that PKR can be activated. This 
would further explain the presence of SGs in EBOV-infected cells treated with As. A similar 
mechanism has been described for TRBP. Dissociation of TRBP and PACT in As-stressed cells 
led to an increased binding and activation of PKR by PACT (Daher et al., 2009; Singh et al., 2011). 
The observed inhibition of SG formation in some As-treated EBOV-infected cells might happen at 
the level of protein interaction with SG components or by inhibiting other pathways leading to As-
induced SG formation.  
 
5.2.7 Formation of DCP1a-containing PBs is altered in EBOV infection 
PBs, like SGs are multicomponent mRNP bodies, which regulate translational silencing. In 
distinction from SGs, PBs store and degrade mRNAs coopting RNAi components. PBs and SGs 
are frequently seen adjacent to one another, raising the possibility that mRNPs traffic from one 
structure to the other (Kedersha et al., 2005; Wilczynska, 2005).  
The dsRNA-binding domain of VP35 has been shown to be important for suppressing the host 
RNAi pathway (Haasnoot et al., 2007; Zhu et al., 2012). A recent study showed that both EBOV 
proteins, VP30 and VP35, interact with various components of active RNA-induced silencing 
complex (RISC) including Dicer, TRBP, and PACT (Fabozzi et al., 2011). 
Since PBs are formed as a result of RNA-mediated gene silencing, the question of whether EBOV-
infection has an influence on PB formation was addressed. The U2OS cell line expressing the PB 
marker protein mRNA-decapping enzyme 1A (DCP1a) fused to mRFP (U2OS DCP1a-mRFP cells; 
Fig. 49) was used for these studies. DCP1a is part of the mRNA degradation complex. 
In the U2OS cell line, DCP1a-mRFP protein expression levels varied and DCP1a-mRFP protein 
aggregates were observed quite frequently, especially in cells of a higher passage number. This 
might be due to non-specific protein aggregation. For consistency all experiments were performed 
in early passages of the cell lines. 
 
Reduced number of PBs in EBOV-infected cells treated with As 
In order to observe PB formation during EBOV infection, U2OS DCP1a-mRFP cells were infected 
with EBOV. In non-infected cells, only a few DCP1a-containing PBs were visible in the absence of 
As which increased in number during As-treatment (Fig. 49A).  
In Fig. 49B different stages of EBOV infection are depicted. In untreated cells, limited PB formation 
was observed and the number of PBs did not substantially differ in infected and non-infected cells. 
Similarly to G3BP-EGFP, DCP1a-mRFP autofluorescence was observed to colocalize with the viral 
inclusions as described previously (see Fig. 33). In As-treated cells, PB formation was observed 
during early stages of inclusion formation (Fig. 49B, right panels). At later stages, cells containing 
larger inclusions exhibited signs of cell death, including shrinkage of the cell, and PBs were not 
detected anymore. However, DCP1a-mRFP still colocalized with the viral inclusions.  
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Fig. 49: Reduced PB formation in EBOV-infected cells following As treatment. U2OS DCP1a-mRFP cells were left 
uninfected (A) or infected with EBOV (B) using a 1:2 dilution of supernatant fluid obtained from EBOV-infected Vero E6 
cells. At 2 dpi, cells were left untreated (left panels) or treated with As (2 mM) (right panels). Cells were subjected to 
immunofluorescence analysis using a mouse anti-VP35 antibody (1:400) and a secondary chicken anti-mouse Alexa 
Fluor 488-labeled antibody. DCP1a-mRFP-containing PBs are red in fluorescence. 
As-induced PBs were observed to be localized next to viral inclusions. This suggests that PBs are 
recruited to viral inclusions (see discussion).  
 
Impact of EBOV proteins on PB formation 
It was further analyzed if the EBOV RNA-binding proteins VP30, VP35, or NP expressed in U2OS 
DCP1a-mRFP cells have an influence on PB formation. 
First, it was examined if NP-derived inclusion formation has an influence on PBs. In U2OS DCP1a-
mRFP cells transfected with NP, inclusion formation was visible (Fig. 50). Formation of PBs was 
not influenced by the expression of NP in the absence of other viral proteins. The inclusions were 
often in close contact to the As-induced DCP1a-mRFP-containing PBs but did not colocalize with 
the PBs. This is similar to the observed interaction between SGs and NP-mediated inclusions.  
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Fig. 50: DCP1a-mRFP-containing PBs interact but do not colocalize with NP-derived inclusions. DCP1a-mRFP cells 
were transfected with 0.75 µg of NP expression plasmid. Cells were treated with As (2 mM) and Hip (1 µM) at 2 dpt. NP 
(green) was detected using a mouse anti-NP antibody (1:15) and a chicken anti-mouse Alexa Fluor 488-labeled 
secondary antibody (1:100).  
Next, the impact of VP30 on PBs was investigated. Therefore, VP30 was expressed in U2OS 
DCP1a-mRFP cells. In some cells, constitutively expressed DCP1a-mRFP accumulated in 
aggregates even in the absence of external stress. These protein aggregations were bigger than 
those seen in cells treated with As to induce PB formation. In VP30-transfected cells, the DCP1a-
mRFP aggregates did not colocalize with VP30 (Fig. 51, no treatment). In the presence of As, PB 
formation was observed. VP30 was seen to form aggregates, which were in close contact to the 
PBs but did not colocalize. Since VP30 was shown to colocalize with SGs (see above), the VP30 
aggregates are considered to be SGs (Fig. 51).  
 
Fig. 51: PBs containing DCP1a-mRFP interacted but did not colocalize with VP30. U2OS DCP1a-mRFP cells were 
transfected with 0.75 µg of VP30 expression plasmid. Cells were treated with As (2 mM) at 2 dpt. For detection of VP30, 
a rabbit anti-VP30 antibody (1:100) and an Alexa Fluor 488-labeled secondary antibody (1:100) were used.  
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In conclusion, VP30 did not colocalize with PBs in As-treated cells. The close proximity to PBs 
might be explained by its shown interaction with SGs. In addition, PB formation did not seem to be 
influenced by VP30 expression.  
Since VP35 was observed to have an effect on As-induced SG formation, it was interesting to 
examine its impact on PBs. U2OS DCP1a-mRFP cells were transfected with VP35 (Fig. 52 A). The 
distribution of VP35 in untreated and As-treated U2OS DCP1a-mRFP was similar to that observed 
in the other used cell lines (see Fig. 41 and 43). In As-treated cells, small VP35 aggregates 
colocalized with the DCP1a-mRFP-positive PBs (Fig. 52, insert).  
  
 
Fig. 52: PBs containing DCP1a-mRFP colocalize with VP35. DCP1a-mRFP cells were transfected with 0.75 µg of 
plasmid expressing VP35HA. For the detection of VP35HA a mouse anti-HA (1:500) and an anti-mouse Alexa Fluor 488-
labled secondary antibody (1:100) were used. Cells were treated with As (2 mM) and Hip (1 µM) at 2 dpt.  
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In Hip-treated cells, the VP35 aggregates showed a punctate, dot-like pattern similar to the VP35 
distribution observed in other Hip-treated U2OS cells (compare Fig. 52 with Fig. xy above). 
Detailed observation revealed that the VP35 aggregates were surrounded by smaller globular 
aggregates of VP35 (Fig. 52 + Hip, insert). Colocalization of these small globular VP35 aggregates 
with the DCP1a-mRFP-positive PBs was observed. It is possible that the punctate pattern 
represents an interaction of VP35 with Hip-induced SGs, which were not detected in these 
samples.  
This suggests that VP35 interacts with PB components during As and Hip-induced stress. PBs 
have been shown to contain components involved in miRNA-mediated gene silencing, such as 
Ago2, and RCK/p54. These constitute potential interaction partners, since VP35 has been shown 
to bind other RISC components (see discussion). In contrast to SG formation, PB formation was 
not influenced by the expression of VP35, neither in As nor in Hip-treated cells. 
VP35 has been shown to interact with both PBs and SGs. However, the interaction was different, 
since SG but not PB formation was observed to be impaired in As-treated cells. To further analyze 
this, U2OS cells constitutively expressing both DCP1a-mRFP and G3BP-EGFP (described in Ohn 
et al., 2008) were transfected with VP35 and treated with As (Fig. 53).  
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Fig. 53: VP35 interaction with DCP1a-mRFP and G3BP-EGFP. U2OS cells constitutively expressing DCP1a-mRFP and 
G3BP-EGFP were transfected with 1 µg of VP35HA expression plasmid. At 2 dpt cells were treated with As (1 mM). 
VP35HA was detected by using a mouse anti-HA (1:1000) antibody and an anti-mouse Alexa Fluor 405-labeled secondary 
antibody. 
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Overall VP35 aggregates colocalized with SGs and PBs. G3BP-containing SG formation was 
inhibited in VP35-positive cells (Fig. 53, detail images 1-4), whereas SG formation was observed in 
VP35-negative cells (Fig. 53, detail 5). These observations are in line with the results obtained 
from the G3BP-expressing cells (Fig. 53). Although SG formation did not occur, G3BP-EGFP 
formed diffuse aggregates, which colocalized with VP35. In contrast, DCP1a-mRFP-containing PB 
formation was not affected by VP35 expression and the PBs also colocalized with VP35. 
Intriguingly, the aggregated G3BP-EGFP, the DCP1a-mRFP-positive PBs, and VP35 colocalized 
and intermingled in VP35-expressing cells. This suggests that VP35 interacts and links 
constituents of PBs and SGs, which might be otherwise separated.  
In order to analyze if VP35-3A might exhibit a different interaction pattern with PBs than the wt 
VP35, DCP1a-mRFP cells were transfected with the VP35-3A mutant (Fig. 54). The VP35-3A 
distribution in non-treated cells was consistent with results described above (see Fig. 45). DCP1a-
mRFP formed aggregates in non-treated cells that were similar to those observed in VP35 wt-
transfected DCP1a-mRFP cells. These DCP1a aggregates were surrounded by ring-like structures 
formed by VP35-3A (described above, Fig. 45). As mentioned above, these ring-like structures 
were only observed in cells expressing VP35-3A but not in cells expressing wt VP35, which needs 
to be further investigated. In As-treated cells, a different distribution was observed, as DCP1a-
mRFP relocalized to form PBs, which colocalized with globular VP35-3A aggregates. This 
suggests that the ability of VP35 to bind dsRNA is not a requirement for the interaction with PBs, 
since VP35-3A was observed to colocalize with PBs.  
 
 
Fig. 54: PBs containing DCP1a-mRFP colocalize with VP35-3AHA. U2OS DCP1a-mRFP cells were transfected with 0.75 
µg of plasmids expressing VP35-3AHA. For As treatment and immunofluorescence staining see Fig. 52.  
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6. Discussion 
6.1. Generation of a recombinant MARV clone expressing EGFP 
The generation of recombinant EGFP-expressing viruses has significantly improved the study of 
their life cycle and opened up the possibility for the rapid screening of antiviral drugs. Rescue 
systems to recover infectious virus from full-length cDNA clones have been established for both 
MARV and EBOV (Enterlein et al., 2006; Ebihara et al., 2007; Halfmann et al., 2008). These 
techniques were used to generate a recombinant EBOV containing the EGFP gene within an ATU 
(Ebihara et al., 2007). Other viruses of the order Mononegavirales containing fluorescence proteins 
have been generated including a recombinant measles virus (Duprex et al., 1999; Duprex and 
Rima, 2011).  
This work describes the successful rescue of an rMARV containing the EGFP ORF inserted in an 
ATU between the VP35 and VP40 genes. The rationale for the positioning of the EGFP ORF near 
the 3’ end of the viral genome was to maximize the number of EGFP transcripts and thereby 
increase the sensitivity of virus detection. At the same time it was essential to avoid alterations in 
the balance between expression of NP (first gene product) and VP35 (second gene product), since 
previous results using a MARV minigenome system suggested that the ratio of NP to VP35 is 
critical for efficient transcription and replication (Muhlberger et al., 1998). EGFP has been 
expressed from the closely related EBOV from multiple positions within the genome. Insertion of 
the ATU between the NP and VP35 genes did not lead to significant growth defects in cell culture 
but showed attenuation in a STAT1 knockout mouse model (Towner et al., 2005; Ebihara et al., 
2007). Similar effects were observed with an rEBOV containing EGFP in an ATU between the 
VP30 and VP24 genes (fifth and sixth genes). This virus showed no or mild growth defects in cell 
culture depending on the cell line used for propagation, was moderately attenuated in the mouse 
model, and was severely attenuated in a non-human primate model (Ebihara et al., 2007). Another 
rEBOV in which the ATU was added between the VP35 and VP40 genes (second and third genes) 
was rescued and propagated in cell culture (Martinez et al., 2008). Taken together, these data 
show that EBOV tolerates the addition of a foreign gene at many different positions, although the 
insertion of extra non-viral genetic material may lead to reduced virulence in animal models.  
In contrast to rEBOV, the rescue of wt MARV from cDNA clones under the control of the T7 RNA 
polymerase promoter was very inefficient and succeeded only after several transfections. 
Interestingly, it has been shown that virus rescue of the recombinant clone of Saffold virus type 3 
(SAFV-3) was impossible due a premature termination of transcription by the T7 RNA polymerase 
(Himeda et al., 2011). SAFV-3 was found to contain a sequence, which is homologous to a 
conserved pausing/termination sequence (A/C/TATCTGTT followed by a T rich sequence) of the 
T7 RNA polymerase (Lyakhov et al., 1998). It is shown that after substitution mutations of the 
sequence, rescue of the recombinant SAFV-3 with virus titers comparable to the wt SAFV-3 were 
observed (Himeda et al., 2011). The same sequence is present in the rMARV-EGFP genome 
(AATCTGTT; nt 9438-9447) but not in the EBOV genome. This sequence therefore might lead to a 
decrease of full-length infectious RNA and subsequently to significantly decreased virus production 
and decreased viral rescue. This will be further addressed in collaboration with Dr. H. Ebihara from 
the Rocky Mountain Laboratories, USA.  
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A growth restriction of rMARV-EGFP has been observed compared to the growth kinetics of wt 
rMARV. This was determined by quantification of the protein expression of NP and VP40. The 
results indicate that the presence of the ATU affects the recombinant MARV-EGFP protein 
expression rate, since genes downstream of the insertion were expressed less efficiently.  
However, viral spread of rMARV-EGFP was successfully monitored in living cells. Our data 
suggest that virus spread occurs predominantly through cell-to-cell-contact. Release of viral 
particles from MARV-infected cells has been shown to take place at filamentous protrusions, the 
filopodia (Kolesnikova et al., 2007). Since filopodia act as sensory organelles to explore the 
extracellular environment and contact neighboring cells (Mellor, 2010), it has been suggested that 
MARV particles may bud into adjacent cells via filopodia-mediated cell-to-cell contact (Kolesnikova 
et al., 2007). Our data received from live cell imaging shows that also virus replication in actively 
dividing cells seems to be an important mechanism of MARV spread in cell culture. Cell division is 
not inhibited by MARV infection, indicating that MARV does not interfere with cell cycle 
progression. Towards the end of the observation period of 9 days cell rounding, blebbing, and 
finally detachment of EGFP-expressing infected cells was observed, which correlates with 
impeding cell death.  
The collected data clearly illustrate the usefulness of live-cell imaging, which allows for the 
investigation of intracellular dynamic processes during the course of infection. Live-cell analysis of 
infected cells also facilitates the fast and quantitative readout of antiviral drug screening assays 
and virus spread studies. 
Surprisingly, EGFP was found to accumulate in filoviral inclusions. A similar observation was 
reported for some members of the nucleorhabdoviruses, where GFP colocalized with viral 
nucleocapsid protein in loci within and around the nuclei (Goodin et al., 2005). In contrast, EGFP 
was found to be homogenously distributed in the nuclei and cytoplasm of cells infected with EGFP-
expressing measles virus, which also produces intracytoplasmic inclusions (Duprex et al., 1999). 
The intracellular distribution of EGFP was examined by live-cell imaging and immunofluorescence 
analysis using infected and transfected cells. The fluorescence intensity of homogenously 
distributed EGFP surrounding the intracytoplasmic EGFP aggregates was higher in living cells, 
making it difficult to distinguish between EGFP aggregates and non-specific distributed EGFP. 
Moreover, when large amounts of EGFP plasmid were used for transfection (500 ng), the punctate 
pattern of EGFP was not observed in cells coexpressing MARV NP and VP35, suggesting that the 
EGFP aggregates were masked when overall EGFP expression was high, illustrating the 
importance of making observations in cells which do not extensively overexpress the protein of 
interest. In fixed and permeabilized cells, punctate EGFP was clearly visible in both infected cells 
and transfected cells coexpressing NP and VP35, suggesting that the intensity of EGFP 
autofluorescence was reduced by the treatment of the cells. EGFP aggregation was induced by 
expression of NP in the absence of other viral proteins but was more pronounced when 
coexpressed with VP35. Expression of VP35 alone does not lead to inclusion formation and EGFP 
was accordingly homogenously distributed in these cells.  
Intriguingly, EGFP not only colocalized with MARV inclusions but also with EBOV and RESTV 
inclusions formed by NP and VP35. EGFP expressed from an ATU between NP and VP35 in 
rEBOV-infected cells was also tested and confirmed the EGFP aggregation. 
In addition to EGFP, other fluorescent proteins were found to colocalize with MARV inclusions. 
These data indicate that the accumulation of ectopic proteins in filoviral inclusions is most likely not 
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mediated by direct, specific protein-protein interaction. The observed colocalization of ectopically 
expressed fluorescent proteins with filovirus inclusions may be useful in the investigation of 
nucleocapsid maturation and transport in infected cells. 
The relocalization of fluorescence proteins into MARV inclusions was further examined using GFP-
tagged proteins. Various versions of GFP fusion proteins involved in cytoplasmic aggresome 
formation were analyzed to determine if MARV NP and VP35 inclusion formation alters their 
localization. GFP-250 is a misfolded chimeric protein that leads to aggresome formation in the 
cytoplasm when overexpressed (García-Mata et al., 1999). Aggresome formation is accompanied 
by the redistribution of the intermediate filament protein vimentin, proteasomes, heat shock protein 
(Hsp) 70, and the chaperonin system of chaperones. Aggresome formation involves retrograde 
transport along the microtubules from the periphery towards the microtubule organization center 
(MTOC) region. Here, GFP-250-induced aggresomes remain as distinct but closely apposed 
particulate structures. In addition, the GFP-tagged dynein motor protein, p50 dynamitin (GFP-
dynamitin), which causes the dissociation of the dynactin complex was tested (Burkhardt et al., 
1997). Taken together, neither of the two GFP-fusion proteins relocated into inclusions formed by 
MARV NP and VP35. This indicates that homogeneously distributed fluorescent proteins are more 
likely to relocate into viral inclusions than GFP fusion proteins that are actively targeted to specific 
cellular compartments. This further suggests that the observed colocalization of fluorescent 
proteins with the MARV NP-derived inclusions is not due to a strong, specific interaction, since the 
intracellular distribution of GFP-fusion proteins was not altered. Aggresome formation itself was 
also not altered by the expression of MARV NP and VP35.  
Interestingly, although aggregation of untagged EGFP in coexpression with MARV NP and VP35 
was visible by EGFP autofluorescence, EGFP aggregation was not detected by 
immunofluorescence analysis using an antibody directed against GFP. This indicates that inclusion 
formation excludes antibody penetration. This has also been shown for the overexpressed cellular 
protein CREB-binding protein (CBP), which forms intranuclear inclusions that could not be 
penetrated by antibodies (McCampbell et al., 2000). These findings suggest that other proteins that 
might be located within the NP-derived inclusions are undetected by antibody-based 
immunofluorescence. 
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6.2. Host cell stress response to EBOV infection 
An important host antiviral defense mechanism is stress-induced translational arrest, which is often 
accompanied by the formation of SGs and an increase in the number of PBs present in the 
cytoplasm of the cell. The eIF2! subunit within the GTP-eIF2-tRNAMet ternary complex plays a 
central role in the control of translation. Phosphorylation of eIF2! by a small range of kinases leads 
to an arrest of the translational machinery and to SG formation. Like many viruses, filoviruses 
depend on the cellular translation apparatus for viral protein synthesis. Therefore, phosphorylation 
of eIF2! is an effective antiviral defense mechanism to which many viruses have evolved a certain 
level of tolerance either by the inhibition of eIF2! phosphorylation or by eIF2!-independent 
translation. The external oxidative stressor As induces eIF2! phosphorylation and SG formation by 
activation of the kinases PKR and HRI (McEwen, 2005; Daher et al., 2009; Singh et al., 2011).  
In this work, the impact of EBOV infection on the SG- and PB-mediated host cell stress response 
was analyzed.  
 
SG formation in EBOV-infected cells 
To analyze the role that the cellular stress response plays in EBOV infection, SG formation was 
determined in EBOV-infected Vero E6 cells. Using an eIF3 antibody to look at SG formation, 
EBOV-infected cells were not found to induce SGs. After treatment with As, SGs were detected in 
EBOV-infected cells albeit in fewer cells compared to the non-infected cells This indicates that 
EBOV is able to partially inhibit As-induced SG formation.  
An inhibition of SG formation, even in response to As treatment, was seen in rotaviruses 
(Reoviridae) and Human immunodeficiency virus 1 (HIV-1) (Retroviridae) infected cells (Montero et 
al., 2008; Abrahamyan et al., 2010). Interestingly, for both infections, high levels of eIF2! 
phosphorylation were shown in response to As treatment, indicating the inhibition of SG formation 
by a mechanism downstream of eIF2!. Junin virus, a member of the arenavirus family, inhibited 
SG formation in response to As treatment by an undefined mechanism, that was dependent on the 
expression of the nucleoprotein (N) or the glycoprotein precursor (GPC) (Linero et al., 2011). 
However, the inhibition of SGs correlated with low levels of eIF2! phosphorylation.  
Since As treatment induces SG formation in a phospho-eIF2!-dependent manner, the question 
arose of whether the observed inhibition of SGs by EBOV is due to the ability of EBOV to block 
PKR-mediated phosphorylation of eIF2! (Hartman et al., 2004; Feng et al., 2006; Schumann et al., 
2009). 
 
G3BP-containing granules in EBOV-infected cells  
For better visualization of SGs, a U2OS cell line expressing the SG maker protein G3BP fused to 
EGFP was used. The most intriguing observation made in the EBOV-infected G3BP-EGFP cells 
was that G3BP-EGFP-containing granules formed within the viral inclusions. In contrast to SGs, 
which were observed in the cytoplasm after treatment with stress inducers during the considerably 
short time window of 30 minutes, these SG-like G3BP-EGFP aggregates were present even in 
non-treated cells. Accumulation of G3BP granules in non-treated cells was restricted completely to 
viral inclusions of all sizes. This indicates that these granules formed concurrently with viral 
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inclusions during the infection period of 2 days. These G3BP granules are distinct from the round, 
globular structure of SGs and are more diffusely aggregated and not round-shaped.  
As treatment induces dephosphorylation of G3BP, which allows self-oligomerization. Only the non-
phosphorylated form of G3BP is able to self-aggregate and thereby initiate SG assembly 
(Tourrière, 2003). G3BP requires phosphorylation for its catalytic endoribonuclease activity 
(Gallouzi et al., 1998). G3BP contains a C-terminal RNA-binding domain that has an especially 
important role in SG formation and participates in mRNA metabolism (Parker et al., 1996; Tourrière 
et al., 2001; Tourrière, 2003; Atlas et al., 2004).  
To date, it is not known if G3BP is phosphorylated in EBOV-infected cells, which would be most 
interesting to analyze. The G3BP of the SG-like aggregates within the viral inclusions could be 
dephosphorylated or partially dephosphorylated, since G3BP is able to aggregate but the 
aggregates appeared to be not as round-shaped as in cytoplasmic SGs. In a dephosphorylated 
state, G3BP would not be able to exhibit its RNase activity, leading to the protection of viral RNA in 
the inclusions 
Several positive-sense RNA viruses, including flaviviruses such as HCV, West Nile virus (WNV), 
and dengue virus (DV) as well as rubella virus (Togaviridae) and poliovirus (Picornaviridae), have 
been shown to induce the redistribution of G3BP. During HCV infection G3BP and other SG 
components are recruited to the viral replication factories, and several SG markers, including 
G3BP, colocalize with the HCV core protein even in the presence of stress (Ariumi et al., 2011). 
G3BP interacts with the HCV RNA-dependent RNA polymerase, NS5B, and the 5’ terminus of the 
negative-strand RNA replication intermediate during HCV infection to mediate efficient replication 
of the viral genomic RNA (Yi et al., 2011). It also has been shown that G3BP binds with the 
genomic 3’ UTR and 5’ UTR of DV (Ward et al., 2011). The function of this interaction is not 
known. Furthermore, both DV and WNV inhibit SG formation in response to exogenous stress by 
sequestering TIA-1 and TIAR through specific binding to the minus strand 3’ terminal stem loop 
structure, an interaction that is required for viral replication (Li et al., 2002; Emara and Brinton, 
2007).  
Since viruses are master manipulators of cellular processes, it is not surprising that SG factors 
such as G3BP or TIA-1 interact with positive-strand RNA virus components. Still, the question 
remains if such sequestration is a result of a selective pressure to inhibit SGs or an active 
requirement to facilitate viral replication. For filoviruses, it is assumed that viral inclusions are sites 
of active viral replication, but this has not been experimentally confirmed. It is also not currently 
known if cellular components are localized at the sites of inclusion formation. This further raises the 
possibility that viral inclusion formation is connected to the cellular stress response and their 
components. 
The location of G3BP granules within the EBOV inclusions as well as their different shape raises 
the question as to whether they are functional SGs. As established by several reports, SGs are 
defined as highly dynamic poly (A)+ RNA-containing cytoplasmic foci that transiently accumulate in 
response to stress, and SGs are in equilibrium with polysomes (Nover et al., 1989; Kedersha et al., 
1999; 2002). Hence, it remains to be further investigated whether the observed G3BP granules 
exhibit SG characteristics. The question could be analyzed using drugs that either stabilize 
polysomes while disintegrating SG formation (e.g. emetine and cycloheximide) or destabilize 
polysomes and consequently enhance assembly of SGs (e.g. puromycin). It is also important to 
analyze the possible presence of other SG maker proteins within filoviral inclusions. The G3BP 
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granules observed in colocalization with viral ssRNA in perinuclear clusters at late stages in 
rubella-infected cells were found to differ from As-induced SGs in composition and response to 
cyclohexamide treatment (Matthews and Frey, 2011).  
However, the observation of G3BP granules within the viral inclusions was only made for EBOV-
infected G3BP-EGFP containing cells and not for eIF3-stained SGs in EBOV-infected Vero E6 
cells. As mentioned above, antibodies might not be able to penetrate the viral inclusions. 
Therefore, it is possible that only fluorescence-tagged proteins can be visualized within viral 
inclusions.  
To further investigate which EBOV component is responsible for the relocation of G3BP-EGFP into 
viral inclusions, cells were transfected with different combinations of viral proteins involved in NC 
formation. Interestingly, Inclusion formation induced by expression of viral nucleocapsid proteins 
was not sufficient for the accumulation of G3BP granules inside the inclusions. Considering the 
known RNA-binding capacity of G3BP and its interaction with viral ssRNA genomes, it is 
conceivable that active replication complexes or viral genomic or antigenomic RNA are key factors 
for the relocalization of G3BP. However, relocalization due to the EGFP portion of G3BP observed 
earlier for ectopic EGFP is not likely to play a role, since aggregation of G3BP-EGFP was not 
observed in transient expression of EBOV NC proteins, which were sufficient for the relocalization 
of EGFP. 
Together this data suggest a mechanism of EBOV to interfere with SGs by sequestering SG 
components in the viral inclusions. 
 
G3BP-containing SG formation in EBOV-infected cells  
In EBOV-infected G3BP-EGFP-expressing cells, SG formation was induced by As and 
hippuristanol (Hip). Cellular stress induced by Hip leads to SG formation by inhibiting eIF4A-
dependent translation initiation, a process, which does not involve phosphorylation of eIF2! 
(Bordeleau et al., 2006). To date it is not known if SGs induced by these two different chemical 
compounds contain a different composition of constituents.  
Cytoplasmic G3BP-EGFP-containing SG formation was observed in EBOV-infected and non-
infected G3BP-EGFP cells upon treatment with As. Although G3BP-positive SG formation was 
reduced in EBOV-infected cells, it occurred in higher numbers than previously detected in EBOV-
infected Vero cells stained for endogenous eIF3. Transient overexpression of G3BP-EGFP has 
been shown to induce spontaneous SG formation in the absence of extracellular stress (Kedersha 
et al., 2005). Unlike transient transfections, G3BP-EGFP constitutively expressed in U2OS cells 
does not exhibit spontaneous SGs but instead displays a homogeneous distribution (Kedersha et 
al., 2008). G3BP-EGFP in the U2OS cell line (characterized by Kedersha and coworkers) exhibits 
a behavior similar to endogenous G3BP albeit G3BP-EGFP is expressed at about 10-fold higher 
levels relative to the endogenous proteins (Kedersha et al., 2008). Therefore it is possible that 
these cells are more sensitive to stress signals and more prone to form G3BP-EGFP-containing 
SGs. This might explain why an increased number of cells were observed to form G3BP-EGFP-
containing SGs in As-treated cells infected with EBOV. However, in a number of EBOV-infected 
cells cytoplasmic SG formation was not observed, even though G3BP-EGFP SG-like granules 
were detected within the viral inclusions. This indicates that these cells were potentially able to 
form SGs, since G3BP-EGFP was expressed, but they were inhibited by the infection with EBOV. 
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As treatment was compared to Hip treatment in EBOV-infected cells. In some cells treated with As, 
G3BP-EGFP was diffusely distributed and SG formation was impaired. This was not seen in Hip-
treated cells, suggesting that EBOV inhibits SG formation in response to phospho-eIF2!-mediated 
stress. This inhibition seemed to be dependent on the size of the viral inclusions, suggesting that a 
certain level of viral protein expression is required.  
In contrast to SG inhibition, accumulation of G3BP-positive SG-like granules within viral inclusions 
(discussed above) was very similar in As/Hip-treated cells as well as in non-treated cells and was 
seen in viral inclusions of all sizes during EBOV infection.  
Interestingly, Junin virus infection led to the inhibition of As-induced SG formation, but did not 
inhibit SG formation induced by Hip (Linero et al., 2011). The mechanism of this inhibition is 
unknown.  
 
Interplay of EBOV proteins with SGs 
Since our results revealed that SG formation induced by exogenous stressors is reduced in EBOV-
infected cells, we sought to identify the viral protein(s) involved in antagonizing SG formation. 
Since many of the proteins located in SGs have the ability to bind RNA, the EBOV RNA-binding 
proteins NP, VP30, and VP35 were examined. SGs interacted with the nucleocapsid proteins VP30 
and VP35, whereas NP-derived inclusions did not colocalize with SGs.  
 
VP30 and SG 
VP30 showed striking colocalization with G3BP-EGFP-containing SGs induced by either As or Hip. 
VP30 has previously been shown to bind ssRNA, and RNA binding activity was dependent on the 
presence of Zn2+ ions (John et al., 2007). VP30 contains an unconventional CCCH Zn-finger motif, 
similar to motifs found in some cellular RNA-binding proteins (Weik et al., 2002; Modrof et al., 
2003). It is not yet clear if the VP30 CCCH motif is directly involved in RNA binding. N-terminal 
VP30 deletion mutants containing the CCCH motif did not bind to RNA, suggesting that the CCCH 
motif alone is not sufficient for RNA binding (John et al., 2007). Proteins containing a CCCH Zn-
finger motif often bind and regulate the stability of mRNAs containing AREs. The CCCH Zn-finger 
proteins TTP and BRF1 have a major regulatory role in controlling ARE-containing cytokine 
mRNAs such as TNF! and Interleukin-6. TTP and BRF1 also accumulate in SGs and PBs during 
environmental stress, where they deliver mRNAs to PBs and promote their deadenylation and 
degradation thereby exerting anti-inflammatory effects (Kedersha et al., 2005; Franks and Lykke-
Andersen, 2008). The observed colocalization of VP30 with SGs suggests that VP30 interacts with 
SG components and likely ARE-containing mRNAs. This raises the possibility that VP30 might play 
a similar regulatory role by binding ARE-containing mRNAs of antiviral cytokines important during 
filovirus infections. SG formation itself was not visibly altered by the expression of VP30. 
Overexpression of TTP and BRF1 also stabilizes the association between SGs and PBs. NP- and 
VP30-derived inclusions were found in close proximity to SGs, seemingly strung together like 
pearls in some cells.  
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VP35 and SG 
A different interaction pattern has been observed between SGs and VP35. EBOV VP35 is a 
component of the nucleocapsid and plays an important role in viral replication. This multifunctional 
dsRNA-binding protein is also a crucial virulence factor that blocks the IFN-mediated antiviral host 
immune response and RNA silencing pathways (Basler et al., 2003; Hartman et al., 2004; 
Haasnoot et al., 2007; Zhu et al., 2012). During As-induced stress, VP35 colocalized with but also 
surrounded SGs, seemingly sequestering them from the cytoplasm. This was observed for both 
G3BP-EGFP-containing and eIF3-containing SGs. In contrast, in the presence of Hip, VP35 
exhibited a punctate pattern that was observed to completely colocalize with the G3BP-positive 
SGs. In treated and untreated cells expressing high levels of VP35, VP35 accumulated in large 
aggregates. Interestingly, As-induced SG formation was reduced or completely inhibited in these 
cells, and the distribution pattern of SG proteins was diffuse. . This was determined by analyzing 
both G3BP-EGFP-positive and eIF3-positive SGs. These results differed from those in Hip-treated 
cells where VP35 did not form large aggregates but showed in a punctate distribution without 
modulating the formation of SGs.  
To investigate if VP35’s ability to bind dsRNA, antagonize interferon-induced pathways, and block 
PKR activation is involved in its ability to interact with SGs, a VP35 mutant (VP35-3A) that is 
inhibited in all three functions was tested (Leung et al., 2009; Schumann et al., 2009; Zhu et al., 
2012). In immunofluorescence analysis VP35-3A colocalized with SGs in a manner similar to 
wildtype (wt) VP35 at low protein expression levels. In contrast to wt VP35, VP35-3A did not inhibit 
As-induced SG formation. Also, VP35-3A did not form large aggregates, which correlated with SG 
inhibition in cells expressing wt VP35. A reduced expression of VP35-3A compared to wt VP35 has 
been reported (Schumann et al., 2009), which might correlate with the inability to inhibit SG 
formation. This was observed in both SGs containing G3BP-EGFP and SGs containing 
endogenous eIF3. These results indicate that EBOV exhibits control strategies at the level of SG 
formation and that the ability to antagonize SG formation depends on the protein expression level 
of VP35.  
Inhibition of SG formation induced by phospho-eIF2!-mediated stress was shown when VP35 was 
expressed at high levels in the absence of other viral proteins, suggesting that this inhibition 
process functions in a dose-dependent manner. Inhibition was not observed when VP35 was 
located in NP-derived inclusions. This indicates that only free VP35 is able to colocalize with SGs 
and that VP35 is preferentially relocated to viral inclusions. Binding of VP35 to NP is facilitated by 
the N-terminus, whereas the C-terminus contains the dsRNA-binding and IFN inhibitory domain 
(IID) (REID et al., 2005). It is conceivable that the N-terminus contains a motif, which interacts with 
components of SGs when VP35 is not bound to NP but is not accessible after binding of VP35 to 
NP. Since the majority of VP35 is relocated into the viral inclusions, it is also possible that the 
amount of free VP35 was not sufficient for the inhibition of SG in cells coexpressing NP.  
Similarly, in the presence of NP, VP30 mainly relocated into NP-derived inclusions. However, 
some colocalization was observed between VP30 and SGs, which also seemed to be dependent 
on the VP30 expression level. In EBOV infection colocalization of VP30 or VP35 with the G3BP-
positive SGs was not detected. It is conceivable that the amount of free VP35 and VP30 in infected 
cells was too low to be detected. Although SG formation was reduced to a certain level in EBOV-
infected cells with As the amount of VP35 expressed in EBOV infection might not be sufficient to 
completely inhibit phopho-eIF2!-induced SGs. Consequently, G3BP-positive SG formation was 
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only inhibited in some infected cells, particularly those in which large viral inclusions were 
observed.  
The diffuse appearance of SGs in VP35-expressing cells indicates that key components for SG 
formation were inhibited. A possible mechanism for the inhibition of SG formation could take place 
at the level of SG assembly by protein aggregation. As mentioned previously, G3BP is a key 
component in SG formation due to its self-aggregation and RNA-binding capacity. For poliovirus 
(PV) it was found that inhibition of SG formation correlated closely to the cleavage of G3BP, which 
is mediated by the viral proteinase 3C. Cleavage of G3BP separates the G3BP RNA-binding motif 
from the protein-interaction domains (White et al., 2007). Thus, it is possible that overexpression of 
VP35 leads to the inhibition of G3BP and accordingly to SG disassembly. If this were the case, a 
decrease in the number of cells containing SGs would also be detected in the eIF3 antibody 
staining. The sequestration of G3BP granules within viral inclusions in EBOV-infected cells, which 
also appeared diffuse in shape, could be a mechanism of EBOV evasion of host antiviral defense 
(also discussed above). 
 
Mechanism of VP35 action 
The type I IFN response is crucial for establishing an antiviral state in the host cell and 
subsequently for activating the adaptive immune response. EBOV encodes several components 
that inhibit the type I IFN response. VP35 has been shown to antagonize the phosphorylation of 
PKR, and consequently, the PKR substrate eIF2! was not phosphorylated in cells expressing 
VP35 (Schumann et al., 2009). The classical activator of PKR is dsRNA, which is produced during 
viral infections. Activation of PKR mediates the arrest of the host translational machinery and 
subsequently leads to SG formation.  
For influenza A it has been shown that SG formation is actively inhibited by the NS1 protein by 
blocking PKR activation (Khaperskyy et al., 2011). VP35 and NS1 both play a role in the inhibition 
of the IFN response and contain similar non-canonical dsRNA-binding domains (Chien et al., 1997; 
Liu et al., 1997; Leung et al., 2009). VP35 is able to functionally substitute for NS1 in growth 
complementation assays using an influenza virus mutant lacking NS1 (Basler et al., 2000). The 
similarities between VP35 and NS1 indicate that VP35 has a similar role in the inhibition of SGs, 
which has to be further investigated. 
 
VP35 does not bind to PACT in cells exposed to exogenous stress  
As-induced SG formation was observed in EBOV-infected cells, albeit in fewer cells, indicating that 
eIF2! may be phosphorylated in these cells. Therefore the phosphorylation status of PKR and its 
substrate eIF2! was determined during As-induced stress in EBOV-infected cells. Interestingly, 
phosphorylation of PKR and eIF2! was detected in these cells, suggesting that EBOV is not able 
to antagonize PKR phosphorylation in cells exposed to As stress. In As-treated cells, 
phosphorylation of PKR by the cellular protein PACT has been described (Patel and Sen, 1998); 
(Daher et al., 2009). PACT only binds and activates PKR during cellular stress. Since it has been 
shown that VP35 is able to bind to PACT in non-stressed cells (Fabozzi et al., 2011), it was 
hypothesized that VP35 bound to PACT inhibits the binding of PACT to PKR and thereby prevents 
activation of PKR in EBOV-infected cells and consequently, formation of SGs. In this thesis, the 
interaction of VP35 and PACT in non-stressed cells was confirmed. In addition, it was shown that 
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VP35 is not able to bind PACT during As stress. This suggests that binding of VP35 to PACT 
sequesters PACT from binding to PKR and thereby inhibits PKR activation. However, during 
phospho-eIF2!-mediated stress induced by As, VP35 loses the ability to bind PACT, leading to the 
phosphorylation of PKR and its substrate eIF2!, as observed in EBOV-infected cells treated with 
As. This would further explain the formation of SGs in these cells. Possible mechanisms for the 
reduced SG formation have been discussed above. As mentioned above, in HIV-1 and rotavirus 
infection, high levels of phosphorylated eIF2! were detected in response to As treatment despite 
an inhibition of SGs (Montero et al., 2008; Abrahamyan et al., 2010).  
The Us11 protein of herpes simplex virus type 1 is an example of a viral protein that can inhibit the 
action of PACT on PKR (Peters et al., 2002). Us11 blocks PKR activation by PACT both in vitro 
and in vivo. Although Us11 can bind to both PKR and PACT, mutational analyses revealed that the 
binding of Us11 to PKR, and not to PACT, was essential for its inhibitory action. The binding of 
Us11 to PKR did not block the binding of PKR to PACT but prevented PKR activation. 
PACT contains two domains implicated in dsRNA binding and responsible for the interaction with 
PKR. The mechanism of how VP35 interacts with PACT, either directly or via a linker protein or 
RNA, remains to be determined.  
Since PACT only activates PKR in certain stress environments (and not through dsRNA), one 
could assume that infection with EBOV induces cellular stress. Moreover, it is possible that this 
represents a redundant mechanism of VP35 to ensure PKR inhibition.  
 
P bodies 
Another important part of the antiviral host stress response is the sequestration and possible 
degradation of RNAs in PBs, which also form as a result of cellular stress. PBs are closely 
associated with the RNA interference system and have been suggested to be involved in long-term 
storage of miRNA-regulated mRNAs (Shih et al., 2011). In non-infected cells, an increased number 
of DCP1a-mRFP-containing PBs were observed during As-induced stress. In EBOV-infected cells, 
DCP1a-containing PBs were observed during early stages of infection, but not at later stages. 
These PBs were localized next to the viral inclusions. Furthermore, DCP1a-positve PBs 
colocalized with VP35 and the VP35-3A mutant, but not with VP30. 
It has been reported that VP35 suppresses the RNAi pathway. This activity depends on an intact 
dsRNA-binding domain, which is destroyed in the VP35-3A mutant (Haasnoot et al., 2007). In 
addition, VP35 has been shown to bind siRNA, whereas the VP35-3A mutant was unable to do so 
(Zhu et al., 2012). Since both, wt VP35 and VP35-3A colocalize with PBs, a miRNA-mediated 
recruitment of VP35 to PBs does not seem likely. However, it is possible that miRNA-dependent 
linker proteins are involved in a relocalization of VP35, leading to the observed colocalization of 
VP35 and PBs. Interestingly, VP35 has been shown to interact with various components of RISC 
including Dicer, TRBP, and PACT but not Ago2 (Fabozzi et al., 2011) A dynamic movement of 
Ago2 from SGs to PBs in a micro-RNA-dependent manner was detected by establishing a stably 
expressing EGFP-Ago2 cell line (Leung et al., 2006). As yet, it is not known if VP35 interacts with 
Ago2. Another potential interaction partner for VP35 is the PB marker protein RCK/p54, which is 
involved in miRNA-mediated gene silencing (Chu and Rana, 2006). This protein has been shown 
to bind to viral RNAs including the genomic 3’UTR and 5’UTR of DV as well as the 5’ terminus of 
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the negative-strand antigenomic RNA of HCV (Ariumi et al., 2011; Ward et al., 2011), Knockdown 
experiments indicate a role in viral replication for both viruses.  
To summarize, the results presented here indicate that EBOV exhibits control strategies at the 
level of SG formation by sequestering components essential for SG formation, such as G3BP, to 
evade the antiviral stress response. The virus further inhibits SG formation via expression of VP35, 
which seems to be a key player in the inhibition of SG formation. VP35 was shown to alter induced 
SG formation and interact with cellular stress components of SGs and PBs. Furthermore, it was 
shown to interact with PACT, a cellular activator of PKR.VP35’s ability to bind dsRNA is most likely 
not important for the interaction with SGs and PBs, since VP35-3A, a VP35 mutant which lost the 
dsRNA binding activity, was observed to colocalize with both. 
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